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Abstract 
 
 Upon entry into a host, carcinogens are subjected to a variety of Phase I and Phase 
II metabolic pathways that result in bioactivation or detoxification. The bioactivation 
pathways are of particular importance because they often generate DNA-damaging 
compounds. It would stand to reason that fully understanding these activation pathways, 
their outcomes, and their differences amongst individuals would aid in combating cancer. 
This dissertation focuses on the metabolic activation of two tobacco carcinogens: 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N-nitrosonornicotine (NNN). 
Concepts pertinent to this work such as tobacco carcinogenesis, chemistry of N-nitroso 
compounds, cytochrome P450 metabolism, and tobacco-specific nitrosamines are 
reviewed. 
 The first study of this dissertation evaluates a hypothesized metabolic pathway for 
N-nitrosamines: processive P450 oxidation of NNK and NNN to N-nitrosamides. In this 
study, the three corresponding N-nitrosamides were synthesized, tested for stability, and 
monitored for formation in vitro. This study shows for the first time that N-nitrosamides 
are direct products of N-nitrosamine metabolism by cytochrome P450s. While these 
compounds were minor metabolites, their relative stability and DNA-damaging properties 
could impart biological relevance. Determining the generality of this metabolic pathway 
requires future work. 
 The second study sought after the structures and abundance of stable 2-
deoxyadenosine (dAdo) damage (DNA adducts) induced by NNK bioactivation. This was 
accomplished by synthesizing hypothetical dAdo-adduct structures based on known 
reactivity and applying them to in vitro and in vivo assays. In vitro data indicates that N6- 
and N1-adducts are formed, however, in vivo data only shows N6-adduct formation, 
indicating extensive repair of N1-adducts. The relative abundance of these adducts were 
determined in rat liver and lung for three different treatment groups. The biological 
activity of these adducts requires future study. 
 The last study measured direct biomarkers for human NNN metabolic activation 
for the first time by using [pyridine-D4]NNN-enriched tobacco. The deuterium-labelling 
 vi 
allows NNN metabolites to be selectively measured by mass spectrometry and removes 
all interference by competing nicotine metabolites. This study is ongoing but current data 
suggests metabolic activation of NNN varies among individuals and is at least partially 
due to the activity of P450 2A6, the dominant enzyme for NNN bioactivation.  
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Chapter 1 Overview of Tobacco Carcinogenesis and Bioactivation of N-Nitroso 
Species 
 
The following chapter gives background and context to the studies carried out in 
this dissertation. Principles of tobacco carcinogenesis, properties of N-nitroso 
compounds, and mechanisms of N-nitrosamine metabolism, in the context of N-
nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 
will be discussed. 
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1.1 Overview of Tobacco Carcinogenesis 
 
1.1.1 Tobacco and Its Relation to Cancer 
 America has a long and painful history with tobacco1. As early as 1 B.C., tobacco 
was smoked by Native American tribes for ceremonial and, ironically, medicinal 
purposes. The tobacco plant was later given to Christopher Columbus as a gift during his 
famous 1492 voyage to the New World, and brought back to Europe where it became one 
of the world’s most desired commodities. This transformed tobacco into one of 
America’s first cash crops and even a colonial currency in Virginia. It wasn’t until the 
1900s, however, that tobacco began being sold in the form of cigarettes we see today2. 
Near the peak of tobacco use in the early 1960’s, when 53% of men and 33% of women 
were regular smokers, over 4,000 per capita cigarettes were smoked annually3. This great 
rise in cigarette use was driven foremost by nicotine addiction, but also fueled by 
misleading advertisement campaigns and limited evidence directly linking tobacco to 
adverse health effects4. In 1964, the perception of tobacco changed with the release of the 
Surgeon General Report where it was noted that “cigarette smoking is causally related to 
lung cancer … and is a health hazard of sufficient importance in the United States to 
warrant appropriate remedial action”5. Due to the objective and authoritative approach of 
this report and the other Surgeon General Reports released in subsequent years4, health 
scientists and legislators began implementing changes to product labeling, advertising, 
taxation, and tar content while also executing plans to limit involuntary exposure and aid 
in cessation. Meanwhile, other types of tobacco and routes of exposure, such as 
smokeless products and second-hand smoke, were shown to cause cancer. These and 
many other public policies over the last 50 years have dramatically decreased the amount 
of tobacco users in the United States and overall in the world4; however, the amount 
remaining is not trivial.  
 As of 2016, an estimated 38,000,000 adults in the United States were smokers, 
while ~1,000,000,000 adults smoked worldwide6. The statistics are significantly less with 
smokeless tobacco (9,000,000 U.S7; ~350,000,000 worldwide8) but still notable due to its 
known carcinogenic properties9. This persistent tobacco use causes 480,000 deaths 
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annually in the U.S.4, maintaining its status as the leading preventable cause of death. Of 
these deaths, 160,000 are cancer-related which accounts for 32% of all U.S. cancer 
deaths10. While it is known that tobacco causes ~90% of all lung cancers11, tobacco 
smoking has also been linked to cancers of the larynx, pharynx, oral cavity, esophagus, 
pancreas, nasal cavity, stomach, bladder, liver, cervix, and colorectum4. Together, this 
illustrates that while we have made significant progress since 1964, tobacco-related 
cancer is still a significant health concern that requires continued study to understand the 
over-arching health impacts of tobacco, identify cancer-susceptible individuals, and 
elucidate the chemical mechanisms of tobacco carcinogenesis.  
 
1.1.2 Tobacco-related Chemicals and Carcinogens 
Tobacco smoke is known to contain >7000 chemicals including carbon monoxide, 
ammonia, lead, arsenic, and polycyclic aromatic hydrocarbons12. One of the most 
important, non-carcinogenic species in tobacco is nicotine (Figure 1-1), the addictive 
compound that encourages tobacco users to repeatedly use the product. On average, one 
cigarette contains 7 – 14 mg of nicotine which is ~2% of the dry weight of tobacco13. 
While the complex mechanisms of nicotine addiction are outside the scope of this thesis, 
it is generally accepted that nicotine releases dopamine in the ventral tegmental region of 
the brain via nicotinic acetylcholine receptor signaling14. Glutamate15 and gamma-
aminobutyric acid (GABA)16,17 have been shown to be upregulated and contribute to the 
rewarding effects of nicotine as well. Chronic activation of these receptors and release of 
dopamine18,19 ultimately leads to the hallmark phenotypes of psychological and physical 
dependence to nicotine, which are demonstrated during withdrawal. It is these aspects of 
nicotine that are particularly troubling as this addiction is remarkably hard to break 
whether at a young or adult age. For that reason, many who begin using tobacco are 
unable to quit in their lifetime and forced into repeated exposure to carcinogens. 
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Figure 1-1: Chemical structures of nicotine and its major metabolites (A) and several Group 1 carcinogens (B) found in 
tobacco smoke 
 To date, at least 70 chemical carcinogens have been identified in tobacco smoke. 
Figure 1-1 displays a few of these including two tobacco-specific nitrosamines: 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N'-nitrosonornicotine (NNN), 
which will be more thoroughly discussed in Section 1.4. All of these compounds have 
been evaluated as carcinogenic to humans, or Group 1 carcinogens, by the International 
Agency for Research on Cancer (IARC). In comparison to nicotine, these compounds are 
generally much less abundant; however, still exhibit strong tumorigenic effects. For 
example, chronic administration of NNK at 5 ppm in drinking water induces tumors in 
rats20. Many of these substances alkylate or intercalate DNA where NNK and 
benzo[a]pyrene are prominent examples, respectively. While some tobacco carcinogens 
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act directly, many require metabolic activation to exert their effects, which is often 
counteracted by a variety of detoxification pathways. 
 
1.1.3 Metabolic Mechanisms of Carcinogen Activation and Detoxification 
Humans have evolved many enzymatic routes to metabolize and eliminate foreign 
chemical entities broadly referred to as xenobiotics. Xenobiotics can include any 
compound originating outside the body such as medicines, vitamins, metals, and 
carcinogens. Metabolism of these compounds is traditionally divided into two main 
categories: Phase I and Phase II. While outside the scope of this dissertation, Phase III 
metabolism, recognized as further enzymatic processing of metabolites like that seen in 
the mercapturic acid pathway21, and human microbial metabolism22,23 are also important 
areas of research. 
Phase I metabolism is generally defined as enzyme-mediated oxidation, reduction, 
and hydrolysis for the purpose of increasing polarity and introducing functional handles 
for Phase II metabolism. A key example of Phase I metabolism is oxidation by 
cytochrome P450s. This class of enzymes can perform a diverse set of reactions including 
carbon and heteroatom hydroxylation, O-, N-, and S-dealkylation, epoxidation, and 
structural rearrangements24. These enzymes and their mechanisms will be more 
thoroughly discussed in Section 1.3. Other examples of Phase I metabolism pertinent to 
this thesis includes alcohol oxidation25, carbonyl reduction26, and ester hydrolysis27. 
Phase II metabolism is generally thought to be enzyme-mediated conjugation 
chemistry28. Similar to Phase I metabolism, these transformations typically increase the 
polarity of the xenobiotic, which aids in its urinary excretion. Examples of this include 
sulfation29, acetylation30, methylation31, glutathione conjugation32, and O- and N- 
glucuronidation33, which is most relevant to this dissertation.  
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Figure 1-2: General N- and O-glucuronidation of alcohols and amines by UGTs. 
Glucuronidation is the transfer of a glucuronosyl group from uridine-5’-
phosphoglucuronic acid to a free alcohol or amine (Fig. 1-2), which may have been 
introduced via Phase I metabolism. The overall reaction is mediated by uridine-
diphosphate glucuronosyltransferases (UGTs) which are mainly found in the liver, 
however, are known to be expressed in many tissues including the kidneys, spleen, 
thymus, and brain34. The importance of this family of enzymes can be exemplified with 
the antibiotic chloramphenicol, which if not glucuronidated, will accumulate and lead to 
adverse effects including hypotension, abnormal respiration, cardiogenic shock, and gray 
skin color35. These effects are often seen in chloramphenicol-treated newborns, who do 
not yet express UGTs, and colloquially known as “gray baby syndrome”. Lastly, it should 
be noted that Phase I and Phase II metabolism occur simultaneously and do not 
necessarily precede each other. 
These two types of metabolism are a critical focus in this thesis as the chemistry 
performed by these enzymes both detoxify and activate tobacco carcinogens. N- and O-
glucuronidation is the primary detoxification pathway explored in this thesis. As stated 
earlier, addition of this large, polar group typically aids in xenobiotic elimination by 
keeping the molecule within the bloodstream, outside of cells, and protected from further 
activating enzymes. This logic is consistent for other conjugative transformations like 
glutathione transfer, sulfation, and acetylation. In some cases, P450 oxidation can be a 
detoxification route. An example relevant to this thesis is the metabolism of nicotine36. 
P450 2A6, which activates N-nitrosamines, sequentially oxidizes nicotine to cotinine 
(Fig. 1-1A)37,38; the analogous reaction for N-nitrosonornicotine is the subject of 
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Chapter 2. Cotinine can be further oxidized by P450 2A6 to 3-hydroxycotinine36, which 
if normalized to cotinine, is a phenotypic biomarker for enzymatic activity39,40. Because 
both cotinine and 3-hydroxycotinine have reduced activity at nicotinic receptors, this is 
viewed as detoxification.  
The most important activation pathway for this thesis is Phase I -hydroxylation 
of N-nitrosamines by cytochrome P450s. As shown in Scheme 1-3A, -hydroxylation 
results in N-dealkylation and production of a highly reactive diazonium ion. This 
outcome is in direct contrast to nicotine, where identical chemistry lead to a 
detoxification product. Cytochrome P450s can also activate carcinogens to alkylating 
agents through epoxidation as seen with benzene and benzo[a]pyrene (Scheme 1-3B & 
C)41. Phase II enzymes can also activate xenobiotics as shown with PhIP (Scheme 1-
3D)42. After initial N-oxidation, the new hydroxylamine can be acetylated or sulfated. 
These compounds can spontaneously lose acetate or sulfate to form highly electrophilic 
nitrenium ions. Due to the high reactivity of all the mentioned compounds and the 
aqueous environment of a cell, most activated carcinogens are hydrolyzed and eventually 
excreted in the urine. The hydrolyzed forms can then serve as biomarkers of carcinogen 
activation; Chapter 4 demonstrates this by measuring activation biomarkers of NNN. If 
hydrolysis does not occur, these compounds can alkylate a variety of biomolecules such 
as DNA in the form of DNA adducts. It is ultimately these adducts that give the discussed 
carcinogens their robust activity and is a major focus of tobacco carcinogenesis. 
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Figure 1-3: Examples of metabolic activation of carcinogens by Phase I and II metabolism. (A) -hydroxylation of N-
nitrosamines. (B-C) Epoxidation of benzene and benzo[a]pyrene. (D) N-hydroxylation and N-acetylation of PhIP. NAT 
= N-acetyltransferase, Nu = nucleophile, PhIP = 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. 
1.1.4 DNA Adducts Resulting from Tobacco Carcinogens: 
DNA damage is produced from many sources including ultraviolet (UV) light43, 
ionizing radiation44, reactive oxygen species45,46, and alkylating agents47. While some of 
the physical agents directly produce single and double-strand breaks, chemical agents 
typically modify the structure of DNA, which then leads to a variety of downstream 
effects. The tobacco carcinogens discussed in this thesis alkylate nucleobases to produce 
covalent addition products referred to as DNA adducts (Figure 1-4). These come in 
multiple forms depending on the location and connectivity of the alkylation. We 
characterize monoadducts, or nucleotides with a single modification, by the site of 
alkylation as shown in Figure 1-4B. Important for work in Chapter 3 is various 
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alkylation sites of 2-deoxyadenosine (dAdo), namely N1, N3, N6, and N7. Alkylating 
agents with two electrophilic sites can bind two nucleotides to produce a DNA crosslink48 
(Fig. 1-4A). These can either be intrastrand or interstrand and often lead to DNA strand 
breaks. These types of chemical agents are also known to bind proteins to form DNA-
protein crosslinks49. Similar to monoadducts, crosslinks can all be uniquely defined by 
the alkylation sites on the nucleobases involved. Besides nucleobase adducts, recent data 
is beginning to show that DNA phosphate adducts are quite abundant and may have 
important biological consequences50–52. 
 
Figure 1-4: (A) Types of DNA adducts and (B) known sites of DNA alkylation (denoted in red). 
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 The fates of these adducts are quite diverse. Alkylation of the N3 or N7 position of 
either guanine or adenine typically results in abasic sites through base depurination 
(Scheme 1-1). Alkylation at these positions creates a delocalized cationic charge that 
destabilizes the glycosidic bond and ultimately releases the damaged nucleobase53. If left 
unrepaired, the newly formed abasic site can lead to a single-strand break via ß-
elimination of the 3’-phosphate54. Abasic sites can also cause interstrand crosslinks with 
guanine or adenine via stabilized Schiff base interactions55. Alkylation of most other sites 
including the N2 and O6 positions of guanine, N4 of cytosine, and O2 and O4 position of 
thymine are generally stable and remain in DNA until encountered by repair enzymes. 
Lastly, alkylation of some sites such as the N1 of adenine can lead to structural 
rearrangements and will be explored more in depth in Chapter 3. 
 
Scheme 1-1: Mechanism and downstream outcomes of nucleobase depurination. 
 
1.1.5 Repair of DNA Adducts 
The formation of DNA adducts can pose many problems to a cell and thus many 
DNA repair pathways have been evolved to combat these lesions. While the entirety of 
DNA repair is outside the scope of this dissertation, base excision repair, nucleotide 
excision repair, and direct repair will be discussed. 
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recognized by a DNA glycosylase and moved into the active site through a “base 
flipping” mechanism57. As an example, alkyladenine DNA glycosylase performs this 
action by intercalating Tyr162 into the minor groove, which pushes the entire nucleotide 
outside of the helix via the major groove58. This structural rearrangement additionally 
kinks the phosphate backbone and coordinates a water molecule towards the C1 of the 
2-deoxyribose sugar. Once in the active site, the glycosidic bond is polarized and cleaved 
which releases the damaged nucleobase and produces an apurinic (AP) site. Enzymes that 
perform this action include uracil DNA N-glycosylase, thymine DNA glycosylase, 
alkyladenine glycosylase, 8-oxo-guanine glycosylase 1 (OGG1), and endonuclease VIII-
like 1 (NEIL1). Interestingly, recent reports have identified AlkD as a “non-base-
flipping” glycosylase, indicating that “base flipping” is not always necessary59. With an 
AP site now present, the phosphate backbone is cleaved at the 5’-position by AP 
endonuclease 1 (APE1) to produce a 5’-deoxyribose phosphate and an opposing 3’-OH, 
which DNA polymerase ß and others use as a handle for nucleotide gap filling56. This can 
be done in either a short-patch or long-patch manner, but both arrive in the same outcome 
of 5’-deoxyribose phosphate removal, gap filling, and strand ligation60. Apurinic sugars 
can sometimes be removed in reverse order due to glycosylases such as OGG1 and 
NEIL1 inherently possessing 3’-endonuclease activity61. In this case, 3’-cleavage occurs 
directly after rupture of the glycosidic bond. This is then followed by 5’-cleavage by 
APE1 and gap filling as previously discussed. Common substrates for BER include 
oxidized bases, small alkylated bases, and deaminated bases such as uracil and 
hypoxanthine, which will become important in Chapter 3. 
 Nucleotide excision repair (NER) acts most commonly on bulky DNA damage 
such as UV-pyrimidine dimers, benzo[a]pyrene adducts, and DNA crosslinks62,63. The 
DNA damage is initially recognized by either transcription-coupled NER or global 
genome NER. Both pathways detect major distortions to the DNA helix and recruit the 
transcription factor IIH complex to the site of damage. Proteins including XPB, XPD, 
RPA, XPA, and XPG help to open the DNA helix, check for DNA damage, and stabilize 
the complex before proceeding further. Once all the necessary proteins are in place, dual 
incision of the damaged strand takes place and a 24 – 32 nucleotide region containing the 
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damaged nucleotide and protein complex is released. At this time, the large gap can be 
filled by a variety of DNA polymerases and ligases.  
Compared to BER and NER, direct repair is relatively simple as all repair occurs 
at the nucleobase and does not involve cleavage of the DNA phosphate backbone. Two 
enzymes important to tobacco-related DNA adducts are O6-alkylguanine DNA 
alkyltransferase (AGT)64,65 and AlkB oxygenases66. AGT is well known for repairing 
highly mutagenic O6-methyl guanine adducts, but can also accommodate other O6-
alkylguanine and O4-alkylthymine adducts. Unlike the enzymes in BER and NER, this 
enzyme works in a stoichiometric fashion and facilitates only one turnover. This is a 
result of the repair mechanism where the alkyl group is transferred to a highly active 
cysteine within the active site through SN2-type chemistry64. After alkyl transfer, the 
enzyme releases an unmodified nucleotide but can no longer function and must be turned 
over. This makes AGT-based repair relatively slow and has major clinical implications 
for individuals who either lack or possess downregulated AGT. For example, mice 
lacking AGT form more colon tumors than wild type when given azoxymethane67. 
Similarly, the anticancer drug Temozolomide is less effective against tumors with 
upregulated AGT as the resulting O6-methylguanine damage is quickly repaired, allowing 
the tumor cells to survive68.  
 AlkB is an -ketoglutarate-dependent hydroxylase and repairs DNA alkylation 
through an oxidative mechanism. -Hydroxylation of the alkyl group relative to the N- or 
O-position of the nucleobase produces a highly unstable structure that releases an 
aldehyde and the native base66,69. This type of reactivity is reminiscent of cytochrome 
P450s and will be revisited in Section 1.3. While monoalkylated adducts are the most 
common substrates, exocyclic-bridging adducts such as 1,N2-etheno-dGuo are also 
repaired by AlkB through a similar mechanism70. Analogous to AGT, AlkB-mediated 
repair also seems to have clinical implications, although the mechanisms are not entirely 
elucidated. Together, it is clear that DNA repair is imperative for host cells to maintain 
genomic integrity but can also be used to resist chemotherapy. 
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1.1.6 Mutations, Cancer Initiation and Progression 
As noted in the previous section, human cells devote high amounts of energy to 
repairing DNA adducts. The reason for this is that accumulation and persistence of DNA 
adducts lead to mutations within the genome that change cellular functions. Mutations 
occur because DNA adducts often stray from traditional Watson-Crick base pairing. For 
example, it is believed that O6-methylguanine mimics the hydrogen bonding of adenine 
and readily accepts thymine during replication, leading to a GC to AT transition. DNA 
adducts can also adapt Hoogstein base pairs where the purine base rotates into a syn 
conformation and hydrogen bonds through the O/N6 and N7 positions.  
If a mutation within onco- or tumor suppressor genes, such as KRAS and TP53, 
cell growth can be dysregulated and initiate tumor formation. Additional mutations can 
aid in tumor progression, where changes that promote survival occur. Typical hallmarks 
associated with survival include changes to metabolism, angiogenesis, nutrient 
acquisition, and genome maintenance. After sufficient DNA-adduct induced changes, a 
tumor can become self-sufficient and invasive leading to all the health effects of cancer 
which are outside the scope of this dissertation. Based on the fact that these changes are 
the result of DNA adducts, often formed by metabolically activated carcinogens, 
understanding the nature of DNA adducts and carcinogen activation are important for 
understanding tobacco carcinogenesis. 
 
1.2 Chemistry and Carcinogenicity of N-Nitroso Compounds 
 
1.2.1 Brief History of N-Nitrosamines and N-Nitrosamides 
N-nitroso compounds are any compounds containing the structure shown in Fig. 1 
-5A. The first N-nitrosamine to be investigated for human toxicity was also the simplest: 
N-nitrosodimethylamine (NDMA). In the early 1950s, two researchers using NDMA as 
an industrial solvent reported cirrhosis of the liver 10 months after the chemical was 
introduced to the plant. In response, Barnes and Magee evaluated the effects of NDMA in 
animals and found LD50 values of 26.5, 15, and 50 mg/kg for rats, rabbits, and dogs71. In 
all cases, the liver showed morphological changes and extensive hemorrhaging into the 
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gut lumen. In 1965, Magee and Barnes confirmed in their landmark study that NDMA 
also produces hepatic tumors when administered at 50 ppm in the diet72. This finding 
established that, at least in one case, N-nitrosamines are potent carcinogens and 
encouraged efforts to characterize other N-nitroso species. By 1984, more than 300 N-
nitroso compounds were examined and over 90% were found to be carcinogenic and have 
organ specificity regardless of route of administration73. For example, symmetrical 
dialkylnitrosamines target the liver while many methylalkylnitrosamines target the 
esophagus; however, if the second alkyl chain is an even carbon length greater than 6, the 
bladder becomes the major target organ. Cyclic nitrosamines generally have broad 
specificity with N-nitrosoproline actually exhibiting no carcinogenicity74 for reasons 
discussed in Section 1.3.3. 
 N-Nitrosamides (Fig. 1-5A) have been similarly investigated for carcinogenic 
potential. In 1960, Schoental was evaluating the effects of macromolecule methylation 
and decided to use N-nitroso-N-methylurethane as a surrogate for diazomethane. High 
oral dose treatments (20% solution v/v) resulted in fatal damage to the lungs, liver, and 
stomach after 2 – 3 days. In low dose treatments (2.5% solution v/v), rats generally 
survived but in some cases developed squamous cell carcinomas of the stomach75. Other 
related N-nitrosamides were later evaluated and shown to induce stomach tumors in rats, 
indicating that it is the common N-nitrosamide functional group initiating these effects76. 
More broadly, it has now been established that the common N-nitroso group77,78 unifies 
the action of both N-nitrosamines and N-nitrosamides and continues to be of interest to 
health science. 
 
1.2.2 Preparation and Reactivity of N-Nitroso Compounds 
 N-nitrosamines and N-nitrosamides can be prepared through nitrosation of amines 
or amides with NaNO2, nitrosyl esters and nitrosyl halides under acidic conditions (Fig 1-
5B). All of these reagents converge with the formation of HNO2, which either dimerizes 
to form N2O3 or loses water to form NO+. Both species can then be attacked by the 
nucleophilic nitrogen of the desired amine or amide to form a N-nitroso species. Amides 
may be more complicated though as computational evidence supports initial O-alkylation 
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followed by a pseudopericyclic 1,3-sigmatropic rearrangement79. A mechanism under 
basic conditions using formaldehyde as a catalyst has also been shown and is depicted in 
Fig. 1-5C73. This could potentially have biological relevance as certain bacterial strains 
can perform nitrosation under basic conditions80,81; however, recent insights into 
streptozotocin biosynthesis imply nitrosation is much more complex82. Nitrosation is 
most well understood for primary and secondary amines and amides, but tertiary amines83 
can also be nitrosated and has major implications for tobacco84,85 as discussed in Section 
1.4. 
 
Figure 1-5: (A) The general structure of N-nitrosamines and N-nitrosamides. (B) Mechanisms of N-nitrosation by 
NaNO2, nitrosyl esters, and nitrosyl halides. (C) A formaldehyde catalyzed N-nitrosation mechanism under basic 
conditions. 
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 Once formed, N-nitrosamines are generally quite stable unless exposed to strongly 
acidic, basic, reducing, or oxidizing conditions. In the presence of concentrated HCl, 
denitrosation can occur through a debated mechanism86,87. Under strongly basic 
conditions such as LDA or n-BuLi, N-nitrosamines display classical umpolung reactivity 
and are deprotonated at their -carbons (Scheme 1-2)88. The resulting carbanions can 
then react with halides, aldehydes, ketones, esters, ,ß-unsaturated ketones, and various 
hetero-electrophiles to form -substituted products89. Some of the products (e.g. ß-
hydroxy-, ß-keto, and ß-carboxynitrosamines) have been reported to be unstable and 
decompose via retroaldol cleavage. If not for their carcinogenicity, N-nitrosamines would 
be excellent synthons for formal -functionalization of secondary amines. The redox 
properties of N-nitrosamines can be summarized with a few representative examples. Zn 
dust in acetic acid90 was the first method to reduce N-nitrosamines to hydrazines, but 
other common reducing agents like lithium aluminum hydride91 and catalytic 
hydrogenation92 have also been used. Oxidation to N-nitroamines is also possible using 
m-chloroperoxybenzoic acid or trifluoroperacetic acid93. 
 
Scheme 1-2: Representative reactions of N-nitrosamines. N-nitrosamines can be nitrosated with conc. HCl, alkylated 
with strong base and electrophiles, reduced, and oxidized. E+ = halides, aldehydes, ketones, esters, ,ß-unsaturated 
ketones, and other electrophiles. 
R1
N
N
O
R2
R1
N
N
O
R2
R1
H
N R2
R1
N
NH2
R2
R1
N
N
O
R2
Li
O
N
OO NaN
OO
R
N
XO
Conc. HCl
R1
N
N
O
R2
E
RCO3H
E+
LDA, nBuLi, etc. Zn-HOAc, LiAlH4,
Pd-C H2,
 17 
In comparison to N-nitrosamines, N-nitrosamides are quite unstable. Due to the electron-
withdrawing effects of the nitroso group, the amide bond is particularly unstable and 
easily cleaved in water (Scheme. 1-3A). This releases a carboxylic acid and a 
diazohydroxide that loses water to form a diazonium ion. Under these conditions, an 
alcohol is formed with release of N294. In addition to hydrolytic instability, Emil White 
demonstrated that N-nitrosamides undergo thermal 1,3-sigmatropic rearrangements to 
give diazoesters (Scheme 1-3B)95,96. These ultimately decompose to an acid-carbocation 
ion pair that is transiently separated by N297. The cation is remarkably strong and 
alkylates not only the acid to make esters, but also solvents such as benzene, toluene98,99, 
pyrrole, N-methylpyrrole, and furan100. Under physiological conditions, the hydrolytic 
mechanism is expected to dominate and is explored in Chapter 2 as a possible route of 
DNA alkylation. 
 
Scheme 1-3: (A) General mechanism for hydrolysis of N-nitrosamides. (B) Thermal decomposition of N-nitrosamides 
by a [1,3] sigmatropic rearrangement resulting in an N2-separated ion pair. 
 As briefly mentioned in Section 1.1.3, the generally stable N-nitrosamines can be 
transformed into carcinogenic species through metabolism (Fig. 1-3A). -Hydroxylation 
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by cytochrome P450s produces a highly unstable -hydroxynitrosamine that 
spontaneously N-dealkylates to give an aldehyde and a diazohydroxide analogous to the 
type seen in N-nitrosamide hydrolysis. Under acidic conditions, the diazohydroxide loses 
water to form a diazonium ion that can either be hydrolyzed or bind to DNA or proteins 
in the form of adducts. As discussed in Sections 1.1.4 and 1.1.5, the accumulation of 
adducts results in mutations and changes to cellular function that can initiate cancer. 
Based on this scheme, one would expect that absence of -C-H bonds would diminish the 
carcinogenic activity of N-nitrosamines. This is indeed true as -deutero species101–103 
and those containing full branched -carbons73 generally have diminished activity. N-
nitrosoproline is an interesting case where not only does it have diminished -C-H 
content, but also is negatively charged at physiological pH, likely preventing it from 
entering cells and evading the cytochrome P450 metabolism104. This general P450-
bioactivation scheme is imperative to the overall dissertation and is further studied for the 
tobacco-specific nitrosamines, NNK and NNN, in Chapters 2-4. 
 
1.2.3 Exogenous and Endogenous Sources of N-Nitroso Compounds  
 Exposure to N-nitroso species can occur from a broad range of exogenous and 
endogenous sources. One major exogenous source is tobacco smoke. Druckrey and 
Preussmann were the first to hypothesize that amines could be nitrosated by the nitric 
oxides produced during tobacco combustion105. This was of course found to be true as 
several N-nitrosamines are found in tobacco and tobacco smoke (Section 1.4). The first 
official confirmation of environmental N-nitrosamines came from work by Ender who 
found NDMA in nitrite-preserved herrings106. This phenomenon of nitrite-induced N-
nitrosamine production, while not too surprising based on chemistry established in the 
previous section, has become a reoccurring theme for exogenous exposure. Nitrite is now 
known to form N-nitrosamines at relatively low levels (< 100 g/kg) in a variety of foods 
such cured meats, beer, bacon, dairy products, and cereal107,108. Nitrite can also be 
implicated in industrial sources of N-nitrosamines after conversion to N2O3 or NO+. A 
prominent example is the near-ubiquitous presence of NDMA at leather tanning 
factories109.  Levels ranged from 19 – 47 g/m3 and were attributed to using 
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dimethylamine sulfate as a hair-removal agent. Under the high-pH of the process and the 
NOx in forklift exhaust, dimethylamine is nitrosated to NDMA. Other occupations found 
to have N-nitrosamine contamination include rubber110 and metal-working plants111. 
Pesticides112, cosmetics113, and pharmaceuticals114 have also been found to contain N-
nitrosamines. Routes of contamination for these products include undesired contact with 
nitrosating agents, use of an N-nitrosamine during chemical synthesis, and storage 
conditions. 
 In addition to exogenous sources, endogenous formation of N-nitroso compounds 
is another large source of exposure. The primary mechanism is believed to be nitrosation 
of amines and amides consumed in the diet. The stomach is one of the most important 
sites as the acidic and aqueous conditions readily convert NO2- to N2O3 and NO+115. 
Additionally, the salt content of the stomach helps catalyze nitrosation through transient 
formation of nitrosyl halides116.  It should also be noted that dietary compounds such as 
-tocopherol, ascorbic acid, and tea extracts inhibit endogenous nitrosation117,118, making 
it difficult to predict the extent of nitrosation in an individual. One method of measuring 
this is by administering L-proline119. When ingested, L-proline is nitrosated and 
quantitatively excreted in the urine as non-carcinogenic, N-nitrosoproline. Use of this 
technique identified that nitrosation must also be occurring outside of the stomach. 
Possible extragastric mechanisms include reduction of nitrate to nitrite by bacteria120, 
synthesis of nitrate by macrophages121,122, and production of nitric oxide by endothelial 
cells123, neurons124, and bacteria125. One example of non-gastric nitrosation is production 
of NNN in the oral cavity of e-cigarette users126. NNN is not a component of e-liquids; 
however, nornicotine is, indicating that endogenous nitrosation by any of the discussed 
mechanisms may be occurring. Based on all these reports of exogenous and endogenous 
N-nitrosamine sources, amines and amides of all types are being recognized as potentially 
less inert than once believed. 
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1.3 Metabolism of N-Nitrosamines by Cytochrome P450s 
 
1.3.1 Structure and Properties of Cytochrome P450 
Cytochrome P450s are transmembrane, heme-containing monooxygenase 
enzymes that coordinate molecular oxygen to perform a variety of oxidative chemistry. 
These enzymes received their name due to the characteristic UV absorption band at 450 
nm upon exposure to carbon monoxide127–130. P450s can be further characterized and 
named by their sequence homology. For example, P450 1A1 denotes this enzyme is of 
family 1, subfamily A, and is the first enzyme of its type to be characterized. P450 2A6 
and 2A13 are most important for this dissertation and will be discussed in Section 1.3.4. 
This type of analysis has identified a total of 57 putative human P450 genes based on 
their ability to bind heme.  
Although this is a relatively small family of enzymes, P450s metabolize ~75% of 
all xenobiotics131. P450s also metabolize many endogenous substrates such as steroids, 
fatty acids, and vitamins. Within the cell, P450s are anchored to the membrane of the 
endoplasmic reticulum and the inner mitochondrial membrane. The opening to the active 
site is near the membrane interface and might explain why steroids, fatty acids, and other 
hydrophobic molecules are preferred substrates. The most important component of the 
active site is the cysteine-coordinated heme containing Fe(III), whose redox potential is 
tightly regulated through a hydrogen bond network132,133. Additionally, the active site is 
organized to facilitate proper electron, oxygen, proton, and water transport134,135. Within 
the body, P450s are mainly found in the liver; however, they are also widely distributed 
to extrahepatic tissues including, but not limited, the lungs, kidney, oral cavity, nasal 
mucosa, and bladder136. Not surprisingly, the tissue distribution of P450s localizes the 
site of action of certain xenobiotics requiring bioactivation and is a major hypothesis for 
what defines the organotropy of N-nitrosamines such as NNK137. Another important 
feature of P450s is their inducibility by substrates138. This allows for P450 expression to 
be upregulated when most needed and ensure xenobiotics are dealt with accordingly. 
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1.3.2 General Catalytic Cycle of Cytochrome P450s  
The catalytic cycle for cytochrome P450s has been well characterized139 and is 
shown in Fig 1-6.  
 
 
Figure 1-6: The general catalytic cycle of cytochrome P450 oxidation. This representation is based on a previous 
reviews136,139,140 
The cycle begins with displacement of the heme-coordinated H2O by substrate. This 
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site and theoretically keeps the enzyme from undergoing futile cycles140. Water 
displacement also converts the Fe(III) center into a pentacoordinated state with high 
reduction potential141. These events together allow NADPH-cytochrome P450 
oxidoreductase (POR) to reduce the Fe(III) to Fe(II). POR is unique in that it accepts two 
electron reductants (NADPH) but only delivers electrons to one electron acceptors 
(heme). This is accomplished by a “1-3-2-1” redox cycle utilizing FAD and FMN 
cofactors142. After reduction to Fe(II), molecular oxygen enters and coordinates to heme 
to form a ferrous-oxy radical. One more electron is transferred to the complex from POR 
to form Compound 0. After two proton transfer steps and loss of water, we arrive at 
Compound I.  Most literature indicates that Compound I conducts most of the known 
P450 reactivity but certain reports may indicate Compound 0 activity143,144. Compound I 
can be formally described as an Fe(V) complex but is more accurately described as a 
Fe(IV)oxo radical cation with charge distributed over the porphoryin ring. This high 
valency and reduction potential is ultimately the driving force in the observed P450 
chemistry. The Fe(IV)-oxo can now abstract hydrogens from carbons to produce an 
Fe(IV)-OH species and a carbon radical. The carbon radical then receives the hydroxide 
radical from the Fe-complex through an “oxygen-rebound” mechanism145,146 and 
regenerates the original Fe(III) center. To close the cycle, the substrate leaves the active 
site and is replaced by H2O; however, recent studies suggest that the product can be 
retained in the active site and undergo another round of oxidation37. This phenomenon 
will be studied in the context of NNK and NNN in Chapter 2. 
 
1.3.3 ,  ß, and -Oxidation of N-Nitrosamines 
The most important P450-mediated reaction for this thesis is C-H hydroxylation. 
For N-nitrosamines, this type of reactivity is observed most commonly at -, ß-, and -
carbons relative to the N-nitroso group. -Hydroxylation is particularly important as it 
initiates the carcinogenic mechanism of N-nitrosamines as discussed in Sections 1.1.3 
and 1.2.2 (Scheme 1-4A).  
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Scheme 1-4: Mechanisms of (A) -hydroxylation, (B) ß-oxidation and decomposition of N-nitrosodipropylamine, and 
(C) tandem -oxidation-Knoop-type ß-oxidation of even-chained N-nitrosomethylalkylamines to N-nitroso-3-
carboxypropylamine. n = any even number 
The outcomes of ß-oxidation can be more complex. In Section 1.2.2, it was 
briefly mentioned that ß-oxidized nitrosamines can be unstable and undergo retroaldol 
cleavage. Rates for decomposition typically increase with the stability of the carbonyl 
product formed73. Another outcome of ß-oxidation is the dual alkylating activity of N-
nitrosodipropylamine147. Based on the canonical -hydroxylation mechanism, one would 
only expect propylating activity, but methylation is also observed. This surprising 
behavior is explained mechanistically in Scheme 1-4B. After two sequential ß-
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5-exo-trig cyclization to form a tetrahedral intermediate, and finally collapses to produce 
acetic acid and diazomethane. This phenomenon has also been observed with other ß-
oxidized species148,149. ß-Oxidation can also lead to alkylating agents via sulfation of ß-
hydroxynitrosamines150. In opposition to these reports, ß-oxidation can also be inert as 
seen with NNN151. 
 -Oxidation has been shown to give tissue specificity to certain N-nitrosamines, 
like unsymmetrical, even-chained methylalkylnitrosamines (Section 1.2.1). In this case, 
-oxidation to an acid occurs (Scheme 1-4C). These types of molecules are then 
intercepted by Knoop-type ß-oxidation enzymes normally participating in fatty acid 
catabolism152, ultimately shortening the N-nitrosamines to N-nitrosomethyl-3-
carboxypropylamine, a known bladder carcinogen149. The carboxylate is hypothesized to 
keep the molecule outside of the cell and direct it to the bladder where it ultimately 
exhibits carcinogenic behavior. -Hydroxylation of the 3-carboxypropyl chain produces 
a species that is stabilized by equilibrating with a lactone structure153 (Scheme 1-4C). 
Together, it is apparent that all three oxidation modes described can act separately or 
together to diversify the carcinogenic activity of seemingly simple N-nitrosamines. 
 
1.3.4 P450 2A6 and 2A13 
Cytochrome P450 2A6 is of great importance to this thesis because nicotine and 
NNN are major substrates. P450 2A6 is primarily expressed in the liver, but also found in 
the trachea, lung, nasal-pharyngeal mucosa154, and esophageal mucosa155, which is 
especially important for NNN (Section 1.4.2). Levels seem to be variable and have been 
measured to be ~4 – 21% of all P450s found in liver microsomes, rivaling the levels of 
P450 3A4156,157. A crystal structure of P450 2A6 has been published and shows similar 
structure to P450 2A13 and 2E1, except for its relatively small and rigid active site158,159.  
In addition to NNN and nicotine, coumarin is the most characteristic substrate and 
has been used to understand mechanistic details of P450 2A6. Prior to establishing total 
3-hydroxycotinine/cotinine as a biomarker for P450 2A6 activity39, coumarin 7-
hydroxylation was a common in vivo human phenotypic assay160. Other substrates for 
P450 2A6 include tegafur (a 5-fluorouracil prodrug)161, pilocarpaine162, bilirubin163, and 
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NNK137. P450 2A6 also has a few known inhibitors including 8-methoxypsoralen and 
menthofuran. Nicotine has also been shown to be converted into a P450 2A6 inhibitor 
through its own oxidation164; however, the inhibitory metabolite has yet to be identified.  
Several groups have started drug discovery programs towards novel P450 2A6 inhibitors 
in hopes of reducing NNN and NNK bioactivation. A few inhibitors and docking studies 
have been reported with only limited success thus far165–167. 
P450 2A6 is highly polymorphic. To date, 86 allelic variants have been found and 
all range in their activity136. For example, CYP2A6*2168 has lowered and non-native 
catalytic activity due to a L160H mutation while CYP2A6*12168 is a splice variant that 
has lost all activity. CYP2A6*4, a complete gene deletion, is also of interest due to its 
bias towards certain ethnicities169. These polymorphisms are ultimately important 
because they have been extensively linked to smoking behavior. Lowered P450 2A6 
activity is not only correlated with reduced smoking behavior,170 nicotine metabolism171, 
and lower tobacco-specific carcinogen burden172, but also reduced risk of lung cancer 
onset40,173,174. These correlations will become important when considering biomarkers of 
NNN bioactivation in Chapter 4. 
P450 2A13 resembles P450 2A6 in many ways136. P450 2A13 has 94% sequence 
homology and has a similar, albeit slightly larger active site. Additionally, P450 2A13 is 
known to metabolize NNK137, NNN, nicotine, cotinine175, the nicotinium 5-iminium 
ion38, and coumarin176. P450 2A13 is also capable of metabolizing aflatoxin B1177, 4-
aminobiphenyl178, and phenacetin179 due to its large active site. P450 2A13 has been 
found in the trachea, lungs, and nasal mucosa at the mRNA level; however, P450 2A13 is 
almost undetectable in the liver, while P450 2A6 is primarily found there154. The 
association of P450 2A13 to the respiratory system, specifically the lungs, is one 
hypothesis for the tissue specificity of NNK and is supported by DNA adduct data found 
in Chapter 3. P450 2A13 is also polymorphic, but less so than P450 2A6 with only 21 
variants having been reported. In analogy to P450 2A6, many have reduced activity180 
and correlate to risk for lung cancer181. For that reason, many inhibitors have been tested 
such as 2-phenethyl isothiocyanate and shown to have modest effects182, however, 
selectivity is a persistent issue183. 
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1.4 Tobacco-Specific Nitrosamines 
 
1.4.1 Overview 
As discussed in Section 1.2.1, the early studies by Magee and Barnes71,72 sparked 
a movement to determine the generality and potency of N-nitrosamines as carcinogens. In 
1962, it occurred to Druckrey and Preussmann that N-nitrosamines may naturally occur 
in tobacco105. By this point, much was known about methods of N-nitrosation (Section 
1.2.2) and thus it was plausible that tobacco alkaloids such as nicotine, nornicotine, 
anabasine, and anatabine could be nitrosated during tobacco curing or pyrolysis. This led 
to the panel of putative, and eventually confirmed, class of compounds called “tobacco-
specific nitrosamines” (TSNAs, Fig. 1-7)184.  
 
Figure 1-7: Chemical structures of known TSNAs. 
Important among these was N-nitrosonornicotine (NNN), a compound previously 
shown to cause pulmonary tumors in mice185. This compound evaded detection in 
tobacco until 1974, where Hoffmann and Hecht measured NNN in both unburned 
tobacco and tobacco smoke at unprecedented levels ranging between 1.9 – 88.6 ppm; N-
nitrosamines were commonly < 0.1 ppm186. Detection of NNN and knowledge of 
established mechanisms for tertiary amine nitrosation83 led to the hypothesis that two 
more nicotine-derived N-nitrosamines are present in tobacco: 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-4-(3-pyridyl)butanal, which were 
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derived nitrosaminoaldehyde), respectively, to reflect their association with NNN (Fig. 1-
7). Indeed, both of these compounds form from the reaction of nicotine and sodium 
nitrite85, but only NNK was found in tobacco84. Follow up bioactivity assays on NNK and 
NNA demonstrated that NNK is a potent lung carcinogen and NNA is inactive187. The 
activity of NNK was remarkable because it defied common organotropy for 
unsymmetrical nitrosamines (Section 1.2.1) and was exceedingly carcinogenic compared 
to NNN. Other TSNAs such as N-nitrosoanatabine (NAT)188 and N-nitrosoanabasine 
(NAB)189 have also been found in tobacco but are weakly or non-carcinogenic. For that 
reason, the majority of research, including this dissertation, has focused on the 
metabolism, DNA adducts, and carcinogenicity of NNN and NNK190. In the next 
sections, each of these three subjects will be briefly reviewed for each compound. For a 
complete review of NNN and NNK, a number of seminal reviews are recommended190–
193.  
 
1.4.2 NNN 
 
1.4.2.1 Metabolism  
NNN is well metabolized through bioactivation and detoxification processes 
(Scheme 1-5) and <1% is excreted unmodified in the urine188. The major detoxification 
routes for NNN include N-oxidation, ß-hydroxylation, denitrosation-oxidation, and N-
glucuronidation, which will become relevant in Chapter 4. N-Oxidation of the pyridine 
ring is a minor pathway in rat and hamster liver (3-11% of dose), and is not observed in 
either monkey or human liver194,195. ß-Oxidation is an extremely minor route and has only 
been reported in one study151. Conversely, formation of norcotinine through a tandem 
denitrosation-oxidation process is observed in several cases . Three mechanisms have 
been proposed196. The first is simply denitrosation to nornicotine that is sequentially or 
processively oxidized to norcotinine. The second mechanism is the reverse where NNN is 
oxidized to N-nitrosonorcotinine and immediately denitrosated. The last mechanism 
invokes 5-radical formation that releases nitric oxide; the resulting iso-myosmine is then 
oxidized to norcotinine. Regardless of mechanism, norcotinine is relatively minor in rat 
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urine195. However, norcotinine, in combination with its N-oxide, were ~30% of all NNN 
metabolites in monkey urine197. Additionally, norcotinine was further metabolized to 3-
hydroxynorcotinine in monkeys and has potential as a human biomarker for NNN197,198. 
Lastly, N-glucuronidation of NNN is very minor, but is used to compute Total NNN, the 
only established biomarker for NNN exposure199,200. 
As expected for all N-nitrosamines, the major bioactivation route for NNN is -
hydroxylation by P450 2A6 (Scheme 1-5)103. P450 3A4 and 1A2 also perform this 
transformation but with reduced activity201,202. Oxidation can occur either at the 2- or 5-
position. 2-HydroxyNNN (1.1) undergoes spontaneous ring opening to diazohydroxide 
1.3. As discussed in Section 1.3.3, this species decomposes to a diazonium ion that can 
either hydrolyze to keto alcohol 1.8 or alkylate DNA to produce pyridyloxobutyl (POB) 
DNA adducts. There is also evidence that diazonium ion 1.5 cyclizes to oxonium ion 1.7 
before hydrolysis or adduct formation203. 5-Hydroxylation follows a similar pathway to 
produce diazonium ion 1.6, which has been shown to hydrolyze to lactol 1.9 or form 
pyridine-pyrrolidine (Py-Py) DNA adducts. Similar to 2-metabolism, it is possible 
oxonium 1.10 forms prior to hydrolysis or adduct formation. Both 1.8 and 1.9 can be 
further oxidized in vivo to keto acid 1.11 or hydroxy acid 1.12. Measurement of these of 
these acids has been achieved in rats204 and monkeys197, but as evaded measurement in 
humans due to the interference of nicotine. An approach to overcome this hurdle and use 
1.12 as a human biomarker is the focus of Chapter 4.  
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Scheme 1-5: Overall metabolism of NNN 
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The preference between 2- and 5-hydroxylation depends on the tissue, species, 
and chirality of NNN. In rats, 2-hydroxylation is a major route of metabolism in the 
esophagus and nasal mucosa while 5-hydroxylation dominates in the liver196. Because 
the esophagus and nasal mucosa are major sites of NNN carcinogenicity, DNA adducts 
resulting from 2-hydroxylation could be important. On the other hand, extensive 5-
hydroxylation is seen in target tissues of Syrian golden hamsters, namely the trachea205. 
Similarly, 5-hydroxylation was found to be a major pathway in A/J mouse lungs and 18-
day-old minipigs206,207. Monkeys also indicate preference for 5-hydroxylation as hydroxy 
acid 1.12 was ~44% of the recovered dose197; however, it is possible that most keto acid 
1.11 (2.7% of recovered dose) is reduced to hydroxy acid 1.12 before urinary excretion. 
For humans, 5-hydroxylation is presumably major based on studies with human liver 
microsomes, isolated P450s, and ex vivo esophagus tissue194,208. Work in Chapter 4 adds 
to this data through measurement of hydroxy acid 1.12 in the urine of smokeless tobacco 
users. This picture of metabolism is even more complex when considering NNN 
enantiomers with respect to the 2-center. As an example, the ratio of 2- to 5-
hydroxylation of (S)-NNN in the rat esophagus is 6-8:1 as determined by keto acid 1.11 
and keto alcohol 1.8 excretion. In contrast, (R)-NNN undergoes almost equal levels of 2- 
and 5-hydroxylation196. The enantiomeric differences in metabolism become even more 
apparent when studied at the DNA adduct level. 
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1.4.2.2 Known Adducts 
Until recently, the only NNN-derived DNA adducts measured in animals were 
four POB adducts: 7-POB-dGuo, O2-POB-Thd, O2-POB-dCyd, and O6-POB-dGuo (Fig. 
1-8).  
 
Figure 1-8: Chemical structures of NNN-derived adducts measured in vivo 
Because 7-POB-dGuo and O2-POB-dCyd have destabilized glycosidic bonds, these 
adducts are measured as 7-POB-Gua and O2-POB-Cyt after neutral thermal hydrolysis. 
All but O6-POB-dGuo were found in a 20-week study involving rats chronically treated 
with 10 ppm (S)- or (R)-NNN209. 7-POB-Gua was most abundant in the majority of 
tissues, followed by O2-POB-Thd and O2-POB-Cyt. In agreement with metabolite levels 
discussed in the previous section, (S)-NNN produced more adducts overall than (R)-NNN 
in the esophagus, liver, and oral cavity; the levels were reversed for the lung and nasal 
mucosa. A follow-up study, in which rats were treated analogously for 70 weeks, was 
conducted and similar enantioselectivity was seen except nasal respiratory mucosa, but 
not nasal olfactory mucosa, had more (S)-NNN-adducts210. 
 More recently, 5-hydroxylation was evaluated in rat and human hepatocytes, 
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dNeo, a dAdo-derived adduct, was also detected but at much lower levels in the lungs 
and nasal cavity; the adduct was not observed in the liver, esophagus, or oral cavity. Py-
Py-dIno was also observed in human liver S9 fraction and human hepatocytes, indicating 
this adduct might be major in humans exposed to NNN; however, efforts to confirm this 
have not yet been successful. In this study, considerable diastereoselectivity was seen for 
(S)- and (R)-NNN and the resulting Py-Py-dIno diastereomers but is out of scope for 
discussion here. 
 One other type of NNN-derived adducts worth noting are DNA-phosphate 
adducts. Originally discovered in the context of NNK50, many B1(POB)pB2 adducts are 
known and also form from chronic NNN treatment (Fig. 1-8)211. All 32 possible POB-
phosphotriesters were observed in rat esophageal and nasal mucosa. When taken 
together, phosphate adducts are less abundant than all POB-/Py-Py-base adducts in the 
oral cavity, nasal mucosa, and liver; the esophagus was the opposite and could indicate 
these adducts are important for carcinogenicity in this tissue. The enantiomers of NNN 
are also discriminated for these adducts. (S)-NNN forms more phosphate adducts in the 
oral cavity, esophagus, and rat liver, which mirrors the distribution of NNN-derived base 
adducts. Trends for each set of dinucleotides were also observed but are complex and 
outside the scope of this dissertation. 
  
1.4.2.3 Known Carcinogenicity 
NNN has been shown to cause tumors in a variety of tissues and animals. In rats, 
NNN mainly causes esophageal and nasal tumors212,213. As previously described, these 
tissues are also major sites of NNN metabolism and POB adduct formation, which helps 
link these lesions to carcinogenicity. A recent study evaluating (S)- and (R)-NNN 
separately showed (S)-NNN to cause >200 tumors amongst 20 rats treated chronically for 
70 week at 14 ppm in the drinking water214. In addition to the esophagus, ~40-50% of 
tumors were found within the oral cavity. (R)-NNN surprisingly showed very little 
carcinogenicity, but seemed to synergize with (S)-NNN as a racemic mixture. It was 
hypothesized that DNA adduct levels would synergize as well, however, little to no 
synergy was seen other than for O6-POB-dGuo215. In mice, NNN causes lung tumors 
 33 
when given i.p.84,185; topical application showed no dose-dependent effects216. Hamsters 
and mink were similar in that trachea and nasal cavity tumors are observed217–219. All this 
data together with the levels of human exposure and concordance with target tissues of 
tobacco-related cancers implicates NNN as a human carcinogen for esophageal and oral 
cancers and is recognized as a Group 1 carcinogen by the International Agency for 
Research on Cancer when in combination with NNK9. Given this proclamation, it may be 
surprising that, prior to this dissertation, no specific NNN bioactivation metabolites or 
DNA adducts have been measured in humans. Thus, the study conducted in Chapter 4 is 
a major step forward in our understanding of human NNN carcinogenesis in that we 
successfully measure NNN bioactivation in humans for the first time. 
 
1.4.3 NNK 
 
1.4.3.1 Metabolism 
The metabolism of NNK is shown in Scheme 1-6. Similar to NNN, NNK 
undergoes pyridine N-oxidation and denitrosation as minor in vitro detoxification 
mechanisms, but not ß-oxidation; however, -oxidation has recently been described220. 
Interestingly, only N-oxidation has been observed in vivo.  
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Scheme 1-6: Metabolism of NNK and NNAL in vivo 
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The key metabolic difference between NNK and NNN metabolism is reduction of 
NNK to NNAL (nicotine-derived nitrosaminoalcohol) by cytosolic carbonyl reductase 
(CR), 11-ß-hydroxysteroid dehydrogenase (11ß-HSD1) and aldo-keto reductases 
(AKR)26,221,222. NNAL is a significant metabolite in rat and human liver, human lung, and 
rat and human pancreas tissue190,223. While NNAL itself is not a detoxification product, 
N- or O-NNAL-glucuronide is a significant detoxification product in vivo and used as a 
urinary biomarker, along with unmodified NNAL, for NNK exposure174. This widely 
applied biomarker is referred to as Total NNAL and is now prospectively linked to lung 
cancer risk172,173. Along with N-oxidation, NNAL can also be enzymatically converted 
back to NNK in an enantioselective process. The ketone in NNK is enantiotopic and 
gives (S)- and (R)-enantiomers after enzymatic reduction. AKR1C1, 1C2, and 1C4 
produce >90% (S)-NNAL which is an agreement with the enantioselectivity of rat and 
human liver, placenta, and lung tissues222. Conversely, (R)-NNAL is 35% and 70% of 
total NNAL from purified 11ß-HSD1 and human microsome reduction, respectively26. 
While the full complexity of NNAL enantioselectivity is outside the scope of this thesis, 
it should be noted that (S)- and (R)-NNAL appear to form different types and levels of 
DNA adducts in vivo, which is a theme supported in Chapter 3. 
NNK and NNAL are both extensively -hydroxylated in vitro and in vivo. In the 
case of NNK, -hydroxylation can occur at the -methyl and -methylene position. 
While a variety of P450s are known to perform this reaction, P450 2A6 and 2A13 are 
believed to be most important due to their tissue expression and productive catalytic 
activity (Section 1.3.4)137. Hydroxylation of the -methyl position creates unstable -
hydroxynitrosamine 1.13 that decomposes by expected mechanisms (Section 1.1.3 & 
1.3.3) to the same diazonium ion, or oxonium ion, seen from 2-hydroxylation of NNN. 
Consequentially, -methyl-hydroxylation produces a series of POB-DNA adducts. 
Likewise, hydrolysis products of NNK are keto alcohol 1.8 and keto acid 1.11. -
Methylene hydroxylation produces -hydroxynitrosamine 1.14 that releases 
methyldiazohydroxide 1.18, a potent methylating agent. The keto aldehyde (1.17) 
released is a major product from in vitro P450 assays, but is commonly not observed in 
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the urine of animals and humans190. Instead, it is believed that keto aldehyde is further 
oxidized to keto acid 1.11.  
NNAL also undergoes -hydroxylation at both the -methyl or -methylene 
position. The -hydroxynitrosamine species (1.15 & 1.16) proceed through identical 
decomposition pathways as NNK to produce pyridylhydroxybutyl (PHB) DNA adducts 
and methyl adducts (Scheme. 1-6). Both hydrolysis products, lactol 1.9 and diol 1.22, are 
observed in vitro but are further oxidized in vivo to hydroxy acid 1.12 and excreted in the 
urine of animals and humans.  
Interestingly, both NNN and NNK produce the same metabolic activation 
biomarkers. Deuterated versions of keto acid and hydroxy acid were recently measured in 
the urine of smokers using [pyridine-D4]NNK cigarettes, establishing -hydroxylation of 
NNK as a major route of human metabolism224. The analogous study with [pyridine-
D4]NNN in smokeless tobacco is the focus of Chapter 4. 
 
1.4.3.2 Known Adducts 
 
NNK produces the same four POB adducts seen with NNN (Fig 1-9). When 
NNKOAc, a precursor to -methyl-hydroxyNNK, is incubated with calf thymus DNA 
and porcine liver esterase (PLE), the relative abundance of DNA adducts is 7-POB-Gua > 
O6-POB-dGuo > O2-POB-Thd > O2-POB-Cyt225. In a 20-week rat study, these relative 
levels changed to O2-POB-Thd > 7-POB-Gua > O2-POB-Cyt > O6-POB-dGuo for nearly 
every time point in the liver, lung, pancreas, nasal and oral mucosas210,226. A follow up 
70-week rat study showed the same trend except O2-POB-Cyt was not observed20, 
possibly due to its instability in vivo and during sample work-up. Attempts to stabilize 
this adduct through bisulfite-mediated deamination were mostly unsuccessful, but did 
reveal two new Cyt-adducts in vitro: N4-POB-dCyd and N3-POB-dCyd227. The change in 
relative adduct levels between in vitro and in vivo implicate a role for DNA repair of 7-
POB-dGuo and O6-POB-dGuo by spontaneous depurination and subsequent BER53 or 
direct repair by AGT228, respectively. In comparison, O2-POB-Thd appears to persist and 
possibly avoid repair; however, NER does seem to be involved in its repair193. In both 
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studies, adduct levels were most abundant in the lung, matching the established 
carcinogenicity of NNK and NNAL. 
 
Figure 1-9: Chemical structures of POB- and PHB-adducts found in NNK- and NNAL-treated rats. 
NNAL produces adducts with identical alkylation sites except with PHB instead 
of POB. NNAL is more complicated at the enantiomer level since (S)-NNAL appears to 
favor POB adduct formation while (R)-NNAL almost exclusively forms PHB adducts229. 
The prevailing hypothesis is (S)-NNAL is rapidly oxidized back to NNK at its site of 
action before exerting its alkylating effects. Notably missing from this panel of DNA 
adducts are 2-deoxyadenosine adducts; Chapter 3 fills this gap by identifying the 
structures and abundance of NNK- and NNAL-derived dAdo adducts in vitro and in rat 
liver and lung tissue. 
As briefly mentioned in the context of NNN, NNK was recently shown to produce 
a variety of POB-phosphate adducts. Similar to NNN, POB-phosphate adducts are minor 
when compared to all NNK-derived base adducts. For example, the total POB phosphate 
adduct content is 5% of all possible POB DNA adducts in vitro and 5-9% in vivo50. PHB 
phosphate adducts resulting from NNK and NNAL enantiomers have also been 
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investigated and have a shockingly high abundance. To date, >100 distinct PHB-
phosphotriesters have been detected and measured in rat tissues. For NNK-treated rats, 
B1p(PHB)B2 adducts are between 34 – 55% of all adducts in the liver and lungs51. The 
high abundance observed is consistent with NNAL being the primary metabolite of NNK 
in vivo. Consistently, B1p(PHB)B2 adducts are 30 – 51% of all adducts for rats 
chronically treated with either NNAL enantiomer230. While the biological effects of these 
adducts are not fully elucidated, their overall abundance indicates they could serve a 
critical role in carcinogenesis.  
NNK and NNAL are potent methylating agents via -methylene hydroxylation. 
While many DNA methyl adducts are possible, the two primarily studied in the context 
of NNK and NNAL are O6-Me-dGuo and 7-Me-dGuo, which are both commonly 
measured as O6-Me-Gua and 7-Me-Gua in vivo. In the same 20-week rat study mentioned 
above, O6-Me-Gua was measured as a relatively major adduct in rat liver and lungs 
during the first 5 weeks of treatment but decreased afterward. This behavior was seen 
again in the follow-up 70 week study, but was a comparatively minor adduct throughout 
the study. O6-Me-dGuo is believed to be the most mutagenic methyl adduct and 
potentially the most mutagenic NNK- and NNAL-derived adduct231. It is known that 
NNK produces this adduct within codon 12 of KRas, which induces GC to AT mutations, 
conferring constitutive activity to the protein232,233. The potency of this adduct is 
enhanced by O6-POB-dGuo potentially due to it acting as a decoy substrate for AGT, 
thus allowing O6-Me-dGuo to persist234,235. 7-Me-dGuo, on the other hand, is clearly 
more abundant in rat liver and lung tissue but has little to no effects on DNA 
replication47. It is likely that 7-Me-dGuo, similar to 7-POB-dGuo, produces an AP site 
that is rapidly repaired by BER.  
 
1.4.3.3 Known Carcinogenicity 
The major target tissue for NNK and NNAL is the lungs. Lung tumors have been 
induced in rats, mice, and hamsters regardless of the route of administration190. For 
example, tumors formed in F-344 rats when administered NNK through the drinking 
water, oral swab, gavage, and subcutaneous injection20,236–238. This indicates that local 
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application is not important and that carcinogenicity relies more on systemic distribution 
of NNK to the site of bioactivation. The potencies of NNK and NNAL were well 
demonstrated in the 70-week rat study described in the previous section20. All rats 
chronically treated with 5 ppm NNK, (S)-NNAL, or (R)-NNAL presented lung tumors at 
necropsy while no tumors were found in any control rat. The NNK-treated rats had 
statistically more carcinomas than (R)-NNAL-treated rats, but were statistically similar 
with the (S)-NNAL-treated rats. Additionally, almost all rats contained adenomas and 
adenocarcinomas and a few showed metastases to the pancreas, an organ also found to 
containing POB- and PHB-adducts. As pointed out in the previous section, the lung-
specificity of NNK and NNAL correlates with DNA adduct formation. This correlation 
was particularly strong in A/J mice where O6-Me-Gua levels directly correlated with 
tumor incidence231. Other tissues targets of NNK and NNAL include rat nasal cavity and 
hamster trachea, but generally require higher doses and subcutaneous injection190. 
As previously stated in Section 1.4.2.3, NNK and NNN have been evaluated as 
Group 1 carcinogens by IARC and NNK is heavily implicated in tobacco-related lung 
cancer. The rationale for this decision stems from the animal work described here along 
with epidemiology linking NNK exposure to cancer risk. To summarize, NNK is found in 
both unburned tobacco and tobacco smoke, is productively activated by lung-specific 
P450 2A13, forms POB-, PHB-, and methyl-DNA adducts in the lungs of animals, 
initiates lung tumors in animals treated at the dose of a chronic smoker, and introduces 
mutations in KRAS that can initiate cancer. Together we build a strong case for human 
carcinogenicity, especially since recent data supports NNK bioactivation as a major 
metabolic pathway in humans224. 
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Chapter 2 N-Nitrosamides are Minor Oxidation Products in N-Nitrosamine 
Metabolism 
 
The following chapter describes work that was previously published in Chemical 
Research in Toxicology (DOI: 10.1021/acs.chemrestox.6b00384) and is adapted with 
permission from the American Chemical Society239. The study was primarily performed 
by Erik S. Carlson and was co-authored by Pramod Upadhyaya and Stephen S. Hecht. 
This study was supported by the U.S. National Cancer Institute through grant CA-81301. 
The authors thank Bob Carlson for editorial assistance, Dr. Peter Villalta and Xun Ming 
for mass spectrometry assistance in the Analytical Biochemistry Shared Resource 
(partially supported by National Cancer Institute grant CA-77598), and Dr. Linda Von 
Weymarn and the laboratory of Dr. Sharon Murphy for allowing use of their facilities and 
providing enzymes for the cytochrome P450 incubations. We also thank Dr. Adam T. 
Zarth and Dr. Anna K. Michel for their valuable discussions and input. 
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2.1 Introduction 
As discussed in Section 1.1, tobacco use remains a public health concern as it 
causes ~30% of all cancer deaths nationwide240. NNK (2.1) and NNN (2.2) are thought to 
play a critical role in this process (Section 1.4) and require metabolic activation to -
hydroxynitrosamines by cytochrome P450s to exert their carcinogenicity (Scheme 2-
1A)190,191,241. Prior work indicates -hydroxynitrosamines have half-lives of ~5 sec242,243 
before decomposing to diazonium ions that either hydrolyze to urinary products 2.10 – 
2.12 or react with DNA and proteins to form adducts190 (Scheme 2-1A). If left 
unrepaired, DNA adducts can cause mutations in critical oncogenes such as K-ras, 
initiating tumor development. Methyl adducts such as O6-methylguanine (O6-meGua) are 
especially tumorigenic in animal models.231 For NNN, α-hydroxylation at the 2′ or 5′ 
position by P450 2A6 initiates a similar cascade leading to a variety of DNA adducts and 
urinary products (Scheme 2-1A). Both NNK- and NNN-derived DNA adducts have been 
identified and quantified in several animal models and show promise as biomarkers for 
carcinogen activation in humans.20,208,244–246 
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Scheme 2-1: (A) Established in vivo metabolism of NNK (2.1) and NNN (2.2) by P450 2A13- or P450 2A6-mediated 
oxidation, respectively. Oxidation results in unstable -hydroxynitrosamines (2.3 – 2.6) which spontaneously 
decompose to diazohydroxides (2.7 – 2.9). These either hydrolyze to products excreted in the urine (2.10 – 2.12) or 
react with DNA to form adducts. (B) Proposed P450-mediated oxidation of NNK (2.1) and NNN (2.2) to N-
nitrosamides (2.13 – 2.15) through retention of the -hydroxynitrosamines 2.3, 2.4, and 2.6 within the P450 active site.  
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While the α-hydroxynitrosamine hypothesis accounts for many of the metabolic 
products and DNA adducts produced in the metabolism of NNK, NNN, and other 
carcinogenic nitrosamines (Section 1.2.1), there are also inconsistencies with this 
hypothesis.247,248 Important among these is the short lifetime of α-hydroxynitrosamines, 
which raises questions about their ability to alkylate nuclear DNA after having been 
formed in the endoplasmic reticulum. A few studies have shown these intermediates exist 
long enough for O-glucuronidation, but measured levels were minor (<1% of the excreted 
dose)249. In addition, it is unclear if this pathway mediates detoxification or intracellular 
transportation to the nucleus249–251. Elespuru et al and Guttenplan have explored the 
hypothesis that the α-hydroxynitrosamines are further oxidized to N-nitrosamides, which 
are also direct DNA alkylating agents, but this alternate hypothesis lacks compelling 
supportive data247,248. In the study reported here, we explore this hypothesis with respect 
to NNK and NNN. We hypothesize that the α-hydroxynitrosamines could be retained in 
the active site of P450 2A13 or P450 2A6 and further oxidized to the corresponding N-
nitrosamides: 4-(methylnitrosamino)-1-(3-pyridyl)-1,4-butanedione (CH2-oxo-NNK, 
2.13), 4-(nitrosoformamido)-1-(3-pyridyl)-1-butanone (CH3-oxo-NNK, 2.14) from NNK 
and N′-nitrosonorcotinine (NNC, 2.15) from NNN.  
There is precedent for retention of substrates in P450s leading to processive 
oxidation. Metabolism of nicotine by P450 2A6 proceeds through a retained iminium ion 
or hemiaminal intermediate before releasing cotinine as the major metabolite.38 The 
Guengerich group has shown that P450 2E1 oxidizes ethanol directly to acetic acid with 
limited substrate dissociation.252 Likewise, they showed that formaldehyde and 
acetaldehyde formed in the metabolism of dimethylnitrosamine and diethylnitrosamine 
by P450 2A6 are directly oxidized to formic acid and acetic acid, respectively, without 
release of the intermediate aldehydes.253 They later proposed an alternate route for acid 
formation via an N-nitrosamide intermediate; however, it was undetectable under their 
conditions.254  
N-Nitrosamides are recognized as direct-acting carcinogens with common half-
lives being on the scale of minutes.94 Extensive research shows that their stability and 
reactivity is dependent on temperature, steric and electronic factors, and solvent 
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composition.95,97,98,255,256 In nucleophilic environments,257 the major products are the 
corresponding carboxylic acid derivatives and the diazonium species discussed earlier 
(Scheme 2-1B & Section 1.2). Thus, if released into a cell, N-nitrosamides should have 
not only better stability for traversing the hydrolytic environment of the cytosol, but also 
the ability to alkylate DNA. If N-nitrosamines are oxidized to N-nitrosamides, this could 
lead to the identification of new classes of DNA adducts and a better understanding of the 
mechanisms of N-nitrosamine carcinogenesis.  
In this study, we examine the hypothesis that NNK and NNN are metabolized to 
their corresponding N-nitrosamides. We synthesized these three N-nitrosamides and 
evaluated their half-lives and major degradation products in vitro. We describe our 
finding that CH2-oxo-NNK and NNC are minor metabolites of NNK and NNN in in vitro 
assays with human cytochrome P450s. Further evaluation of CH2-oxo-NNK 
demonstrated that it methylates dGuo in DNA and is thus potentially mutagenic. 
Together, this work provides the first account of an N-nitrosamine being converted 
metabolically to an N-nitrosamide and furthers our understanding of the metabolism of 
NNK and NNN. 
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2.2 Experimental Procedures 
 
CAUTION: NNN and NNK are carcinogenic in animal models and are IARC Group 1 
carcinogens. All nitrosamides are presumed to be carcinogens based on their structure 
and reactivity. Handle these in a well-ventilated fume hood with personal protective 
equipment and extreme care. 
 
2.2.1  Chemicals and Enzymes 
NNK, NNN, 4-oxo-4-(3-pyridyl)-butanol (keto alcohol, 2.11), 5-(3-pyridyl)-2-
hydroxytetrahydrofuran (lactol, 2.12), O6-methylguanine (O6meGua), and 
[CD3]O6meGua were synthesized as previously described.258–261 5-(3-Pyridyl)-2-
pyrrolidinone (norcotinine, 2.28) was obtained from AKos GmbH (Steinen, Germany). 
P450 2A6 Baculosomes, regeneration system and reaction buffer were available as a 
Vivid CYP450 Screening Kit from Life Technologies (Carlsbad, CA). Purified P450 
2A13 and P450 reductase were a generous gift from Dr. Sharon Murphy (University of 
Minnesota). All other chemicals and solvents used were obtained from either Sigma 
Aldrich (Milwaukee, WI) or Thermo Scientific (Waltham, MA) in reagent grade and used 
without further purification.  
 
2.2.2  General Synthetic Procedures 
NMR spectra were recorded on a Bruker 500 MHz spectrometer. Chemical shifts 
are reported as parts per million (ppm). Residual solvent peaks were used as an internal 
reference for 1H-NMR (7.26 ppm CDCl3; 2.50 ppm D6-DMSO) and 13C-NMR (77.2 ppm 
CDCl3; 39.5 ppm D6-DMSO). Peak splitting used the following abbreviations: s = 
singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of 
triplets, ddd = doublet of doublet of doublets, bs = broad singlet, and m = multiplet. High 
resolution mass spectrometry (HRMS) for selected compounds was performed on an 
LTQ Orbitrap Velos (Thermo Scientific, Carlsbad, CA) and reported as m/z. Thin-layer 
chromatography (TLC) utilized Polygram pre-coated silica gel TLC plate (40 x 80 mm, 
0.2 mm thick) with 254 nm fluorescent indicator. TLC plates were visualized with 
 46 
permanganate stain when necessary, otherwise UV lamp irradiation sufficed. Flash 
chromatography was performed on SiliCycle 60 (70-150) mesh silica gel. Reactions were 
performed under an atmosphere of N2 unless specified otherwise.  
 
2.2.3  Synthesis of Chemical Standards 
 
Methyl 4-oxo-4-(3-pyridyl)-1-butanoate (2.18): 
Sodium cyanide (0.104 g, 2.12 mmol) was suspended in anhydrous N,N-
dimethylformamide (DMF, 10 mL) and brought to 35 °C. 3-Pyridinecarboxaldehyde 
(2.27 g, 21.2 mmol, 2 mL) was added dropwise to the suspension. After 10 min of 
stirring, the resulting red solution was treated dropwise with methyl acrylate (1.90 g, 22.1 
mmol, 2 mL). Over 4 h, the solution became increasingly yellow and slightly viscous. 
The reaction was quenched with acetic acid (100 L). The resulting yellow solution was 
diluted in CH2Cl2 and washed with H2O and brine. The organic layer was dried over 
MgSO4, filtered, and concentrated in vacuo to a crude, yellow solid. Purification by 
column chromatography (50 to 100% EtOAc in hexanes) yielded pure product as a white, 
crystalline solid (3.02 g, 73.8%). 
1H-NMR (500 MHz; CDCl3): δ 9.21 (dd, J = 2.2, 0.8 Hz, 1H, 2-Py), 8.79 (dd, J = 
4.8, 1.7 Hz, 1H, 6-Py), 8.25 (ddd, J = 8.0, 2.2, 1.8 Hz, 1H, 4-Py), 7.43 (ddd, J = 8.0, 4.8, 
0.9 Hz, 1H, 5-Py), 3.72 (s, 3H, CH3), 3.33 (t, J = 6.5 Hz, 2H, COCH2CH2), 2.80 (t, J = 
6.5 Hz, 2H, COCH2CH2).; 13C-NMR (126 MHz; CDCl3): δ 197.1 (CO), 173.2 (CO2CH3), 
153.8 (2-Py), 149.8 (5-Py), 135.5 (4-Py), 131.9 (3-Py), 123.8 (5-Py), 52.1 (CH3), 33.8 
(COCH2CH2CO2), 27.9 (COCH2CH2CO2) ppm. 
 
4-Oxo-4-(3-pyridyl)-butanoic acid (2.19): 
Compound 2.18 (393 mg, 2.03 mmol) was dissolved in 1N NaOH (4 mL) and 
stirred for 3 h at room temperature. The solution went from colorless to yellow. The pH 
was adjusted to ~5-6 with an equal volume of 1N HCl and a precipitate formed. The solid 
was filtered and dried under vacuum to give a white, crystalline solid (251 mg, 69%). 
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1H-NMR (500 MHz; DMSO-d6): δ 12.18 (s, 1H, COOH), 9.14 (d, J = 2.1 Hz, 1H, 
2-Py), 8.80 (dd, J = 4.8, 1.6 Hz, 1H, 6-Py), 8.31 (dd, J = 8.0, 1.8 Hz, 1H, 4-Py), 7.57 (dd, 
J = 8.0, 4.8 Hz, 1H, 5-Py), 3.30 (t, J = 6.3 Hz, 2H, COCH2), 2.60 (t, J = 6.3 Hz, 2H, 
CH2COOH). 13C-NMR (126 MHz; DMSO): δ 198.1 (CO), 173.7 (COOH), 153.5 (2-Py), 
149.1 (6-Py), 135.4 (4-Py), 131.7 (3-Py), 123.9 (5-Py), 33.4 (COCH2), 27.7 (CH2COOH) 
ppm. 
 
Methyl 4-oxo-4-(3-pyridyl)-butanamide (2.20a): 
A solution of 2.19 (43.57 mg, 0.243 mmol), methylamine hydrochloride (25.41 
mg, 0.376 mmol), and N-hydroxysuccinimide (NHS, 45.2mg, 0.393 mmol) in anhydrous 
dimethylsulfoxide (DMSO, 3 mL) was treated with N,N-diisopropylethylamine (DIPEA, 
75.7 mg, 0.586 mmol, 102 L) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDAC, 196 mg, 1.03 mmol). The reaction was stirred for 22 h at room temperature 
before diluting with EtOAc. The mixture was washed with H2O and brine, dried over 
MgSO4, filtered, and concentrated in vacuo to yield a crude, pink oil. Purification by 
column chromatography (5:100 MeOH/CH2Cl2) yielded pure product as an off-white 
solid (32.9 mg, 70%). 
1H-NMR (500 MHz; DMSO-d6): δ 9.13 (d, J = 1.2 Hz, 1H, 2-Py), 8.79 (dd, J = 
4.7, 1.3 Hz, 1H, 6-Py), 8.30 (d, J = 7.9 Hz, 1H, 4-Py), 7.84 (s, 1H, NH), 7.57 (dd, J = 7.9, 
4.7 Hz, 1H, 5-Py), 3.27 (t, J = 6.6 Hz, 2H, COCH2), 2.57 (d, J = 4.6 Hz, 3H, CH2CONH), 
2.48 (t, J = 6.6 Hz, 2H, NHCH 3). 13C NMR (126 MHz; DMSO): δ 198.6 (CO), 171.3 
(CONH), 153.3 (6-Py), 149.1 (2-Py), 135.4 (4-Py), 131.8 (3-Py), 123.9 (5-Py), 33.7 
(COCH2), 29.0 (CH2CONH), 25.5 (NHCH3) ppm. 
 
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanedione (CH2-oxo-NNK, 2.13): 
A solution of 2.20a (31.4mg, 0.163 mmol) in a 5:1 mixture of acetic anhydride 
and acetic acid (6 mL) was brought to 0 °C. To this was added NaNO2 (30.7 mg, 0.445 
mmol) all at once. After 4 h, the mixture was poured onto ice-cold H2O. The aqueous 
mixture was extracted with CH2Cl2. The pooled organics were dried over MgSO4, 
filtered, and concentrated in vacuo to yield a crude yellow oil. Purification by column 
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chromatography on silica gel (100% EtOAc) yielded pure product as a bright, yellow oil 
(28.8 mg, 65%). 
 1H-NMR (500 MHz; CDCl3): δ 9.27 (s, 1H, 2-Py), 8.83 (d, J = 4.1 Hz, 1H, 6-Py), 
8.31 (d, J = 7.9 Hz, 1H, 4-Py), 7.48 (dd, J = 7.8, 4.9 Hz, 1H, 5-Py), 3.67 (t, J = 6.0 Hz, 
2H, COCH2), 3.55 (t, J = 6.0 Hz, 2H, CH2CON), 3.14 (s, 3H, CH3). 13C NMR (126 MHz; 
CDCl3): δ 196.7 (CO), 175.9 (CONNO), 153.5 (6-Py), 149.4 (2-Py), 135.6 (4-Py), 131.9 
(3-Py), 123.8 (5-Py), 33.0 (CH2CONNO), 28.7 (COCH2), 25.9 (NCH3) ppm. HRMS 
Calc: 222.08732, Found: 222.08719 
 
CH2-oxo-NNK from 5′-Hydroxycotinine: 
5'-Hydroxycotinine (54.23 mg, 0.282 mmol) in CH2Cl2 (25 mL) was brought to 0 
°C and treated with p-toluenesulfonic acid (111 mg, 0.584 mmol). After 5 min of stirring, 
NaNO2 (151.2 mg, 2.2 mmol) was added. Stirring was continued for 3 h before pouring 
onto ice-cold H2O. The organic layer was separated and the aqueous extracted with 
CH2Cl2. The pooled organics were dried over MgSO4, filtered, and concentrated in vacuo 
to give a crude orange oil. The product was purified by HPLC using a 150 x 4.6 mm, 5 
m, Kinetix HILIC column (Phenomenex) with 1:1 hexanes/CHCl3 and isopropanol as 
mobile phases. The gradient was 5% to 20% isopropanol over 10 min at 1 mL/min. The 
product eluted at ~4 min. The purified product was a bright, yellow oil (4.98 mg, 8%). 
 
N′-Nitrosonorcotinine (NNC, 2.15): 
A solution of norcotinine (31.4 mg, 0.163 mmol) in a 5:1 mixture of acetic 
anhydride and acetic acid (6 mL) was brought to 0 °C. To this was added NaNO2 (30.7 
mg, 0.445 mmol) all at once. After 4 h, the mixture was poured onto ice-cold H2O. The 
aqueous mixture was extracted with CH2Cl2. The pooled organics were dried over 
MgSO4, filtered, and concentrated in vacuo to yield a crude yellow oil. Purification by 
column chromatography (100% EtOAc) yielded pure product as a bright, yellow oil 
(92%). 
 1H-NMR (500 MHz; CDCl3): δ 8.56 (d, J = 4.3 Hz, 1H, 6-Py), 8.46 (d, J = 1.8 
Hz, 1H, 2-Py), 7.36 (d, J = 8.0 Hz, 1H, 4-Py), 7.30-7.28 (m, 1H, 5-Py), 5.29 (dd, J = 9.1, 
 49 
3.1 Hz, 1H, NCH), 2.97 (dt, J = 18.6, 9.4 Hz, 1H, COCH2), 2.87 (ddd, J = 18.5, 9.4, 4.0 
Hz, 1H, COCH2'), 2.66 (dq, J = 13.4, 9.4 Hz, 1H, CHCH2), 2.15-2.09 (m, 2H, CHCH2') 
ppm; 13C-NMR (126 MHz; CDCl3): δ 172.7 (CO), 149.4 (6-Py), 147.1 (2-Py), 134.1 (3-
Py), 132.7 (4-Py), 123.8 (5-Py), 55.7 (NCH), 26.2 (COCH2), 22.2 (CHCH2) ppm. HRMS 
Calc: 192.07675, Found: 192.07670 
 
2-(3-Pyridyl)-1,3-dithiane (2.21): 
A solution of 3-pyridylcarboxaldehyde (114 mg, 1.06 mmol, 100 L) and 1,3-
propanedithiol (162 mg, 1.50 mmol, 150 L) in anhydrous tetrahydrofuran (THF, 5 mL) 
was treated with BF3•Et2O (173 mg, 1.22 mmol 300 L) dropwise at room temperature. 
The mixture was then heated to reflux at 80 °C and stirred for 24 h before quenching with 
sat'd NaHCO3 solution. The aqueous phase was extracted several times with CH2Cl2. The 
pooled organic layers were washed with brine, dried over MgSO4, filtered, and 
evaporated in vacuo to give crude yellow crystals. Purification by column 
chromatography (hexanes/EtOAc 1:1) yielded the product as a fine, white powder (199.4 
mg, >95%). 
1H-NMR (500 MHz; CDCl3): δ 8.72 (d, J = 2.0 Hz, 1H, 2-Py), 8.57 (dd, J = 4.9, 
1.5 Hz, 1H, 6-Py), 7.85 (dt, J = 7.9, 2.0 Hz, 1H, 4-Py), 7.31 (dd, J = 7.9, 4.9 Hz, 1H, 5-
Py), 5.21 (s, 1H, S2CH), 3.10 (ddd, J = 14.6, 12.3, 2.4 Hz, 2H, SCH2CH2 -ax), 2.96 (dt, J 
= 14.0, 3.8 Hz, 2H, SCH2CH2 -eq), 2.22 (dtt, J = 14.2, 4.6, 2.4 Hz, 1H, SCH2CH2 -ax), 
2.02-1.93 (m, 1H, SCH2CH2 -eq) ppm; 13C NMR (126 MHz; CDCl3): δ 150.1 6-Py, 149.5 
(2-Py), 135.7 (4-Py), 135.4 (3-Py), 124.0 (5-Py), 48.8 (S2CH), 32.3 (SCH2CH2), 25.2 
(SCH2CH2) ppm. 
 
tert-Butyl 3-(2-(3-pyridyl)-1,3-dithianyl)-1-propylcarbamate (2.22): 
A solution of 2.21 (222 mg, 1.13 mmol) and tetramethylethylenediamine 
(TMEDA, 131.8 mg, 1.13 mmol, 170 L) in anhydrous THF (6 mL) was cooled to -78 °C 
and treated with n-BuLi in hexanes dropwise (1.28 mmol, 800 μL). The resulting dark red 
solution was stirred at -78 °C for 30 min before dropwise addition of 2.27 in THF (360 
mg, 1.26 mmol, 3 mL). The mixture was stirred at -78 °C for 2 h before allowing the bath 
 50 
to come to room temperature. After 14 h of stirring, the reaction was quenched with H2O. 
The aqueous phase was extracted several times with EtOAc. The pooled organics were 
dried over MgSO4, filtered, and concentrated in vacuo to give a crude, yellow oil. 
Purification by column chromatography (hexanes/EtOAc 1:1) yielded the product as 
yellow crystals (290 mg, 72.5%). 
1H-NMR (500 MHz; CDCl3): δ 9.13 (d, J = 2.1 Hz, 1H, 2-Py), 8.52 (dd, J = 4.7, 
1.6 Hz, 1H, 6-Py), 8.20 (ddd, J = 8.1, 2.4, 1.6 Hz, 1H, 4-Py), 7.32 (ddd, J = 8.1, 4.7, 0.6 
Hz, 1H, 5-Py), 4.41 (bs, 1H, NH), 3.03-3.00 (m, 2H, NHCH2), 2.72-2.61 (m, 4H, 
SCH2CH2), 2.03-2.00 (m, 2H, CCH2), 1.99-1.91 (m, 2H, SCH2CH2), 1.48-1.42 (m, 2H, 
CH2CH2CH2), 1.40 (s, 9H, C(CH3)3) ppm; 13C NMR (126 MHz; CDCl3): δ 155.9 
(NHCO), 150.8 (2-Py), 148.4 (6-Py), 137.6 (3-Py), 136.8 (4-Py), 123.4 (5-Py), 79.4 
(C(CH3)3), 56.5 (SCS), 42.5 (CCH2), 40.4 (NHCH2), 28.5 (CH3), 27.6 (SCH2CH2), 25.1 
(SCH2CH2), 24.7 (CH2CH2CH2) ppm. 
 
3-(2-(3-Pyridyl)-1,3-dithianyl)-1-propylformamide (2.23): 
A solution of 2.22 (87.6 mg, 0.247 mmol) in CH2Cl2 (3 mL) was treated with 
trifluoroacetic acid (TFA, 1.49 g, 13.1 mmol, 1 mL), which resulted in gas evolution. 
After 3 h, the solvent was evaporated in vacuo to remove excess TFA. The resulting oil 
was reconstituted in CH2Cl2 and washed with sat'd. NaHCO3 solution and brine. The 
organic layer was dried over MgSO4, filtered, and concentrated in vacuo to give a yellow 
oil. This was dissolved in MeOH (5 mL) and treated with triethylamine (29.04 mg, 0.288 
mmol, 40 L) and methyl formate (95.7 mg, 1.60 mmol, 110 L). The flask was sealed 
and heated to 55 °C with stirring. After 4 h, the mixture was concentrated in vacuo to 
yield a yellow oil. 1H-NMR indicated the product was a 9:1 mixture of cis- and trans-
formamide isomers. Purity was sufficient to carry forward without column purification. 
1H-NMR (500 MHz; CDCl3): δ 9.09 (d, J = 2.5 Hz, trans-2-Py), 9.08 (d, J = 2.1 
Hz, 1H, cis-2-Py), 8.49 (dd, J = 4.8, 1.6 Hz, trans-6-Py), 8.48 (dd, J = 4.7, 1.5 Hz, 1H, 
cis-6-Py), 8.19-8.16 (m, 1H, 4-Py), 8.07 (d, J = 1.1 Hz, 1H, cis-NHCHO), 7.92 (d, J = 
11.9 Hz, trans-NHCHO ), 7.32-7.29 (m, 1H, 5-Py), 5.94 (s, 1H, cis-NHCHO), 5.84 (s, 
trans-NHCHO ), 3.18 (q, J = 6.7 Hz, 2H, cis-CH2NH), 3.10 (q, J = 6.8 Hz, trans-
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CH2NH), 2.63 (m, 4H, SCH2), 2.02-1.99 (m, 2H, CCH2), 1.98-1.85 (m, 2H, SCH2CH2), 
1.52-1.46 (m, 2H, CH2CH2NH). 13C-NMR (126 MHz; CDCl3): δ 164.4 (trans-CHO), 
161.2 (cis-CHO), 150.5 (2-Py), 148.37 (trans-6-Py), 148.25 (cis-6-Py), 137.45 (cis-3-Py), 
137.35 (trans-3-Py), 136.73 (cis-4-Py), 136.67 (trans-4-Py), 123.33 (trans-5-Py), 123.29 
(cis-5-Py), 56.28 (cis-SCS), 56.17 (trans-SCS), 42.3 (cis-CCH2), 42.0 (trans-CCH2), 41.4 
(trans-NHCH2), 37.6 (cis-NHCH2), 27.5 (SCH2), 25.7 (trans-CH2CH2CH2), 24.85 (cis-
SCH2CH2), 24.79 (trans-SCH2CH2), 24.1 (cis-CH2CH2CH2) ppm. 
 
4-(Formamido)-1-(3-pyridyl)-1-butanone (2.24): 
N-Chlorosuccinimide (NCS, 101.8 mg, 0.762 mmol) and AgNO3 (168.5 mg, 
0.992 mmol) were suspended in 1:1 MeCN/H2O (1 mL) and cooled to 0 °C. To this was 
added a solution of 2.23 in MeCN (0.247 mmol, 1.5 mL), which resulted in immediate 
precipitate formation. After 30 min, the reaction was quenched with sat. Na2SO3, sat'd 
NaHCO3, and brine solutions in succession (1 mL each). The mixture was filtered and 
extracted with CH2Cl2. The pooled organics were dried over MgSO4, filtered, and 
concentrated in vacuo to give a crude solid. Purification by column chromatography on 
silica gel (6% MeOH in CHCl3) yielded pure product as a white solid (20.5 mg, 43% over 
three steps). 
 1H-NMR (500 MHz; CDCl3): δ 9.15 (dd, J = 2.2, 0.7 Hz, 1H, 2-Py), 8.78 (dd, J = 
5.5, 1.7 Hz, 1H, trans-6-Py), 8.77 (dd, J = 4.8, 1.7 Hz, 1H, cis-6-Py), 8.22 (dt, J = 8.0, 
2.1 Hz, 1H, trans-4-Py), 8.21 (dt, J = 8.0, 2.0 Hz, 1H, cis-4-Py), 8.18 (s, 1H, cis-CHO), 
8.06 (d, J = 11.9 Hz, trans-CHO ), 7.42 (m, 1H, 5-Py), 5.96 (s, 1H, NHCHO), 3.41 (q, J 
= 6.6 Hz, 2H, cis-CH2NH), 3.36 (q, J = 6.8 Hz, trans-CH2NH), 3.08 (t, J = 6.9 Hz, 2H, 
cis-COCH2), 3.07 (t, J = 6.8 Hz, trans-COCH2), 2.01 (quintet, J = 6.9 Hz, 2H, cis-
CH2CH2CH2), 2.01 (quintet, J = 6.9 Hz, trans-CH2CH2CH2); 13C-NMR (126 MHz; 
CDCl3): δ 198.6 (CO), 161.5 (CHO), 153.8 (6-Py), 149.7 (2-Py), 135.5 (4-Py), 132.0 (3-
Py), 123.8 (5-Py), 37.8 (CH2NH), 36.3 (COCH2), 23.5 (CH2CH2CH2) ppm.  
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tert-Butyl 3-hydroxypropyl-1-carbamate (2.26): 
A solution of 3-amino-1-propanol (4.94 g, 65.8 mmol, 2.25) and triethylamine 
(7.26 g, 71.7 mmol, 10 mL) in CH2Cl2 (175 mL) was treated with Boc anhydride (16.15 
g, 74.0 mmol,17 mL) dropwise, which resulted in vigorous gas evolution. Once bubbling 
ceased, the reaction was quenched with sat'd NH4Cl. The organic layer was collected and 
the aqueous layer was further extracted with CH2Cl2. The pooled organics were washed 
with brine, dried over MgSO4, filtered, and concentrated in vacuo. NMR indicated the 
product was sufficiently pure to be brought directly to the next step. 
1H-NMR (500 MHz; CDCl3): δ 4.84 (bs, 1H, OH), 3.67 (q, J = 5.5 Hz, 2H, 
HOCH2), 3.30 (d, J = 5.7 Hz, 2H, CH2NH), 3.07 (bs, 1H, NH), 1.68 (quintet, J = 5.7 Hz, 
2H, CH2CH2CH2), 1.46 (s, 9H, t-Bu) ppm. 13C NMR (126 MHz; CDCl3): δ 157.2 
(CONH2), 79.6 (C(CH3)3, 59.2 (HOCH2), 36.9 (CH2NH), 32.9 (CH2CH2CH2), 28.4 (t-Bu) 
ppm.  
 
tert-Butyl 3-iodopropyl-1-carbamate (2.27): 
Imidazole (Im., 5.42 g, 79.7 mmol) and triphenylphosphine (20.72 g, 79.0 mmol) 
were dissolved in CH2Cl2 (250 mL) and brought to 0 °C. To this was added I2 (20.50 g, 
80.8 mmol) scoopwise, resulting in a dark orange solution. After 20 min of stirring, 2.26 
in CH2Cl2 (11.5 g, 65.7 mmol, 50 mL) was added and the solution was allowed to come 
to room temperature. After 22 h of stirring, the mixture was filtered over Celite and 
washed with 5% Na2S2O3. The organics were dried over MgSO4, filtered, and 
concentrated in vacuo to give a yellow solid. Purification by column chromatography 
(hexanes/EtOAc 4:1) gave pure product as a light yellow solid (83.2% over 2 steps). 
1H-NMR (500 MHz; CDCl3): δ 4.63 (bs, 1H, NH), 3.19 (m, 4H, NHCH2/ICH2), 
2.00 (quintet, J = 6.6 Hz, 2H, CH2CH2CH2), 1.44 (s, 9H, t-Bu) ppm. 13C NMR (126 
MHz; CDCl3): δ 155.9 (CONH), 79.4 (C(CH3)3), 41.0 (CH2NH), 33.4 (CH2), 28.4 
(C(CH3)3), 3.1 (ICH2) ppm. 
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4-(Nitrosoformamido)-1-(3-pyridyl)-1-butanone (CH3-oxo-NNK, 2.14) 
A solution of 2.24 (31.4mg, 0.163 mmol) in a 5:1 mixture of acetic anhydride and 
acetic acid (6 mL) was brought to 0 °C. To this was added NaNO2 (30.7mg, 0.445 mmol) 
all at once. After 4 h, the mixture was poured onto ice-cold H2O. The aqueous mixture 
was extracted with CH2Cl2. The pooled organics were dried over MgSO4, filtered, and 
concentrated in vacuo to yield a crude yellow oil. Purification by column 
chromatography (100% EtOAc) yielded pure product as a bright, yellow oil (28.8mg, 
80%). 
1H-NMR (500 MHz; CDCl3): δ 10.00 (s, 1H, CHO), 9.13 (d, J = 1.1 Hz, 1H, 2-
Py)), 8.80 (dd, J = 4.8, 1.1 Hz, 1H, 6-Py), 8.24 (dd, J = 8.0, 1.6 Hz, 1H, 4-Py), 7.47 (dd, J 
= 8.0, 4.9 Hz, 1H, 5-Py), 4.11 (q, J = 7.1 Hz, 1H, NCH2), 2.92 (t, J = 6.9 Hz, 2H, 
COCH2), 1.91 (quintet, J = 6.9 Hz, 2H, CH2CH2CH2) ppm. 13-C NMR (126 MHz; 
CDCl3): δ 196.8 (CO), 168.5 (CHO), 153.1 (6-Py), 149.0 (2-Py), 136.0 (4-Py), 132.2 (3-
Py), 124.1 (5-Py), 37.6 (NCH2), 35.8 (COCH2), 20.9 (CH2CH2CH2) ppm; HRMS Calc: 
222.08732, Found: 222.08719 
 
2.2.4  Determination of t1/2 of N-Nitrosamides 
HPLC-UV analysis was performed using a 250 x 4.6 mm Gemini-NX C18 
column (Phenomenex, Torrance, CA) with the following solvent gradients for the 
analyses indicated below: (1) isocratic for 5 min at 4% B followed sequentially by a 
linear gradient to 12% B over 15 min, a 10 min hold, a linear gradient to 30% B over 10 
min, and a final linear gradient to 40% B over 2 min; (2) isocratic for 5 min at 12% B 
followed sequentially by a linear gradient to 30% B over 10 min, a linear gradient to 40% 
B over 15 min, and a final linear gradient to 70% B over 2 min. In both systems, solvent 
A was 15 mM NH4OAc and solvent B was methanol.  
For t1/2 determination, an aliquot of NNC (180 nmol) in CH2Cl2 was dried and 
reconstituted in 30 L of 0.5X P450 2A6 Reaction Buffer (Life Technologies) and 
incubated for 0 to 30 min at 37 °C. After the desired incubation time, 5 μL of sample was 
analyzed by HPLC using gradient 1. A254 was monitored and the peaks for NNC and its 
decomposition products were integrated. NNC eluted at 36.0 min. Peak area for NNC 
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was fit to a single-order exponential plot while using the 0 min incubation peak area as a 
normalizing factor. The analysis was similarly performed for CH2-oxo-NNK and CH3-
oxo-NNK, except HPLC gradient 2 was used. CH2-oxo-NNK and CH3-oxo-NNK eluted 
at 33.0 and 29.5 min, respectively. Decomposition products were identified by retention 
time comparisons and co-injection with synthetic standards.  
 
2.2.5  In vitro Detection of CH2-oxo-NNK using P450 2A13 
Incubations with P450 2A13 were performed as previously reported.262 Briefly, 
purified P450 2A13 and cytochrome P450 reductase were reconstituted with 
dilauroylphosphatidylcholine (DLPC, Sigma Aldrich) for 45 min on ice before diluting 
with Tris buffer to give a final concentration of 1 M P450 2A13, 2 M P450 reductase, 
0.1 g/L DLPC, and 50 mM Tris, pH = 7.4. To initiate the reaction, an aliquot of this 
(containing 5 pmol P450) was added to a Tris-buffered solution of NNK (4 M) and 
NADPH (0.2 mM). Final reaction volumes were always 100 L. The mixture was 
brought to 37 °C for 1–60 min before quenching with 10 L of both Ba(OH)2 and ZnSO4. 
After centrifuging the sample at 8000 g for 4 min, the supernatant was collected and 2 L 
were immediately analyzed by liquid chromatography-positive nanoelectrospray-
ionization high-resolution tandem mass spectrometry (LC-NSI+-HRMS/MS) with an 
LTQ Orbitrap Velos (Thermo Scientific, Carlsbad, CA). LC employed a hand-packed, 
Luna C18 (5 m), 100 mm x 75 m, 15 m orifice capillary column with a multi-step 
gradient. Initially, 5% B at 1 μL/min from 0–5 min was used to load the sample. 
Afterwards, the flow rate was dropped to 0.3 μL/min and a linear gradient was started 
from 5% to 20% B over 4 min, followed by a ramp to 55% B over 10 min, and re-
equilibration, where solvent A was 5 mM NH4OAc and solvent B was acetonitrile. CH2-
oxo-NNK and CH3-oxo-NNK were monitored by both full scan and MS2 fragmentation. 
Full scan was performed at a resolution of 60,000 and the accurate parent mass of both 
nitrosamides (m/z = 222.0872) was extracted at a mass tolerance of 5 ppm. For MS2 
fragmentation, parent ions were isolated (2.0 amu isolation width) and fragmented by 
collision-induced dissociation (CID) with a collision energy of 25 eV, resolution of 
15,000, and scan time of 30 ms. Accurate product ion masses from characteristic 
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transitions for CH2-oxo-NNK (m/z 222 → m/z 180.0654, -H3CNNO +OH), CH3-oxo-
NNK (m/z 222 → m/z 106.0285), NNK (m/z 208 → m/z 178.1100), and keto alcohol 2.11 
(m/z 166 → m/z 148.0756) were extracted at a mass tolerance of 5 ppm.  
 
2.2.6  In vitro Detection of NNC using P450 2A6 
Incubations with P450 2A6 were performed as described by the manufacturer 
with modifications.263 After thawing the P450 2A6 Baculosomes and Vivid-NADPH-
Regeneration System (Life Technologies) on ice, aliquots were combined and diluted 
1:10 and 1:50, respectively, with 0.5X Vivid Reaction Buffer (Life Technologies). For 
each incubation, an aliquot of the combined-enzyme system (containing 5 pmol P450) 
was added to a 0.5X Reaction-Buffered solution of NNN (4 M) and this new mixture 
was pre-incubated for 2 min at 37 °C. To initiate the reaction, an aliquot of NADP+ 
(containing 3 nmol) was added. Final reaction volumes were 100 L. The incubation and 
work-up were as described earlier for NNK-P450 2A13 incubations. NNC detection was 
performed by adapting the NNK-P450 2A13 LC-NSI+-HRMS/MS method described 
above to the accurate parent mass of NNC (m/z 192.0767) in full scan. Likewise, the MS2 
analysis was used to monitor for the accurate product ion masses from characteristic 
transitions of NNC (m/z 192 → m/z 134.04739, 162.0787), NNN (m/z 178 → m/z 
148.0994), and lactol 2.12 (m/z 166 → m/z 148.0757). 
 
2.2.7  In vitro Methylation of dGuo by CH2-oxo-NNK 
A solution of CH2-oxo-NNK in CH2Cl2 was dried under a stream of N2 and 
reconstituted in a phosphate-buffered solution of dGuo (4.34 mM dGuo, 25 mM 
NaHPO4, pH = 7.4) so that the molar ratio of CH2–oxo-NNK to dGuo was 1:1. This was 
brought to 37 °C and incubated for 18 h. To assess methylation, 200 fmol of 
[CD3]O6meGua was added as internal standard. Samples were brought up to 1 mL with 
0.1N HCl and incubated at 90 °C for 30 min. After cooling on ice, the samples were 
neutralized with 1.0N NaOH and purified by solid-phase extraction (Strata-X polymeric 
reversed phase, 30 mg, Phenomenex, Torrance, CA). Before sample addition, the 
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cartridge was activated using 1 mL each of MeOH and H2O. After sample addition, the 
cartridge was washed with 1 mL of both H2O and 10% MeOH. The sample was eluted 
and collected with 1 mL of MeOH. The collected fraction was evaporated to dryness in a 
Speedvac. The residue was reconstituted in 30 μL of H2O and analyzed by LC-
MS/MS.226 
 We used a well-established liquid chromatography-positive electrospray 
ionization-tandem mass spectrometry (LC-ESI+-MS/MS) method. A 0.5 x 150 mm 
Zorbax SB-C18, 5 μm column (Agilent, Santa Clara, CA) was eluted with a multi-step 
gradient and flow rate of 10 μL/min. After a linear gradient from 5% to 10% B over 10 
min, the eluent was brought to 40% B over 5 min, followed by a wash at 90% B and re-
equilibration, where solvent A was 15mM NH4OAc and solvent B was methanol. MS 
was performed on a TSQ Vantage triple quadrupole mass analyzer (Thermo Scientific). 
The SRM transitions were m/z 166.1 → m/z 149.1 and m/z 166.1 → m/z 124.1 for 
O6meGua and m/z 169.1 → m/z 152.1 for [CD3]O6meGua using a collision energy of 30 
eV and a 0.2 amu scan width. 
 
2.2.8  In vitro Methylation of Calf Thymus DNA by CH2-oxo-NNK 
A solution of CH2-oxo-NNK was dried under a stream of N2 and reconstituted in 
a phosphate-buffered solution of calf thymus DNA so that the ratio was 3 nmol CH2-oxo-
NNK :1 μg DNA. This was brought to 37 °C and incubated for 18 h. The aqueous sample 
was extracted twice with equal volumes of CHCl3:isoamyl alcohol (24:1). The DNA was 
precipitated by addition of an equal volume of isopropanol and gentle shaking. Isolated 
DNA was washed with 500 μL of 70% EtOH and 100% EtOH, and dried under N2. To 
assess methylation, isolated DNA was dissolved in 100 μL of sodium phosphate buffer 
(25 mM, pH = 7.4) and 200 fmol of [CD3]O6meGua was added as internal standard. The 
samples were then processed and analyzed as described above for dGuo methylation. 
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2.3 Results 
 
2.3.1  Synthesis of N-Nitrosamides 
Retrosynthetic analysis identified 3-pyridinecarboxaldehyde (2.17) as a common 
precursor for both NNK-derived nitrosamides (Scheme 2-2).  
 
Scheme 2-2:  Synthesis of Nitrosamides (A) Methyl Acrylate, NaCN, DMF, 40 °C, 4h; (B) NaOH, H2O, RT, 3h; (C) 
EDAC, NHS, MeNH2•HCl, DMSO, RT, 22h; (D) NaNO2, Ac2O:HOAc, 0 °C, 4h; (E) HS(CH2)3SH, BF3•OEt2, THF, 
80 °C, 24h; (F) (i) n-BuLi, TMEDA, THF, -78 °C, 1h; (ii) 27, THF, -78 °C to RT, 16h; (G) 25% TFA, CH2Cl2, RT, 3h; 
(H) HCO2Me, Et3N, MeOH, 55 °C, 4h; (I) AgNO3, NCS, MeCN:H2O (1:1), 0 °C, 30 min; (J) Boc2O, Et3N, CH2Cl2, 
RT, 30 min; (K) I2, PPh3, Im., CH2Cl2, 0 °C-RT, 22h 
The synthesis of CH2-oxo-NNK started with the formation of keto acid 2.19 by first 
coupling aldehyde 2.17 with methyl acrylate under Stetter conditions264, followed by 
basic hydrolysis. This method is a convenient alternative to more commonly used routes 
to this compound265,266. Keto acid 2.19 was coupled to methylamine using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDAC) and N-hydroxysuccinimide (NHS) in 
dimethylsulfoxide (DMSO), resulting in the open-chain and lactam conformers of 2.20 in 
a 2:1 ratio, respectively. Nitrosation of the open-chain conformer produced CH2-oxo-
NNK (2.13) as a single rotamer267. Nitrosation of the lactam conformer also produced 
CH2-oxo-NNK; however, new conditions using a strong acid catalyst were required. 
These conditions also degraded the product which limited the isolatable yield (<10%). 
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Ultimately, only the open-chain route was synthetically useful for CH2-oxo-NNK 
production.  
Synthesis of CH3-oxo-NNK (Scheme 2-2) started with protection of 2.17 with 
1,3-propanedithiol in nearly quantitative yield to give 2.21. This was coupled to 2.27 by 
classic umpolung chemistry268 to give 2.22 in excellent yield. Compound 2.27 was 
prepared in two steps from 2.25 on a multi-gram scale by first Boc-protecting the amine 
and then converting the alcohol to an iodide using a modified Appel reaction.269 After 
Boc removal from 2.22 and N-formylation to achieve 2.23, the dithiane group was 
oxidatively removed270 to produce 2.24 in 43% yield over 3 steps. To complete the 
synthesis, 2.24 was nitrosated to give CH3-oxo-NNK (2.14) in excellent yield.  
NNC (2.15) was prepared by nitrosation of norcotinine (2.28) in 92% yield. The 
three nitrosamides were stored in CH2Cl2 at 4 °C. They were stable for at least three 
months under these conditions. Attempts to store these compounds neat or in H2O-
miscible solvents (MeOH, MeCN, acetone, etc.) resulted in decomposition.  
 
2.3.2  Stability of N-Nitrosamides 
The stabilities of the N-nitrosamides were determined in buffers to be used in our 
P450 assays at pH 7.4 and 37 ⁰C. Reactions were followed by HPLC and major products 
were identified (Figure 2-1).  
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Figure 2-1: HPLC-UV chromatograms of the decay of (A) NNC, (B) CH2-oxo-NNK, and (C) CH3-oxo-NNK in assay 
buffer at 37 °C. Chromatograms are the 15-min, 25-min, and 10-min time point for NNC, CH2-oxo-NNK, and CH3-
oxo-NNK, respectively. All decomposition products are noted if their identity was supported by a synthetic standard.  
R
e
g
io
n
 1
R
e
g
io
n
 2
R
e
g
io
n
 3
R
e
g
io
n
 4
10:00 20:00 30:00 mm:ss
0.0
20.0
40.0
60.0
80.0
100.0
mV
Hydroxy 
Acid 2.29
Lactone
NNC
A
N
O O
R
e
g
io
n
 1
R
e
g
io
n
 2
10:00 20:00 30:00 mm:ss
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
mV
Keto Acid 2.19
CH2-oxo-NNK
B
R
e
g
io
n
 1
R
e
g
io
n
 2
R
e
g
io
n
 3
R
e
g
io
n
 4
R
e
g
io
n
 5
15:00 20:00 25:00 30:00 mm:ss
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
160.0
180.0
200.0
220.0
240.0
mV
Keto Alcohol 2.11
Keto Formate
Keto Acetate
CH3-oxo-NNK
C
N
O
O H
O
N
O
O
O
 60 
Decay curves for each nitrosamide are shown in Figure 2-2. The half-lives of CH2-oxo-
NNK and CH3-oxo-NNK were 35.5 min and 6.7 min, respectively. The half-life of NNC 
under these conditions was 12.3 min.  
 
Figure 2-2: Stability of CH2-oxo-NNK (blue diamonds), CH3-oxo-NNK (green triangles), and NNC (red squares) in 
reaction buffer at 37 °C. The half-lives were determined to be 35.5, 6.7, and 12.3 min, respectively, by HPLC-UV. 
Nitrosamide peak areas were normalized to the 0-min peak area and fit to a first-order exponential. Relative amounts of 
each nitrosamide were determined at each time point in triplicate with error bars denoting the standard deviation. 
The major product in each case was that expected by nitrosamide hydrolysis, namely keto 
acid 2.19 from CH2-oxo-NNK, keto alcohol 2.11 from CH3-oxo-NNK, and hydroxy acid 
2.29 from NNC (Scheme 2-3).  
 
Scheme 2-3: (A) Mechanism of hydrolysis of nitrosamides. Hydrolysis results in a carboxylic acid and an alcohol via a 
transient diazohydroxide that decomposes to a diazonium ion. (B) The hypothesized decomposition products of CH2-
oxo-NNK, CH3-oxo-NNK, and NNC in assay buffer (pH = 7.4) at 37 °C. 
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2.3.3  In vitro Cytochrome P450-catalyzedMetabolism of NNK to CH2-oxo-NNK 
With synthetic N-nitrosamide standards in hand and an understanding of their 
stability, we designed an assay to detect their formation by P450-mediated metabolism. 
P450 2A13 is the most efficient enzyme for α-hydroxylation of NNK and was chosen for 
this part of the study137. The NNK concentration was set at 4 μM, the Km for production 
of hydroxylated products. Samples were analyzed immediately after work-up to minimize 
nitrosamide decomposition. We used an LTQ High-Resolution Orbitrap Velos MS 
system to enhance sensitivity and minimize background noise. We monitored for the 
accurate masses of the most abundant product ions of CH2-oxo-NNK and CH3-oxo-NNK 
resulting from MS2 fragmentation, and extracted their accurate parent masses in full scan 
mode. Similar monitoring was performed for NNK and keto alcohol 2.11 to ensure 
catalytic turnover as 2.11 is the most abundant product from -methyl 
hydroxylation.137,190 
When NNK was incubated with the relevant enzymes and cofactors, we detected 
a peak that matched the accurate parent ion mass, accurate product ion mass resulting 
from MS2 of [M+H]+ = 222, and the retention time of synthetic CH2-oxo-NNK (Figure 
2-3). This peak was detectable as early as the 1-min time point, reached its maximum 
concentration at 5 min, tapered off by 10–30 min, and was nearly undetectable by 60 min 
(Figure 2-3C-F). We did not detect CH3-oxo-NNK at any time point.  
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Figure 2-3: LC-NSI-HRMS chromatograms resulting from the NNK-P450 2A13 incubations. For all sections, the top 
chromatogram is the accurate parent mass extracted from full scan for CH2-oxo-NNK and CH3-oxo-NNK. The middle 
and bottom chromatogram is the accurate product ion masses extracted from MS2 fragmentation for CH2-oxo-NNK and 
CH3-oxo-NNK, respectively. Sections are as follows: (A) CH2-oxo-NNK standard, (B) CH3-oxo-NNK standard, and 
NNK-P450 2A13 incubations containing all relevant enzymes and cofactors with incubation times of (C) 1 min, (D) 5 
min, (E) 10 min, and (F) 60 min.  RT = Retention Time; MA = Mass Area 
The signal for NNK decreased 8-fold while the signal for keto alcohol 2.11 
simultaneously increased 4-fold over the 60-min period (data not shown). This indicates 
that NNK metabolism was rapid over the assay time period. CH2-oxo-NNK was a minor 
metabolite as its signal was >4000-fold less than that of keto alcohol 2.11. No 
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metabolites were observed in control incubations lacking enzyme or cofactors (data not 
shown).  
When identical incubations containing CH2-oxo-NNK (10 nM) were performed, 
the peak area was 10-fold higher than in unspiked samples, indicating that CH2-oxo-NNK 
was recoverable under our conditions. Based on this, we estimate that CH2-oxo-NNK was 
produced at concentrations less than 1 nM in our incubations.  
 
2.3.4  In vitro Cytochrome P450-catalyzed Metabolism of NNN to NNC 
The NNN incubations were performed in essentially the same way as those with 
NNK except that P450 2A6 was used instead of P450 2A13 as it is the most efficient 
enzyme for NNN metabolism.201 Catalytic turnover was assessed by measuring lactol 
2.12, because it is the major product from 5′-hydroxylation of NNN (Scheme 2-1A).271 
We detected NNC as early as the 1-min time point (Figure 2-4). The peak matched the 
synthetic standard with respect to the accurate parent ion mass in full scan, the accurate 
mass of the most abundant product ions in the MS2 of [M + H]+ = 192, and retention 
time.  
 The NNC signal was maximal at 5 min and was approximately 1000-fold lower in 
intensity than that of lactol 2.12 (Scheme 2-1A). The concentration of NNC at the 5-min 
time point was estimated to be ~10 nM.  
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Figure 2-4: LC-NSI+-HRMS chromatograms resulting from the NNN-P450 2A6 incubations. For all sections, the top 
chromatogram is the accurate parent mass extracted from full scan for NNC. The middle and bottom chromatograms 
are two accurate product ion masses extracted from MS2 fragmentation for NNC. Sections are as follows: (A) NNC 
standard, and NNC-P450 2A6 incubations containing all relevant enzymes and cofactors with incubation times of (B) 1 
min, (C) 5 min, and (D) 10 min. RT = retention time; MA = Mass Area. 
 
2.3.5  In vitro Methylation of dGuo and DNA by CH2-oxo-NNK 
We tested the ability of CH2-oxo-NNK to methylate DNA by incubating it with a 
molar equivalent of dGuo and calf thymus DNA in phosphate buffer for 18 h. Levels of 
O6-meGua were 61.7 and 802 mol/mg Gua for the dGuo and DNA reactions, 
respectively, as determined by LC-MS/MS analysis (Figures 2-5). Formation of 7-
meGua was also noted, but not quantified.  
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Figure 2-5: LC-MS/MS chromatograms resulting from in vitro methylation of dGuo and DNA by CH2-oxo-NNK. For 
all sections, the top and middle chromatogram are the characteristic SRM transition for 7-meGua (eluting first) and 
O6meGua (eluting second). The bottom chromatogram showcases the SRM transition for the internal standard, [D3]-
O6meGua. Chromatograms are as follows: CH2-oxo-NNK:dGuo type reactions containing (A) no CH2-oxo-NNK or 
dGuo, (B) only dGuo, (C) CH2-oxo-NNK with dGuo; CH2-oxo-NNK-DNA type reactions containing (D) no CH2-oxo-
NNK or DNA, (E) calf thymus DNA, (F) CH2-oxo-NNK with calf thymus DNA. 
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2.4 Discussion 
This study presents the first account of N-nitrosamines being directly converted to 
N-nitrosamides by P450 catalysis. This breaks new ground in our knowledge of 
nitrosamine metabolism and provides an impetus to determine if this phenomenon applies 
to all nitrosamines. Specifically, we found that CH2-oxo-NNK and NNC are novel 
metabolites of P450-mediated oxidation of NNK and NNN, respectively. We did not 
observe formation of CH3-oxo-NNK, perhaps due to its short half-life (6.7 min). These 
novel metabolites also provide a potentially new mechanism for NNK- and NNN-DNA 
adduct formation (Scheme 2-1B). It has long been known that the -hydroxynitrosamine 
intermediates 2.3–2.6 (Scheme 2-1A) alkylate DNA, but their short lifetimes raise 
questions regarding their ability to traverse the hydrolytic cytosol. The detected 
nitrosamides had half-lives of 12–35 min, 100-fold more than those of the -
hydroxynitrosamines.242,243 Additionally, we showed that CH2-oxo-NNK methylates both 
dGuo and calf thymus DNA (Figure 2-5). Thus, in the case of NNK, it is plausible that 
CH2-oxo-NNK could be partially responsible for the methyl adducts previously thought 
to be formed purely by -hydroxynitrosamine 2.3. 
However, we note that both CH2-oxo-NNK and NNC are quite minor metabolites 
of NNK and NNN. It was estimated that CH2-oxo-NNK and NNC form at concentrations 
of ~1 nM and 10 nM, respectively, while keto alcohol 2.11 and lactol 2.12, the hydrolysis 
products of -hydroxyNNK and -hydroxyNNN, form at levels ~4000-fold higher. 
Because P450 2A13 and P450 2A6 are the most efficient enzymes for NNK and NNN 
oxidation and the formation of their known products keto alcohol 2.11 and lactol 2.12 
(Scheme 2-1A) was rapid, it is unlikely that the low levels of CH2-oxo-NNK and NNC 
result from low catalytic turnover. Likewise, the positive controls indicate that analyte 
recovery was achievable under our incubation conditions. We noted that formation of 
both CH2-oxo-NNK and NNC started at 1 min, peaked at 5 min, and that both were 
nearly undetectable by 30 min. This may indicate that as metabolism proceeds, newly 
formed side products and P450-related reactive-oxygen species are eliminating the 
nitrosamides via secondary reactions at a rate faster than nitrosamide formation. 
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We were not able to quantify nitrosamide formation in these reactions. We 
initially attempted quantification by HPLC-radioflow techniques, but this approach was 
not sensitive enough (LOD = 400 fmol on column, data not shown). After nitrosamide 
detection was achieved by LC-NSI+-HRMS, we attempted to trap these products with N-
-acetyl-lysine and N--acetyl-cysteine. Though trapping was achieved with synthetic 
standards, this method was unsuccessful in our assay due to low trapping efficiency and 
low sample recovery after solid phase extraction (SPE), which resulted in no analyte 
detection even with accurate mass detection (data not shown). Therefore, we settled on 
estimating formation levels by comparing peak areas to those of spiked positive controls. 
Despite being minor metabolites, the long half-lives and strong DNA-binding 
properties of the nitrosamides suggest potential biological relevance. However, 
determining whether it is more important to be low-forming and stable versus high-
forming and unstable would require further study. Additionally, though CH2-oxo-NNK 
and NNC are formed to low extents, the nitrosamide pathway may be more efficient for 
other nitrosamines. For example, studies by Chowdhury et al noted considerable, 
processive conversion of dimethylnitrosamine and diethylnitrosamine to acid byproducts 
by P450 2A6.253 It was hypothesized that the -hydroxynitrosamine intermediate 
decomposed within the active site and the resulting aldehyde was then oxidized to the 
acid. The nitrosamide hypothesis was also tested, but detection was unsuccessful. Given 
our results, it is plausible that nitrosamides were readily produced, but instability limited 
their detection. 
Our synthesis of each nitrosamide proceeded essentially as expected, except for a 
few key findings. First, our method for keto acid 2.19 (Scheme 2-2), though not entirely 
novel,272 is considerably more convenient than previously reported routes.265,266 The two-
step process involves milder conditions, gives reproducible yields, and simpler product 
purification; the latter step provides >99% pure product after only filtration. Next, the 
conversion of keto acid 2.19 to keto amide 2.20 (Scheme 2-2) was noteworthy because a 
previous study273 reported compound 2.20 to be in a ring-chain equilibrium heavily 
favoring the lactam (~6:1). In our hands, the compounds were readily separable on silica 
gel and showed no isomerization while stored neat at 2–8 °C. They were clearly distinct 
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by NMR (Figure 2-6). The open-chain product had two clean triplets integrating to 2H 
each while these signals collapsed into non-distinct multiplets integrating to 4H in the 
ring product. Additionally, the methyl resonance in the lactam is a singlet as opposed to a 
doublet in the open-chain product. In support of the results reported by Nguyen et al,273 
when we performed this reaction in solvents other than DMSO, the lactam 5′-
hydroxycotinine (2.20b, Scheme 2-2), predominated. Similarly, 2.20b was the major 
product when harsher amide coupling conditions were used, such as in situ acid chloride 
formation by oxalyl chloride or AlMe3-mediated amide formation274,275 from 2.18. It is 
apparent that DMSO and mild coupling conditions favor the open chain conformer.  
 
 
 
Figure 2-6: 1H-NMR spectra for compound 2.20a and 2.20b. The top spectra is of the open-chain conformer, while the 
bottom spectra is of the lactam conformer 
Our nitrosamides were each isolated exclusively as one rotamer. This is in 
contrast to nitrosamines that are commonly mixtures of both (E)- and (Z)-isomers. Past 
studies indicate that the (E)-conformer is electronically favored for most N-
2.20a 
2.20b 
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nitrosamides.94 Furthermore, rotation to the (Z)-conformer is commonly believed to be 
the rate-limiting step for N-nitrosamide decomposition by a pericyclic process94 and thus, 
may not be isolatable. 
The order of compound stability was CH2-oxo-NNK > NNC > CH3-oxo-NNK. 
This ranking fits with known factors contributing to nitrosamide decomposition.94,255,267 
In hydrolytic environments,257 nitrosamides with bulkier groups adjacent to the carbonyl 
group are more stable. This suggests that CH3-oxo-NNK should be the least stable, 
consistent with our observations. Likewise, bulky groups adjacent to the nitrogen 
decrease stability. This is consistent with CH2-oxo-NNK being most stable and NNC 
being relatively less stable. The decomposition products suggest that the mechanism is 
primarily hydrolysis. The products shown in Scheme 2-3B were all either the major or 
only identified product. However, for NNC and CH3-oxo-NNK, we did identify a lactone 
and ester as minor products, respectively (Figure 2-1). These presumably result from the 
extensively studied 1,3-sigmatropic rearrangement mechanism.97 Though this 
rearrangement is highly favored when nitrosamides are heated in organic solvents, 
aqueous conditions seem to favor hydrolysis and are most relevant to the in vivo 
situation.  
With data supporting the formation of CH2-oxo-NNK, we were interested in 
testing one of its possible modes of DNA damage: methylation. Methylation was 
expected since keto acid is the major product of CH2-oxo-NNK hydrolysis (Scheme 2-3). 
This implies that methane diazohydroxide, a known methylating agent, is also released. 
Our results clearly demonstrated the forrmation of O6meGua in these reactions, indicating 
that CH2-oxo-NNK methylates DNA. In addition to the methyl DNA adducts readily 
formed by CH2-oxo-NNK, both CH2-oxo-NNK and NNC could potentially generate a set 
of novel DNA adducts (Scheme 2-1B). Further studies are needed to establish the 
structures, level, and importance of possible adducts derived from the nitrosamide 
pathway.  
In summary, we hypothesized that NNK and NNN are metabolized by P450 2A13 
and P450 2A6, respectively, to their corresponding nitrosamides in vitro. We tested this 
by synthesizing CH2-oxo-NNK, CH3-oxo-NNK, and NNC and evaluating their stability 
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at pH = 7.4 and 37 °C. They were quite stable relative to the corresponding -
hydroxynitrosamines. We then showed that CH2-oxo-NNK and NNC are novel, though 
minor, metabolites of NNK and NNN, respectively, in an in vitro P450 model. With the 
knowledge that CH2-oxo-NNK has a relatively long half-life and methylates DNA, it 
could potentially play a role in the mechanism of carcinogenesis by NNK. More broadly, 
this is the first direct evidence for the conversion of N-nitrosamines to N-nitrosamides by 
P450 catalysis and provides rationale for further studies to determine whether this is a 
general transformation in N-nitrosamine metabolism. 
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2.5 Conclusion 
NNK and NNN were shown to be converted to the minor metabolites CH2-oxo-
NNK and NNC through processive P450 oxidation in vitro. To our knowledge, this is the 
first direct evidence of a nitrosamine being metabolized to a nitrosamide, a phenomenon 
that could be general for all nitrosamines. The resulting nitrosamides were generally 
more stable than the corresponding -hydroxynitrosamines, indicating the small amount 
of nitrosamides formed could still be biologically relevant if able to productively reach 
the nucleus. CH2-oxo-NNK was found to be a potent DNA methylating agent, but future 
studies are required to elucidate the full biological significance of the newly discovered 
compounds.   
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Chapter 3 Formation and Quantitation of 2-Deoxyadenosine Adducts resulting 
from NNK Bioactivation in vitro and in vivo 
 
The following chapter describes work that was previously published in Chemical 
Research in Toxicology (DOI: 10.1021/acs.chemrestox.8b00056) and is adapted with 
permission from the American Chemical Society276. The study was primarily performed 
by Erik S. Carlson and was co-authored by Pramod Upadhyaya, Peter W. Villalta, Bin 
Ma, and Stephen S. Hecht. This study was supported by the U.S. National Cancer 
Institute through grant CA-81301. The authors thank Bob Carlson for editorial assistance, 
Xun Ming and Makenzie Pillsbury for mass spectrometry assistance in the Analytical 
Biochemistry Shared Resource (partially supported by National Cancer Institute grant 
CA-77598). We also thank Dr. Adam T. Zarth for valuable discussions and NMR 
assistance. 
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3.1 Introduction 
Understanding the mechanisms of tobacco-induced carcinogenesis can potentially 
lead to new approaches to cancer prevention by identifying cigarette smokers particularly 
susceptible to lung cancer and other tobacco-related cancers. In this chapter, we will 
focus solely on the carcinogenic mechanisms of NNK (3.2). As previously mentioned 
(Section 1.4), NNK is found solely in tobacco products and readily causes 
adenocarcinoma of the lung in rats, mice, hamsters, and ferrets regardless of the route of 
administration and at relatively low doses.190 Additionally, epidemiological studies have 
correlated NNK metabolites in smokers’ urine to future lung cancer onset.172–174  
A brief overview of NNK metabolism leading to DNA adduct formation is 
presented in Scheme 3-1.  
 
Scheme 3-1: Overview of NNK (3.2) and NNAL (3.3) metabolism and DNA adduct formation in vivo. NNK is in 
enzymatic equilibrium with NNAL, which is commonly glucuronidated. Both NNK and NNAL can alternatively be 
oxidized to -hydroxynitrosamines 3.4 or 3.5. These further decompose to diazonium ions 3.8 or 3.9 and ultimately 
hydrolyze to 3.10 or 3.11, or form DNA adducts. 
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NNK is converted in humans to both enantiomers of the carcinogenic metabolite 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL, 3.3) by enzymatic carbonyl 
reduction.26,190 Studies suggest that this process may be partially reversible as (S)-NNAL 
can be enzymatically oxidized to NNK in vivo while (R)-NNAL commonly remains 
reduced.210 Both enantiomers are O- or N-glucuronidated and excreted in the urine.249 
These and unmodified NNAL serve as useful biomarkers and were the basis of the 
epidemiology studies noted above.172–174  
Both NNK and NNAL are metabolized by P450s, activating them to DNA-
alkylating agents190. These mechanisms were fully elaborated in Section 1.4, but will be 
briefly summarized here. Initial hydroxylation of the terminal methyl group of NNK or 
NNAL by either P450 2A6 or P450 2A13137 produces the unstable -hydroxy species 3.4 
or 3.5. In the previous chapter, we found that a small fraction of these may be converted 
to nitrosamides,239 but most will rapidly decompose to diazonium ions 3.8 and 3.9, which 
hydrolyze to form metabolites 3.10 and 3.11, which are excreted in the urine after further 
enzymatic processing. However, 3.8 and 3.9 can also react with DNA to form 
pyridyloxobutyl- (POB) or pyridylhydroxybutyl- (PHB) DNA adducts, respectively 
(Section 1.4.2.2 & 1.4.3.2.). The POB-DNA adducts can also be formed in vitro from 
NNKOAc, a precursor to 3.4 that does not require P450 metabolism. Analogously, the -
methylene group can be hydroxylated to ultimately form methyl DNA adducts. DNA 
adducts left unrepaired can cause mutations and initiate tumor development.190,277 To 
date, only four POB- and three PHB- base adducts have been detected and quantified in 
animal models (Figure 1-10).20,209,210,229 In addition to these base adducts, a large family 
of DNA phosphate adducts have recently been uncovered and quantified in vivo.50,51  
Notably missing from this panel of adducts are those formed with 2′-
deoxyadenosine (dAdo). Therefore, the goal of this study was to determine the structure 
and levels of dAdo-derived POB- and PHB-adducts in NNK- and NNAL-treated rats. We 
hypothesized that initial alkylation of dAdo would occur at the N1-position (Scheme 3-2).  
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Scheme 3-2: Proposed mechanism for dAdo adduct formation. After initial N1-alkylation, the resulting cationic 
intermediate either undergoes Dimroth rearrangement or deamination to yield N6-dAdo (3.20-3.21) or N1-dIno (3.22-
3.23) DNA adducts, respectively. 
This results in an unstable cationic intermediate (3.19), which can deprotonate and 
undergo spontaneous Dimroth rearrangement to give N6-dAdo adducts 3.20 and 3.21.278–
280 Alternatively, deamination via an addition-elimination mechanism can occur yielding 
N1-dIno adducts 3.22 and 3.23.280–283 In support of this general mechanism, N6-dAdo and 
N1-dIno type adducts have been found after in vitro treatment of DNA with styrene oxide 
and butadiene monoxide.284,285 Along with these adduct types, previous studies have 
identified  N3- and N7-dAdo adducts, but these are known to be unstable and generate 
abasic sites,286,287 thus were not considered in this study. N1-dIno adducts are thought to 
be potentially important as they can cause A:G mutations through Hoogstein base 
pairing,288 while N6-dAdo adducts may interfere with base pairing due to their steric bulk. 
Regardless of their potential mutagenicity, these adducts also may serve as DNA damage 
biomarkers.192 Therefore, to meet the goals of this study, we synthesized standards for all 
four proposed dAdo-derived adducts, detected POB adduct formation in vitro, and 
quantified dAdo adduct formation in the livers and lungs of rats treated chronically with 
NNK and NNAL.  
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3.2 Experimental Procedures 
 
CAUTION: NNK and NNAL are carcinogenic in animal models. NNKOAc, an activated 
form of NNK, is mutagenic and is presumed to be carcinogenic. Handle these compounds 
in a well-ventilated fume hood while wearing proper personal protective equipment. 
 
3.2.1 Chemicals and Enzymes 
NNK and NNKOAc were purchased from Toronto Research Chemicals. (S)-
NNAL, (R)-NNAL, N6-PHB-dAdo, 2-(3-pyridyl)-1,3-dithiane, tert-butyl 3-(2-(3-
pyridyl)-1,3-dithianyl)-1-propylcarbamate, and [pyridine-D4]tert-butyl 3-(2-(3-pyridyl)-
1,3-dithianyl)-1-propylcarbamate were synthesized as previously described.239,289,290 
[15N5]2′-deoxyadenosine (>99% 15N5 incorporation) was obtained from Cambridge 
Isotope Laboratories (Tewksbury, MA). 6-Chloropurine-2′-deoxyriboside was obtained 
from Carbosynth (Compton, United Kingdom). Reagents for DNA isolation were 
purchased from Qiagen (Hilden, Germany). Calf thymus DNA, phosphodiesterase II, and 
micrococcal nuclease were obtained from Worthington Biochemical Co. (Lakewood, NJ). 
Alkaline phosphatase was procured from Roche Diagnostics GmbH (Mannheim, 
Germany). Porcine liver esterase and all other chemicals and solvents were obtained from 
either Sigma Aldrich (Milwaukee, WI) or Thermo Scientific (Waltham, MA) in reagent 
grade or higher and used without further purification.  
 
3.2.2 General Synthetic Procedures 
NMR spectra were recorded on a Bruker 500 MHz spectrometer. Chemical shifts 
are reported as parts per million (ppm). Residual solvent peaks were used as an internal 
reference for 1H-NMR (7.26 ppm CDCl3; 2.50 ppm D6-DMSO) and 13C-NMR (77.2 ppm 
CDCl3; 39.5 ppm D6-DMSO). Peak splitting was abbreviated as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of triplets, ddd = 
doublet of doublet of doublets, bs = broad singlet, and m = multiplet. High resolution 
mass spectrometry (HRMS) of selected compounds was performed on an LTQ Orbitrap 
Velos (Thermo Scientific, Waltham, MA) and reported as m/z. Thin-layer 
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chromatography (TLC) utilized Polygram pre-coated silica gel TLC plate (40 x 80 mm, 
0.2 mm thick) with 254 nm fluorescent indicator. TLC plates were visualized with 
permanganate stain when necessary, otherwise UV lamp irradiation sufficed. Flash 
chromatography was performed on SiliCycle 60 (70-150) mesh silica gel. Reactions were 
performed with oven-dried glassware and under an atmosphere of N2 unless specified 
otherwise. 
 
3.2.3 Synthesis of Chemical Standards 
 
[15N5]6-N-(4-(3-pyridyl)-4-hydroxy-1-butyl)-2′-deoxyadenosine ([15N5]N6-PHB-
dAdo, 3.21): 
This was prepared as previously described290 for N6-PHB-dAdo except using 
[15N5]2′-deoxyadenosine as starting material. 
1H-NMR (500 MHz; DMSO-d6): δ 8.51 (d, J = 10.4 Hz, 1H, 2-Pyr), 8.42 (d, J = 
4.7 Hz, 1H, 6-Pyr), 8.33-8.29 (m, 1H, C8), 8.18 (s, 1H, C2), 7.87 (bs, 1H, NH), 7.71-7.69 
(m, 1H, 4-Pyr), 7.32 (dd, J = 7.8, 4.8 Hz, 1H, 5-Pyr), 6.34 (t, J = 7.0 Hz, 1H, C1’), 5.31 
(m, 2H, 3’-OH/CHOH), 5.24 (s, 1H, 5’-OH), 4.62 (m, 1H, CH), 4.41-4.40 (m, 1H, C3’), 
3.88 (d, J = 2.2 Hz, 1H, C4’), 3.62 (m, 1H, C5’), 3.50 (m, 3H, C5’/NHCH2), 2.72 (dt, J = 
12.0, 5.5 Hz, 1H, C2’), 2.25 (dd, J = 12.4, 4.4 Hz, 1H, C2’), 1.69-1.54 (m, 4H, CH2CH2). 
13C-NMR: (126 MHz; DMSO-d6): δ 152.6 (C2), 148.4 (6-Pyr), 148.1 (2-Pyr), 139.5 (C8), 
133.9 (4-Pyr), 123.5 (5-Pyr), 88.5 (C4’), 84.3 (C1’), 71.4 (C3’), 70.4 (CH), 62.4 (C5’), 
39.9 (C2’), 39.8 (NCH2), 36.8 (CHCH2)), 25.9 (NCH2CH2). 3-Pyr, C4, C5, and C6 not 
observed. HRMS: calc’d: 406.17835; found: 406.17756 
 
3-(2-(3-Pyridyl)-1,3-dithianyl)-1-propylamine (3.26): 
A solution of 3.25 (87.6 mg, 0.247 mmol) in CH2Cl2 (3 mL) was treated with 
trifluoroacetic acid (TFA, 1,49 g, 13.1 mmol, 1 mL) and stirred at room temperature. 
After 3h, the solution was concentrated by rotary evaporation to remove excess TFA. The 
resulting oil was dissolved in CH2Cl2 and washed with sat’d NaHCO3 solution and brine. 
The organic layer was then dried over MgSO4, filtered, and concentrated in vacuo to give 
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a yellow oil. Purification by column chromatography (CH2Cl2/MeOH/Et3N 85:15:1) 
yielded the product as a light, yellow oil (41.4 mg, 66%). 
1H-NMR (500 MHz; CDCl3): δ 9.11 (d, J = 1.8 Hz, 1H), 8.49-8.48 (m, 1H), 8.21 
(d, J = 8.1 Hz, 1H), 7.31 (dd, J = 8.0, 4.8 Hz, 1H), 2.72-2.64 (m, 6H), 2.10-2.06 (m, 2H), 
1.95 (dd, J = 8.9, 4.7 Hz, 2H), 1.53-1.49 (m, 2H). 13C-NMR (126 MHz; CDCl3): δ 150.5, 
148.1, 137.6, 136.9, 123.3, 56.3, 42.1, 41.2, 27.5, 26.2, 24.9 
 
6-N-(4-(3-pyridyl)-4-oxo-1-butyl)-2'deoxyadenosine (N6-POB-dAdo, 3.20): 
A solution of 3.26 (6.35 mg, 0.0250 mmol), 6-chloropurine-9-2'-deoxyriboside 
(10.4 mg, 0.0384 mmol), and iPr2EtN (7.42 mg, 0.0574 mmol,10 L) in DMSO (300 L) 
was heated to 60 °C for 16 h. The compound was crudely isolated by solid-phase 
extraction using a Strata-X 33 m polymeric reversed phase cartridge (30 mg/mL; 
Phenomenex, Torrance, CA). The cartridge was preconditioned with 1 mL of MeOH, 
followed by 1 mL of H2O. After sample addition, the cartridge was washed with 2 mL of 
H2O, 1 mL of 5% (v/v), 10%, and 50% MeOH, and eluted with 1 mL of 80% MeOH. The 
eluent was evaporated to dryness in a Speedvac. 
The isolated product was dissolved in 4:1 MeCN/H2O (1 mL) and added to a 
suspension of N-chlorosuccinimide (NCS, 11.9 mg, 0.0891 mmol) and AgNO3 (20.2 mg, 
0.1188) in 4:1 MeCN/H2O (1 mL) at 0 °C. The reaction was stirred at 0 °C for 30 min 
before quenching with sat’d Na2SO3, sat’d NaHCO3, and brine solutions in succession (1 
mL each). The product was isolated by HPLC using a 250 mm x 10 mm, 5 m, Luna C-
18 column (Phenomenex) with H2O and MeCN as mobile phases. The gradient was 30% 
to 45% MeCN over 5 min at 3 mL/min. The product eluted at 4.1 min. The product was a 
light yellow solid (2.37 mg, 24% over two steps). 
1H-NMR (500 MHz; DMSO-d6): δ 9.09 (d, J = 1.1 Hz, 1H, 2-Pyr), 8.77 (dd, J = 
4.7, 0.8 Hz, 1H, 6-Pyr), 8.32 (s, 1H, C-8), 8.25 (d, J = 8.0 Hz, 1H, 4-Pyr), 8.12 (s, 1H, C-
2), 7.94-7.93 (bs, 1H, NH), 7.54 (dd, J = 7.9, 4.8 Hz, 1H, 5-Pyr), 6.34 (t, J = 7.0 Hz, 1H, 
C1’), 5.30 (d, J = 3.9 Hz, 1H, 3’-OH), 5.22 (t, J = 5.7 Hz, 1H, 5’-OH), 4.41-4.40 (m, 1H, 
C3’), 3.88 (d, J = 2.5 Hz, 1H, C4’), 3.64-3.50 (m, 4H, C5’+ NHCH2), 3.15 (t, J = 6.9 Hz, 
2H, COCH2), 2.74-2.69 (m, 1H, C2’), 2.27-2.23 (m, 1H, C2’), 1.96 (quintet, J = 6.8 Hz, 
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2H, COCH2CH2). 13C-NMR (126 MHz; DMSO-d6): δ 199.5 (CO), 155.1 (C6), 153.7 (6-
Pyr), 152.7 (C2), 149.6 (2-Pyr), 148.5 (C4), 139.8 (C8), 135.7 (4-Pyr), 132.4 (3-Pyr), 
124.3 (5-Pyr), 120.1 (C5), 88.5 (C4’), 84.4 (C1’), 71.4 (C3’), 62.4 (C5’), 39.9 (C2’), 39.3 
(NHCH2), 36.0 (COCH2), 21.6 (COCH2CH2). HRMS: calc’d: 399.17753; found: 
399.17742 
 
[Pyridine-D4]3-(2-(3-Pyridyl)-1,3-dithianyl)-1-propylamine: 
This compound was prepared analogously to 3.26 except [pyridine-D4]3.25 
(>98% D4-incorporation) was used as starting material. The product was a light-yellow 
oil (7.67 mg, 35%). 
1H-NMR (500 MHz; CDCl3): δ 2.71-2.64 (m, 4H), 2.61 (t, J = 7.0 Hz, 2H), 2.05 
(dt, J = 7.9, 4.2 Hz, 2H), 1.98-1.93 (m, 2H), 1.47-1.41 (m, 2H). 13C-NMR (126 MHz; 
CDCl3): δ 56.5, 42.5, 41.8, 27.52, 27.42, 25.0 
 
[Pyridine-D4]6-N-(4-(3-pyridyl)-4-oxo-1-butyl)2'-deoxyadenosine ([pyridine-D4]N6-
POB-dAdo): 
This compound was prepared analogously to N6-POB-dAdo except [pyridine-
D4]3.26 (7.67mg, 0.0297 mmol) was used as the starting material. The isolated product 
was a light yellow solid (2.08 mg, 18% over two steps).  
1H-NMR (500 MHz; DMSO-d6): δ 8.32 (s, 1H, C8), 8.11 (s, 1H, C2), 7.94 (bs, 
1H, NH), 6.33 (dd, J = 7.7, 6.2 Hz, 1H, C1’), 5.33 (d, J = 0.3 Hz, 1H, 3’-OH), 5.24 (m, 
1H, 5’-OH), 4.41-4.40 (m, 1H, C3’), 3.88 (q, J = 3.4 Hz, 1H, C4’), 3.62-3.50 (m, 4H, 
C5’/COCH2), 3.15 (dd, J = 10.6, 5.9 Hz, 2H, NHCH2), 2.71-2.69 (m, 1H, C2’), 2.25 
(ddd, J = 13.1, 6.1, 2.8 Hz, 1H, C2’), 1.96 (t, J = 6.9 Hz, 2H, CH2). 13C-NMR (126 MHz; 
DMSO-d6): δ 199.6 (CO), 155.1 (C6), 152.7 (C2), 147.0 (C4), 139.7 (C8), 132.3 (3-Pyr), 
120.4 (C5), 88.5 (C4’), 84.4 (C1’), 71.4 (C3’), 62.3 (C5’), 39.6 (C2’), 39.2 (NHCH2), 
36.1 (COCH2), 23.8 (COCH2CH2). HRMS: calc’d: 403.20264; found: 403.20173 
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3',5'-bis-O-(tert-butyldimethylsilyl)-2'-deoxyinosine (3.29): 
2'-Deoxyinosine (463 mg, 1.84 mmol) and imidazole (554.5 mg, 8.14 mmol) were 
suspended in anhydrous pyridine (5 mL) and treated with tert-butyldimethylsilyl chloride 
(TBS-Cl, 585 mg, 3.88 mmol). The mixture was stirred at room temperature. After 4 h, 
the mixture became completely homogenous, and the reaction was quenched with H2O 
(10 mL). The solution was extracted twice with CH2Cl2 (15 mL). The pooled organics 
were dried over MgSO4, filtered, and concentrated. The resulting product was evaporated 
from toluene (5 mL) multiple times to remove residual pyridine. NMR indicated that 
purity was sufficient to carry forward without further purification. 
1H-NMR (500 MHz; CDCl3): δ 12.61 (s, 1H), 8.19 (s, 1H), 8.08 (s, 1H), 6.40 (t, J 
= 6.4 Hz, 1H), 4.60 (dt, J = 5.6, 3.6 Hz, 1H), 4.01 (q, J = 3.5 Hz, 1H), 3.85-3.75 (m, 2H), 
2.58-2.42 (m, 2H), 0.90 (d, J = 2.6 Hz, 18H), 0.10-0.08 (m, 12H).13C NMR (126 MHz; 
CDCl3): δ 158.7, 148.3, 144.6, 138.4, 125.0, 88.0, 84.5, 71.7, 62.7, 41.6, 26.0, 25.7, 18.4, 
18.0, -4.67, -5.40. 
 
1-N-(2,4-dinitrophenyl)-3',5'-bis-O-(tert-butyldimethylsilyl)-2'-deoxyinosine (3.30): 
A mixture of 3.29 (1384 mg, 2.14 mmol), K2CO3 (608.6 mg, 4.40 mmol), and 1-
chloro-2,4-dinitrobenzene (499.5 mg, 2.22 mmol) in DMF (10 mL) was heated to 80 °C 
for 2.5 h. The bright red solution turned orange during the reaction. After 2.5 h, the 
reaction mixture was cooled to room temperature and diluted with EtOAc (10 mL). The 
mixture was filtered over Celite and concentrated to a thick, red oil. Purification by 
column chromatography (EtOAc/hexanes 1:2 →1:1) yielded pure product as a yellow 
solid (1.26 g, 91% over 2 steps).  
1H-NMR (500 MHz; CDCl3): δ 9.05 (d, J = 1.2 Hz, 1H), 8.68-8.66 (m, 1H), 8.21 
(d, J = 10.3 Hz, 1H), 8.00 (s, 1H), 7.72-7.68 (m, 1H), 6.47-6.41 (m, 1H), 4.64-4.61 (m, 
1H), 4.06-4.04 (m, 1H), 3.89-3.79 (m, 2H), 2.60-2.45 (m, 2H), 0.93 (s, 18H), 0.13-0.11 
(m, 12H). 13C-NMR (126 MHz; CDCl3): δ 155.2, 148.2, 147.1, 146.50, 146.48, 144.72, 
144.61, 139.2, 138.9, 135.9, 131.96, 131.83, 128.75, 128.70, 124.37, 124.17, 121.43, 
121.38, 88.32, 88.18, 84.64, 84.44, 71.87, 71.71, 62.77, 62.63, 42.1, 41.8, 26.0, 25.7, 
18.4, 18.0, -4.63, -4.66, -5.37, -5.48 
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1-N-(3-hydroxypropyl)-3',5'-bis-O-(tert-butyldimethylsilyl)-2'-deoxyinosine (3.31): 
A solution of 3.30 (701.2 mg, 1.08 mmol) was dissolved in DMF (10 mL) and 
treated with 3-amino-1-propanol (810.2 mg, 10.8 mmol, 820 L). The yellow solution 
immediately became red. The solution was brought to 80 °C for 2 h, then back to room 
temperature. It was concentrated to a dark red oil. Purification by column 
chromatography (EtOAc/hexanes 2:1 → 1:0) yielded pure product as a yellow oil that 
solidified upon refrigeration (522.9 mg, 90%). 
1H-NMR (500 MHz; CDCl3): δ 8.08 (s, 1H), 8.03 (s, 1H), 6.35 (t, J = 6.4 Hz, 1H), 
4.58 (dt, J = 5.7, 3.1 Hz, 1H), 4.24 (t, J = 6.4 Hz, 2H), 3.99 (d, J = 3.4 Hz, 1H), 3.82-3.73 
(m, 2H), 3.59 (t, J = 5.5 Hz, 2H), 2.52 (dt, J = 13.0, 6.4 Hz, 1H), 2.40 (ddd, J = 13.0, 5.9, 
4.0 Hz, 1H), 1.97 (quintet, J = 5.9 Hz, 2H), 0.89 (d, J = 3.9 Hz, 18H), 0.09-0.06 (m, 
12H). 13C-NMR (126 MHz; CDCl3): δ 157.4, 147.29, 147.18, 138.5, 124.6, 88.0, 84.2, 
71.8, 62.7, 57.9, 43.1, 41.5, 32.6, 25.9, 18.4, 18.0, -4.7, -5.4 
 
1-N-(3-iodopropyl)-3',5'-bis-O-(tert-butyldimethylsilyl)-2'-deoxyinosine (3.32): 
Imidazole (69.0 mg, 1.01 mmol) and triphenylphosphine (222.7 mg, 0.849 mmol) 
were dissolved in CH2Cl2 (7 mL) and brought to 0 °C. To this was added I2 (218.8 mg, 
0.862 mmol). After 15 min, the color of the mixture changed from yellow to dark orange. 
A CH2Cl2-diluted solution of 3.31 (415.9 mg, 0.772 mmol, 7 mL) was then added. After 
10 min, the reaction was warmed to room temperature and stirred for 2 h. Then the 
mixture was filtered over Celite and washed with sat’d Na2S2O3 solution. The organic 
layer was separated and further washed with brine, dried over MgSO4, filtered, and 
concentrated to a yellow solid. Purification by column chromatography (EtOAc/hexanes 
3:1) yielded pure product as a yellow oil (461.4 mg, 95%). 
1H-NMR (500 MHz; CDCl3): δ 8.26 (s, 1H), 8.08 (s, 1H), 6.39 (t, J = 6.4 Hz, 1H), 
4.60 (dt, J = 5.9, 3.2 Hz, 1H), 4.19 (t, J = 6.6 Hz, 2H), 4.03 (q, J = 3.5 Hz, 1H), 3.85-3.76 
(m, 2H), 3.17 (t, J = 6.4 Hz, 2H), 2.59-2.43 (m, 2H), 2.33 (quintet, J = 6.5 Hz, 2H), 0.91 
(d, J = 4.7 Hz, 18H), 0.11-0.08 (m, 12H). 13C-NMR (126 MHz; CDCl3): δ 155.5, 147.5, 
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146.9, 138.3, 123.8, 88.3, 84.7, 71.8, 62.7, 47.5, 41.6, 31.9, 26.0, 25.7, 18.4, 18.0, 2.3, -
4.65, -4.78, -5.35, -5.45. 
 
1-N-(3-(2-(3-Pyridyl)-1,3-dithianyl)propyl)-3',5'-bis-O-(tert-butyldimethylsilyl)-2'-
deoxyinosine (3.34): 
A solution of 3.33239 (78.1 mg, 0.396 mmol) and tetramethylethylenediamine 
(TMEDA, 46.5 mg, 0.400 mmol, 60 L) in anhydrous THF (4 mL) was cooled to -78 °C 
and treated with n-BuLi in hexanes dropwise (0.480 mmol, 300 L). The resulting red 
solution was stirred for 10 min. A THF-diluted solution of 3.32 (228.5 mg, 0.352 mmol, 
3 mL) was then added dropwise. The mixture was stirred for 4 h and the color slowly 
transitioned from red to yellow. The reaction was quenched with H2O (5 mL) and 
warmed to room temperature. The mixture was diluted with EtOAc and washed with 
brine. The aqueous phase was extracted twice with EtOAc. The pooled organics were 
dried over MgSO4, filtered, and concentrated to an orange oil. Purification by column 
chromatography (100% EtOAc) yielded the product as a yellow solid (179.4 mg, 71%). 
1H-NMR (500 MHz; CDCl3): δ 9.12 (d, J = 1.9 Hz, 1H), 8.53 (d, J = 3.9 Hz, 1H), 
8.30 (m, 1H), 8.05 (s, 1H), 7.85 (s, 1H), 7.42 (dd, J = 8.0, 4.9 Hz, 1H), 6.38-6.33 (m, 
1H), 4.59-4.55 (m, 1H), 4.27 (s, 1H), 3.97 (m, 4H), 3.82-3.59 (m, 2H), 2.77-2.49 (m, 6H), 
2.06 (dd, J = 9.8, 6.4 Hz, 2H), 1.98-1.76 (m, 4H), 0.78 (s, 18H), 0.07 (m, 12H). 13C-NMR 
(126 MHz; CDCl3): δ 156.5, 149.0, 147.2, 146.86, 146.69, 139.5, 138.6, 138.3, 124.9, 
89.9, 84.8, 73.2, 63.5, 56.1, 46.2, 41.9, 41.7, 27.6, 26.1, 24.7, 18.6, 18.1, -4.53, -4.67, -
5.35, -5.39 
 
1-N-(4-oxo-4-(3-pyridyl)-butyl)-2'-deoxyinosine (N1-POB-dIno, 3.22): 
N-Chlorosuccinimide (NCS, 11.5 mg, 0.0861) and AgNO3 (15.5 mg, 0.0912) 
were suspended in 1:1 MeCN/H2O (400 L) and cooled to 0 °C. To this was added a 
solution of 3.34 in MeCN (11.1 mg, 0.0155 mmol, 600 L). The reaction mixture was 
stirred at 0 °C for 30 min before quenching with sat’d Na2SO3, sat’d NaHCO3, and brine 
solutions in succession (1 mL each). The mixture was diluted with CH2Cl2 (5 mL) and 
filtered. The organic layer was collected and the aqueous phase further extracted once 
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with CH2Cl2. The pooled organics were dried over MgSO4, filtered, and concentrated to a 
yellow oil. The crude product was then transferred and concentrated into a 2-mL 
polypropylene tube and reconstituted in THF (200 L). To this was added 5 L of a 
K2HPO4-buffered solution of tetra-n-butylammonium fluoride (TBAF, 3.4M, 25mM 2:1 
K2PO4, pH 7.1/THF). The solution immediately turned orange and was shaken for 24 h. 
The solvent was evaporated to give an orange solid, which was reconstituted in H2O (2 
mL) and purified by HPLC using a 250 mm x 10 mm, 5 m, Luna C-18 column 
(Phenomenex) with H2O and MeCN as mobile phases. The gradient was 30% to 45% 
MeCN over 5 min at 3 mL/min. The product eluted at 10.7 min. The product was a white 
solid (2.37 mg, 24% over two steps). 
1H-NMR (500 MHz; DMSO-d6): δ 9.09 (d, J = 1.7 Hz, 1H, 2-Pyr), 8.78 (dd, J = 
4.8, 1.6 Hz, 1H, 6-Pyr), 8.42 (s, 1H, C2), 8.31 (s, 1H, C8), 8.25 (dt, J = 8.0, 1.9 Hz, 1H, 
4-Pyr), 7.56 (dd, J = 7.9, 4.8 Hz, 1H, 5-Pyr), 6.30 (t, J = 6.9 Hz, 1H, C1’), 5.32 (d, J = 
3.7 Hz, 1H, 3’-OH), 4.97 (t, J = 5.5 Hz, 1H, 5’-OH), 4.39-4.37 (m, 1H, C3’), 4.09 (t, J = 
7.0 Hz, 2H, NCH2), 3.86 (q, J = 3.7 Hz, 1H, C4’), 3.61-3.49 (m, 2H, C5’), 3.16 (t, J = 
7.0 Hz, 2H, COCH2), 2.62 (ddd, J = 13.3, 7.2, 6.1 Hz, 1H, C2’), 2.31-2.27 (m, 1H, C2’), 
2.05 (t, J = 7.0 Hz, 2H, COCH2CH2). 13C-NMR (126 MHz; DMSO-d6): δ 198.6 (CO), 
156.1 (C6), 153.3 (6-Pyr), 149.1 (2-Pyr), 148.4 (C2), 147.1 (C4), 139.3 (C8), 135.3 (4-
Pyr), 131.8 (3-Pyr), 123.8 (5-Pyr), 123.4 (C5), 88.6 (C4’), 83.6 (C1’), 70.6 (C3’), 61.5 
(C5’), 45.2 (NCH2), 40.4 (C2’), 35.2 (COCH2), 23.5 (COCH2CH2). HRMS: calc’d: 
400.16155; found: 400.16162 
 
1-N-(4-hydroxy-4-(3-pyridyl)-butyl)- 3',5'-bis-O-(tert-butyldimethylsilyl)-2'-
deoxyinosine (3.35): 
N-Chlorosuccinimide (NCS, 12.9 mg, 0.0966) and AgNO3 (20.6 mg, 0.121) were 
suspended in 1:1 MeCN/H2O (200 L) and cooled to 0 °C. To this was added a solution 
of 3.34 in 1:1 MeCN:H2O (15.6 mg, 0.0217 mmol, 800 L). The reaction mixture was 
stirred at 0 °C for 30 min before quenching with sat’d Na2SO3, sat’d NaHCO3, and brine 
solutions in succession (1 mL each). The mixture was diluted with CH2Cl2 (5 mL) and 
filtered. The organic layer was collected and the aqueous phase extracted once with 
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CH2Cl2. The pooled organics were dried over MgSO4, filtered, and concentrated to a 
yellow oil. The crude product was then dissolved in MeOH (800 L) and treated with 
NaBH4 (7.0 mg, 0.185 mmol) at room temperature. After 1 h, the reaction mixture was 
quenched with sat’d NH4Cl, diluted with CH2Cl2 and washed with sat’d NaHCO3. The 
aqueous phase was further extracted three times with CH2Cl2. The pooled organics were 
dried over MgSO4, filtered, and concentrated to a white solid (6.15 mg). The crude 
material was carried forward without further purification. 
 
1-N-(4-hydroxy-4-(3-pyridyl)-butyl)-2'-deoxyinosine (N1-PHB-dIno, 3.23): 
A solution of 3.35 (3.4 mg, 0.00540 mmol) in THF (450 L) was treated with 
TBAF in THF (0.0150 mmol, 15 L) at room temperature. After 1 h, the reaction mixture 
was diluted with H2O and filtered through a 4 mm Acrodisc syringe filter (Sigma 
Aldrich). The resulting solution was purified by HPLC using a 250 mm x 10 mm, 5 m, 
Luna C-18 column (Phenomenex) with H2O and MeCN as mobile phases. The gradient 
was 30% to 45% MeCN over 5 min at 3 mL/min. The product eluted at 7.1 min. The 
product was a white solid (1.61 mg, 34% over 3 steps).  
1H-NMR (500 MHz; DMSO-d6): δ 8.51-8.51 (m, 1H, 2-Pyr), 8.43 (dd, J = 4.7, 
1.5 Hz, 1H, 6-Pyr), 8.40 (s, 1H, C2), 8.33 (s, 1H, C8), 7.70 (dd, J = 7.8, 1.6 Hz, 1H, 4-
Pyr), 7.33 (dd, J = 7.7, 4.7 Hz, 1H, 5-Pyr), 6.29 (dd, J = 7.7, 2.8 Hz, 1H, C1’), 5.43 (m, 
2H, 3’-OH/5’-OH), 4.85 (s, 1H, OH), 4.63-4.61 (m, 1H, CH), 4.32-4.29 (m, 1H, C3’), 
4.14-4.11 (m, 1H, C4’), 4.03-4.00 (m, 2H, NCH2), 3.48-3.41 (m, 2H, C5’), 2.76-2.70 (m, 
1H, C2’), 2.33-2.29 (m, 1H, C2’), 1.79-1.56 (m, 4H, CH2CH2). 13C-NMR (126 MHz; 
DMSO-d6): δ 156.4 (C6), 148.8 (C2), 148.5 (6-Pyr), 148.0 (2-Pyr), 146.8 (C4), 139.8 
(C8), 136.5 (3-Pyr), 133.8 (4-Pyr), 125.5 (C5), 123.7 (5-Pyr), 89.5 (C4’), 84.1 (C1’), 71.0 
(C3’), 70.2 (CH), 62.0 (C5’), 46.1 (NCH2), 36.3 (CHCH2), 26.1 (CHCH2CH2). HRMS: 
calc’d: 402.17720; found: 402.17661 
 
3.2.4 In vitro Detection of POB-DNA Adducts using NNKOAc 
Calf thymus DNA (0.99 mg) was dissolved in 1.0 mL of 25 mM phosphate 
buffer, pH 7.4. To this was added porcine liver esterase (1.33 mg, 24U) and NNKOAc (1 
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mg, 3.7 mol in 20 L of MeOH) and the mixture was placed in a 37 °C water bath with 
shaking for 24 h. Then, the solution was diluted with 1 mL of H2O and extracted twice 
with 2 mL of CHCl3/isoamyl alcohol (24:1). The DNA was precipitated by addition of 
0.4 mL of 5M NaCl and 2 mL of ice-cold isopropyl alcohol. The DNA was further 
washed with 1 mL of 70% EtOH, followed by 1 mL of 100% EtOH and dried under a 
stream of N2. DNA was stored at -20 °C. 
Isolated DNA was dissolved in 0.5 mL of 10 mM sodium succinate, 5 mM CaCl2 
buffer and incubated at 37 °C with micrococcal nuclease (30 U) and phosphodiesterase II 
(0.5 U) for 5 h, followed by 37 °C incubation with alkaline phosphatase (150 U) for 16 h. 
[Pyridine-D4]N6-POB-dA (100 fmol) was added as an internal standard. Samples were 
placed in 0.45 m Nylon SpinX centrifugal tube filters and centrifuged at 12,000 g for 10 
min. A 20 L aliquot was removed from each sample and diluted as necessary for dGuo 
quantitation by HPLC.20,225 The remaining sample was purified by solid-phase extraction 
using a Strata-X 33 m polymeric reversed phase cartridge (30 mg/mL; Phenomenex, 
Torrance, CA). The cartridge was preconditioned with 1 mL of MeOH, followed by 1 mL 
of H2O. After sample addition, the cartridge was washed with 2 mL of H2O and 1 mL of 
10% (v/v) MeOH, and eluted with 1 mL of 100% MeOH. The eluent was evaporated to 
dryness in a Speedvac. The residue was dissolved in 25 L of H2O and analyzed by 
liquid chromatography-positive electrospray ionization-tandem mass spectrometry (LC-
ESI+-MS/MS). 
A previously reported LC-ESI+-MS/MS method was performed with 
modifications.20 Briefly, a 0.5  150 mm Zorbax SB-C18, 5 μm column (Agilent, Santa 
Clara, CA) was eluted with a multi-step gradient and flow rate of 10 μL/min. After a 5-
min hold at 5% B, the eluent was brought to 65% B over 25 min, followed by a wash at 
85% B and re-equilibration, where solvent A was 15 mM NH4OAc and solvent B was 
methanol. MS was performed on a TSQ Vantage triple quadrupole mass analyzer 
(Thermo Scientific). The selected reaction monitoring (SRM) transitions were m/z 400.1 
→ m/z 284.1 for N1-POB-dIno, m/z 399.1 → m/z 265.1 for N6-POB-dAdo, and m/z 403.1 
→ m/z 269.1 for [pyridine-D4]N6-POB-dAdo using collision energies of 10, 20, and 20 
eV, respectively, and a 0.4 amu scan width for all transitions. 
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3.2.5 In vivo Detection and Quantitation of POB- and PHB-DNA Adducts in Rat 
Liver and Lung Tissues 
The lung and liver tissues were obtained from a previous study in which male F-
344 rats were treated with 5 ppm of NNK, (S)-NNAL, or (R)-NNAL in drinking water for 
50 weeks.20,225 Control rats were given unmodified tap water. DNA was isolated from 
these tissues (n = 3) using a modified Qiagen protocol that has been applied in previous 
studies.225,229,291 Isolated DNA was stored at -20 °C until further analysis. 
Isolated DNA samples were hydrolyzed and spiked with [pyridine-D4]N6-POB-
dAdo and [15N5]N6-PHB-dAdo as described above for our in vitro experiment, then 
analyzed for adducts as described previously.20,226,229,291 LC-ESI+-MS/MS conditions 
were the same as described above for our in vitro experiment except SRM transitions 
were added for N6-PHB-dAdo (m/z 401.1 → m/z 132.1), N1-PHB-dIno (m/z 402.1 → m/z 
286.1), and [15N5]N6-PHB-dAdo (m/z 406.1 → m/z 132.1) at collision energies of 26, 10, 
26 eV, respectively. Corresponding fragmentation patterns are shown in Figure 3-1. 
 
 
Figure 3-1: Structures and fragmentation patterns for the monitored N6-dAdo and N1-dIno adducts. dR: 2’-deoxyribose 
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Samples were further analyzed by an optimized liquid chromatography-positive 
nanoelectrospray ionization-high resolution tandem mass spectrometry (LC-NSI+-
HRMS/MS) method. A New Objective (Woburn, MA) emitter (75 m ID, 10 m orifice) 
was hand-packed with Luna (Phenomenex) C18, 5 m stationary phase to create a 200 
mm capillary column and a multistep gradient was used for chromatographic separation. 
With 5 mM NH4OAc and MeCN as solvents A and B, respectively, the sample was 
loaded onto the column by running 2% B at 1 L/min for 5 min. Then the flow rate was 
decreased to 0.3 L/min over 1 min, the injection valve was removed from the flow path, 
and a linear gradient was started that ramped from 2% B to 40% B over 20 min. This was 
followed by an increase to 98% B over 1 min, in which the column was washed for 2 min 
at 1 L/min before a 5 min re-equilibration at 2% B. All dAdo and dIno adducts were 
monitored by MS2 fragmentation on an Orbitrap Fusion Tribrid mass spectrometer 
(Thermo Scientific, Waltham, MA). The spray voltage was 2.2 kV, the capillary 
temperature was 300 °C, and the S-Lens RF level was 60%. Each parent ion was isolated 
(1.5 amu isolation width) and fragmented by higher-energy collision dissociation (HCD) 
at a normalized energy of 22% with a resolution of 60,000 and mass range of m/z 100 – 
425. Accurate product ion masses from characteristic transitions for N1-POB-dIno (m/z 
400 → 284.1140, 148.0757), N1-PHB-dIno (m/z 402 → 286.1296, 268.1191), N6-POB-
dAdo (m/z 399 → 283.1300, 265.1194), N6-PHB-dAdo (m/z 401 → 287.1550, 269.1445), 
[D4]N6-POB-dAdo (m/z 403 → 285.1456, 267.1350), and [15N5]N6-PHB-dAdo (m/z 406 
→ 290.1307, 272.1202) were extracted at a mass tolerance of 5 ppm. 
Quantitation of other DNA base adducts (3.12, 3.14, and 3.15) for comparison 
was performed as previously described using similar DNA isolation and LC-ESI+-
MS/MS or LC-NSI+-HRMS/MS techniques.20,50,230 
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3.3 Results 
 
3.3.1 Synthesis of DNA Adduct Standards 
N6-PHB-dAdo was previously synthesized by a 2-step procedure290 (Scheme 3-
3A) which was applied to produce a 15N5-labelled standard starting from [15N5]2′-
deoxyadenosine. 
 
Scheme 3-3: Synthetic route for N6-PHB-dAdo and N6-POB-dAdo. dAdo = 2'-deoxyadenosine, TFA = trifluoroacetic 
acid, NCS = N-chlorosuccinimide 
Initial attempts to oxidize N6-PHB-dAdo to N6-POB-dAdo were unsuccessful. 
Therefore, we devised a new route that utilized previously prepared compound 3.25 as 
starting material239 (Scheme 3-3B). After Boc deprotection by TFA, primary amine 3.26 
was coupled to 6-chloropurine-2′-deoxyribose. The synthesis was completed by a final 
oxidative dithiane deprotection270 and HPLC purification resulting in a 17% overall yield. 
A [pyridine-D4]-labeled standard was synthesized analogously using [pyridine-D4]3.25, 
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which was prepared in 2 steps239 from commercially available [pyridine-D4]3-
pyridylcarboxaldehyde. 
The synthesis of N1-POB-dIno (3.22, Scheme 3-4A) began with protection of both 
hydroxyl groups of 2′-deoxyinosine with tert-butyldimethylsilyl chloride and N1-arylation 
with 1-chloro-2,4-dinitrobenzene to produce 3.30 as a 1:1 mixture of atropisomers in 
excellent yield. Compound 3.30 was heated with 3-amino-1-propanol to give 3.31 in 
good to excellent yield through a transamidation-like mechanism.292 This was converted 
into iodide 3.32269 and further coupled to dithiane 3.34 under Seebach’s conditions268 
with good yields for both steps. Lastly, the keto and hydroxyl groups were deprotected by 
N-chlorosuccinimide oxidation and a pH-neutral, catalytic TBAF procedure,293 
respectively, to produce N1-POB-dIno (3.22) in modest yield over these two steps. 
 
Scheme 3-4: Synthetic Scheme for (A) N1-POB-dIno and (B) N1-PHB-dIno. TBSCl = tert-butyldimethylsilyl chloride, 
Imid = imidazole, Pyr = pyridine, DMF = N,N-dimethylformamide, DCM = dichloromethane, TMEDA = N,N,N,N-
tetramethylethylenediamine, TBAF = tetra-n-butylammonium fluoride. 
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N1-PHB-dIno (3.23, Scheme 3-4B) was obtained by reducing the ketone after 
deprotection of 3.34 and removing the TBS groups with an unbuffered TBAF solution 
with moderate yield. All final DNA adduct structures were confirmed by one- and two-
dimensional NMR experiments (1H, 13C, HSQC, HMBC) and high-resolution mass 
spectrometry.  
 
3.3.2 In vitro Detection of 2'-Deoxyadenosine-derived POB Adducts 
Mixtures of calf thymus DNA, NNKOAc, and porcine liver esterase were 
incubated at 37 °C and pH 7.4 for 24 h. After DNA hydrolysis and enrichment, samples 
were analyzed by LC-ESI+-MS/MS using [pyridine-D4]N6-POB-dAdo as an internal 
standard. As shown in Figure 3-2, peaks corresponding to both N6-POB-dAdo and N1-
POB-dIno were observed. Based on relative quantitation, N1-POB-dIno was 25 times 
more abundant than N6-POB-dAdo. These peaks were not detected in control incubations 
that either contained esterase alone or lacked NNKOAc. This indicates that both 
deamination and Dimroth rearrangement occur under these conditions and implicates the 
N1-position as the initial site of alkylation.  
 
Figure 3-2: Representative LC-ESI+-MS/MS chromatograms for in vitro formation of N6-POB-dAdo and N1-POB-
dIno. In each case, the top two channels are monitoring separate transitions for the N1-POB-dIno adducts (m/z 400 → 
m/z 284, 148). The bottom two channels are monitoring the N6-POB-dAdo adduct (m/z 399 → m/z 265) and its 
isotopically-labeled internal standard (m/z 403 → m/z 269). 
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3.3.3 In vivo Detection and Quantification of 2'-dAdo Adducts 
DNA was extracted from the livers and lungs of rats chronically treated with 5 
ppm NNK, (S)-NNAL, or (R)-NNAL in the drinking water for 50 weeks.20 Hydrolysis 
and analysis by LC-ESI+-MS/MS of these samples were performed as in our in vitro 
experiment. Representative chromatograms for lung samples are shown in Figure 3-3.  
 
Figure 3-3: Representative chromatograms obtained from the LC-ESI+-MS/MS analyses of (A) POB- and (B) PHB-
DNA adducts in the lungs of rats chronically treated with 5 ppm NNK for 50 weeks. In each case, the top two channels 
are monitoring separate transitions for the N1-dIno adducts (POB: m/z 400 → m/z 284, 148; PHB: m/z 402 → m/z 286, 
132). The bottom two channels are monitoring the N6-dAdo adducts (POB: m/z 399 → m/z 265; PHB: m/z 401 → m/z 
132) and its isotopically-labeled internal standard (POB: m/z 403 → m/z 269; PHB: m/z 406 → m/z 132). 
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N6-POB-dAdo and N6-PHB-dAdo were detected, while both N1-POB-dIno and N1-PHB-
dIno remained unobserved. Though a characteristic peak at 20.9 min, possibly 
corresponding to N1-POB-dIno, was found in the m/z 400 → m/z 148 SRM channel, the 
corresponding peak in the m/z 400 → m/z 284 SRM channel was not observed. The 20.9 
min peak was detected in all control samples indicating this signal is ubiquitous to the 
sample matrix. This same trend was also seen for N1-PHB-dIno. 
In the liver, levels of N6-POB-dAdo were higher in the NNK and (S)-NNAL 
treatment groups (27-32 fmol/mg DNA or 9-10.7 adducts/109 nts) as compared to the (R)-
NNAL group (4 fmol/mg DNA or 1.3 adduct/109 nts). The trend was reversed for N6-
PHB-dAdo in that levels were lower in the NNK and (S)-NNAL treatment groups (4-6 
fmol/mg DNA or 1-2 adducts/109 nts) than in the (R)-NNAL group (21-25 fmol/mg DNA 
or 7-8.3 adducts/109 nts) (Figure 3-4).  
 
Figure 3-4: Levels of N6-POB-dAdo and N6-PHB-dAdo in the liver and lung DNA of rats treated with NNK-, (S)-
NNAL, and (R)-NNAL at a dose of 5 ppm in their drinking water for 50 weeks. Values are the average of three 
replicates and error bars denote their standard deviation. POB- and PHB-adducts are represented in blue and red, 
respectively. Liver and lung tissue are differentiated by light and dark hues, respectively. 
Analysis of rat lung DNA revealed the same trend, however, at higher overall 
levels. N6-POB-dAdo was relatively abundant in the NNK and (S)-NNAL groups at 99 
fmol/mg DNA (33 adducts/109 nts) and 130 fmol/mg DNA (43.3 adducts/109 nts), 
respectively, while N6-PHB-dAdo was relatively high in the (R)-NNAL group at 125 
fmol/mg DNA (41.7 adducts/109 nts). Similar to the liver, N6-POB-dAdo was a minor 
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product after (R)-NNAL treatment (16 fmol/mg DNA or 5.3 adducts/109 nts) and N6-
PHB-dAdo was less abundant in both NNK and (S)-NNAL treatment groups (35 fmol/mg 
DNA or 11.7 adducts/109 nts). Control rats given unmodified tap water showed no adduct 
formation. To evaluate if the lack of dIno adducts was due to insufficient sensitivity, 
these samples were reanalyzed by a LC-NSI+-HRMS/MS method utilizing accurate mass 
detection. After extensive method optimization, the dIno adducts were still undetectable, 
while dAdo adducts were easily observed (Figure 3-5).  
 
Figure 3-5: Representative chromatograms obtained from the LC-NSI+-HRMS/MS analyses of POB- and PHB-DNA 
adducts in the lungs of rats chronically treated with 5 ppm NNK, (S)-NNAL, or (R)-NNAL for 50 weeks. Each channel 
is monitoring the two most abundant product ions from MS2-fragmentation of a particular DNA adduct. Adduct 
identity and product ions are the following: (A) N1-POB-dIno (400 → 283.1300, 265.1194), (B) N1-PHB-dIno (402 → 
286.1296, 268.1191), (C) N6-POB-dAdo (399 → 283.1300, 265.1194), (D) [D4]N6-POB-dAdo (403 → 285.1456, 
267.1350), (E) N6-PHB-dAdo (401 → 287.1550, 269.1445), (F) [15N5]N6-PHB-dAdo (406 → 290.1307, 272.1202). 
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3.4 Discussion 
We describe the first characterization of dAdo base adducts formed in the 
metabolism of NNK by α-hydroxylation. Synthesis of the standards N6-POB-dAdo, N6-
PHB-dAdo, N1-POB-dIno, and N1-PHB-dIno as well as stable isotope-labelled analogues 
allowed us to interrogate their presence and abundance in vitro and in vivo. Detection of 
both N6-dAdo and N1-dIno type adducts in vitro, from reactions of NNKOAc with calf 
thymus DNA, supports our hypothesized mechanism of formation involving either a 
spontaneous Dimroth rearrangement or deamination, respectively. Likewise, quantitation 
of the N6-dAdo adducts in liver and lung DNA of NNK and NNAL-treated rats supports 
the occurrence of this mechanism in vivo. 
Levels of the dAdo adducts in liver and lung of rats treated chronically with NNK 
or enantiomers of NNAL in their drinking water for 50 weeks are compared to those of 
some other characterized NNK-DNA adducts50 in Table 3-1. dAdo adduct levels were 
relatively low in both tissues, exceeding only those of O6-POB-dGuo when measurable. 
Levels were otherwise considerably lower than the 7-Gua and O2-Thd POB- and PHB-
DNA adducts. Levels of the dAdo adducts were higher in lung than in liver of the NNK 
treated rats, consistent with the comparative tissue levels of the other DNA adducts.20 
This reflects extensive metabolic activation of NNK and NNAL in rat lung upon 
treatment with relatively low doses of these carcinogens. Consistent with previous 
studies, levels of N6-POB-dAdo were higher in rats treated with NNK or (S)-NNAL than 
those found in rats treated with (R)-NNAL. In comparison, N6-PHB-dAdo amounts were 
highest in lung and liver DNA of (R)-NNAL-treated rats. These consistent findings 
presumably result from the facile conversion of (S)-NNAL to NNK in vivo and slow 
conversion of (R)-NNAL to NNK as compared to direct metabolic activation by P450s.210 
In contrast to the results of our in vitro studies, in which NNKOAc was reacted 
with calf thymus DNA, we found no evidence for the presence of either N1-dIno adduct 
in lung and liver DNA of rats treated with NNK or enantiomers of NNAL. This was in 
spite of the use of a highly sensitive and specific LC-NSI+-HRMS/MS method. The 
accurate mass detection feature of this method, when coupled with nano-spray ionization, 
guarantees both high specificity and sensitivity in detection of analytes. Even after 
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rigorous application of this method, the dIno adducts remained undetected, perhaps due 
to their efficient repair in vivo. Since other N1-dIno adducts form Hoogstein base pairs 
and partially flip outside the DNA helix, it is possible that our POB- and PHB-N1-dIno 
adducts are prime targets for base excision repair or other DNA repair 
mechanisms.193,288,294 
In our preliminary studies of the reaction of NNKOAc with calf thymus DNA, we 
observed an HPLC peak which decreased relatively rapidly with time, as peaks 
corresponding to N6-POB-dAdo and N1-POB-dIno increased (data not shown). We 
presume that this peak was N1-POB-dAdo. Ultimately, the concentration of N1-POB-dIno 
was about 25 times greater than that of N6-POB-dAdo in these in vitro reactions. This 
preference is consistent with previous studies where deamination dominated under 
neutral pH and when the N1-alkyl group possessed a nucleophilic oxygen group.280–283 In 
the case of styrene oxide, the latent alcohol was shown to facilitate the addition-
elimination mechanism of deamination,281 however, it is unclear how these results 
translate to the POB- and PHB-adducts. While Dimroth rearrangement is the most 
plausible explanation for the presence of N6-POB-dAdo and N6-PHB-dAdo, direct N6-
alkylation cannot be excluded as there is some evidence for this in reactions of acrolein295 
and 1,2,3,4-diepoxybutane296 with DNA. 
Synthesis of the adduct standards proceeded as expected with the exception of 
two major findings. First, the transformation of 3.30 (Scheme 3-4) to N1-alkyl structures 
showed a dependence on steric features. It was our original plan to directly produce 3.34 
by using 3.26 (Scheme 3-3 & 3-4) as the nucleophile, but this reaction gave little to no 
yield. We believe that steric repulsion between the dithiane and TBS-groups blocked the 
amino group from engaging the C2-position of the nucleoside. Therefore, we simplified 
the attacking group to 3-amino-1-propanol and obtained good yields of 3.31, which was 
further elaborated to the final product. Next, we found TBS-deprotection of 3.34 to be 
very sensitive to pH. After dithiane removal, unbuffered TBAF removed not only the 
TBS groups, but also the entire POB moiety, perhaps due to the basicity of fluoride. We 
surmise that N1-POB cleavage occurred via an enolate-ring closure that released dIno and 
presumably a cyclopropyl byproduct.203 When recently developed conditions using 
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catalytic fluoride and neutral pH buffer were applied,293 selective TBS cleavage was 
observed. In agreement with the enolate-ring closure hypothesis, unbuffered TBAF could 
be used to deprotect compound 3.35 with no cleavage of the PHB group.
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Table 3-1: Levels of DNA adducts in lung and liver DNA from rats chronically treated with NNK, (S)-NNAL, or (R)-NNAL (5 ppm in their drinking water) for 50 weeks. Values 
are the average of three replicates and their standard deviations. 
Tissue Treatment N6-POB-dAdo 
(fmol/mg 
DNA) 
O6-POB-dGuo 
(fmol/mg 
DNA) 
7-POB-Gua 
(fmol/mg 
DNA) 
O2-POB-Thd 
(fmol/mg DNA) 
O2-POB-Cyt 
(fmol/mg DNA) 
Liver NNK 32 ± 9 < LOQa 257 ± 32a 1531 ± 161a < LOQ 
 (S)-NNAL 27 ± 6 < LOQ 356 ± 18 1680 ± 100 < LOQ 
 (R)-NNAL 4 ± 1 < LOQ 28 ± 5 130 ± 27 < LOQ 
Lungb NNK 99 ± 3 9 ± 2 688 ± 65 4409 ± 320 < LOQ 
 (S)-NNAL 130 ± 1 10 ± 5 568 ± 68 3951 ± 328 < LOQ 
 (R)-NNAL 16 ± 7 < LOQ 136 ± 10 584 ± 45 < LOQ 
 
 
N6-PHB-dAdo 
(fmol/mg 
DNA) 
O6-PHB-dGuo 
(fmol/mg 
DNA) 
7-PHB-Gua 
(fmol/mg 
DNA) 
O2-PHB-Thd 
(fmol/mg DNA) 
 
Liver NNK 6 ± 1 < LOQ 295 ± 42 658 ± 107 
 (S)-NNAL 5 ± 1 < LOQ 133 ± 15 422 ± 36 
 (R)-NNAL 24 ± 2 < LOQ 436 ± 23 2995 ± 121 
Lungb NNK 35 ± 5 < LOQ 129 ± 34 1259 ± 66 
 (S)-NNAL 36 ± 8 < LOQ 100 ± 25 1152 ± 41 
 (R)-NNAL 125 ± 34 < LOQ 379 ± 19 6291 ± 885 
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Though adduct levels were relatively low in vivo, they may play a biological role. 
As discussed earlier, O6-POB-dGuo is found at very low or undetectable levels in vivo 
(Table 3-1); however, this adduct is thought to contribute to tumorigenesis as it is 
strongly mutagenic in a variety of cell models.193 Though efficient repair tempers this 
mutagenicity in vivo, it may increase the persistence of other adducts such as O6-Me-
dGuo, since previous work identified GC to AT transitions as a major NNK-induced 
mutation.232 The same study also found moderate levels of AT to GC mutations, perhaps 
due to the persistence of N6-dAdo adducts. This is reasonable as the bulky N6-linkage 
could block base pairing with Thd. In studies with 1,3-butadiene, particular N6-dAdo 
adducts were bypassed by several DNA polymerases and in some cases caused mutations 
in vitro.297 However, in a follow-up study,298 the same adducts were found to be far less 
mutagenic, possibly due to base-excision repair. In studies with polycyclic aromatic 
hydrocarbons (PAHs), N6-dAdo adducts were highly mutagenic, and sometimes 
tumorigenic, depending on the PAH structure and location on the DNA strand.299,300 
When adducts significantly distorted the DNA helix, cells were found to halt during DNA 
replication, possibly alluding to DNA polymerases stalling near the adduct site.299 
Together, these findings seem to indicate that effective N6-dAdo adducts require steric 
balance; adducts should be large enough to disrupt base pairing, but small enough to 
evade detection by cellular machinery. It is currently unknown how POB- and PHB- 
adducts fit into this context and thus requires future study. Along with possible biological 
effects, N6-POB-dAdo and N6-PHB-dAdo have potential as biomarkers. These products 
directly link to the DNA damaging properties of NNK and NNAL and could be used to 
study differences between demographic groups.192 With analytical power continuing to 
increase, measurement of low levels of DNA adducts in humans is starting to become an 
achievable feat.301 
In summary, this work has identified and quantified the first dAdo-derived DNA 
adducts of NNK and its enantiomers NNAL formed in vitro and in vivo. We found 
general support for our proposed adduct formation mechanism by quantifying both N1-
POB-dIno and N6-POB-dAdo in vitro. Though N1-dIno type adducts were the major ones 
formed in vitro, they were undetectable in vivo. N6-dAdo adduct levels were relatively 
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modest in vivo when compared to most DNA adducts of NNK and NNAL previously 
detected. This research allows and encourages future studies on the biological properties 
of these adducts and their potential utility as specific DNA damage biomarkers. 
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3.5 Conclusion 
This study identified that NNK and NNAL form two stable dAdo-derived adduct 
types: N6-dAdo and N1-dIno. This implicates that dAdo is initially alkylated at the N1-
position and the undergoes either Dimroth rearrangement or deamination to stabilize its 
structure. When evaluated in vitro, N6-POB-dAdo and N1-POB-dIno were found with the 
latter being most abundant. To our surprise, only N6-POB-dAdo and N6-PHB-dAdo could 
be measured in NNK- or NNAL-treated rats, implying that the N1-dIno adducts are 
extensively repaired in vivo. The two N6-dAdo adducts had relatively modest levels and 
followed the expected tissue and enantiomer trends seen for NNK, (S)-NNAL, and (R)-
NNAL. In the future, the biological consequences of these adducts will be evaluated in 
hopes of understanding their role in tobacco carcinogenicity. 
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Chapter 4 Measurement of N'-Nitrosonornicotine Bioactivation in Humans 
Using Deuterium-Labeled Analogs 
 
The following chapter describes work that is currently in progress and working 
towards publication. The study was primarily performed by Erik S. Carlson, whom 
conducted this research in collaboration with Andrew Goode, Vadim Gurvich, Hanna 
Vanderloo, Joshua Ikuemonisan, Irina Stepanov, Dorothy Hatsukami, Stephen S. Hecht. 
This study was supported by the U.S. National Cancer Institute through grant CA-81301. 
We thank Anshu Jain and Dr. Jing Yang for providing useful advice on performing the 
hydroxy acid and NNN assays, respectively; Dr. Peter Villalta, Xun Ming, Makenzie 
Pillsbury, and Yingchun Zhao for assistance in the Analytical Biochemistry Shared 
Resource (partially supported by National Cancer Institute grant CA-77598); and the 
Tobacco Research Programs staff for recruiting subjects and collecting the primary 
samples. The authors also thank Bob Carlson for editorial assistance. 
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4.1 Introduction 
 Consistent with all N'-nitrosamines (Section 1.2), NNN requires metabolism to 
elicit its carcinogenic effects. The mechanistic details of NNN metabolism were 
discussed in Section 1.4.2. and are reviewed again here. Upon absorption and distribution 
to various target tissues, NNN is bioactivated through -hydroxylation by cytochrome 
P450 2A6 (Scheme 4-1). If -hydroxylation occurs at the 2-position, species 4.2 is 
produced which spontaneously ring opens and loses water to deliver diazonium 4.3. This 
compound is an excellent electrophile and can either hydrolyze to 4.4 or, if in the 
presence of DNA, alkylate a nucleobase or the phosphate backbone to form a POB DNA 
adduct. Likewise, if -hydroxylation occurs at the 5-position, a similar cascade of ring 
opening, water loss, and hydrolysis produces 4.8; alkylation of DNA produces Py-Py 
adducts where Py-Py-dIno is the major product observed in vivo208. NNN can also be 
metabolized through non-carcinogenic pathways such as N-glucuronidation, tandem 
denitrosation-oxidation, and N-oxidation (Section 1.4.2).  
 
 
Scheme 4-1: Convergent metabolism of NNN and nicotine in vivo 
To date, the only human biomarker for NNN is the combination of NNN-
glucuronide and unmodified NNN, referred to as total NNN302. However, this accounts 
for ~1% of the overall dose200 and only truly measures NNN exposure. We hypothesize 
that individuals who productively activate NNN are at a higher risk for cancer, and thus 
we would like to develop a biomarker specific to NNN bioactivation. The most direct 
approach would be measuring known DNA adducts, but past attempts to quantify DNA 
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adducts in humans have been exceedingly difficult analytical challenges301. Instead, 
measurement of the hydrolysis byproducts 4.4 and 4.8 could be a viable alternative. In 
rats and patas monkeys, these compounds are excreted in the urine after further oxidation 
to keto acid 4.5 and hydroxy acid 4.9, respectively. However, this strategy has been 
thwarted in humans because nicotine, which is >10,000 fold more abundant in tobacco 
products, is also metabolized to these compounds through minor pathways303–305. For this 
reason, it is unclear what fraction of keto acid 4.5 and hydroxy acid 4.9 in the urine is 
NNN-derived. A past attempt to circumvent this issue was measuring (S)-hydroxy acid, 
since rats almost exclusively metabolize nicotine to (R)-hydroxy acid 4.5 and metabolize 
NNN to a racemic hydroxy acid 4.9204. Unfortunately, this approach failed in humans 
because nicotine and NNN were metabolized to identical levels of (S)-hydroxy acid 
4.9306.  
In this study, we envisioned overcoming the issue of nicotine interference by 
enriching Swedish Snus, which contains low levels of NNN (0.98 g/g tobacco)307, with 
[pyridine-D4]NNN. Because of this labeling, all [pyridine-D4]NNN metabolites are 
distinct from nicotine-derived products by LC-ESI+-MS/MS (Scheme 4-2). This 
approach was successfully used in a related study assessing NNK metabolism in cigarette 
smokers and thus gave us confidence in applying this to NNN224. To execute this 
approach, we developed a spray-based method for enriching smokeless tobacco with 
[pyridine-D4]NNN and recruited 10 subjects to use the product for 3 days, where 
individual 24-hour urine samples were collected. After extensive sample work up, urinary 
levels of [pyridine-D4]hydroxy acid, [pyridine-D4]keto acid, and total [pyridine-D4]NNN 
were determined. When normalized by total [pyridine-D4]NNN, this study showed that 
[pyridine-D4]hydroxy acid 4.9 is a major metabolite of NNN, providing the first direct 
evidence of human NNN bioactivation.  
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Scheme 4-2: Metabolism of [pyridine-D4]NNN and nicotine. Due to the deuterium-labeling, metabolites are 
distinguishable by LC-MS analysis. 
4.2 Experimental Procedures 
Caution: NNN and [pyridine-D4]NNN are carcinogenic in animal models and evaluated 
as Group 1 carcinogens by IARC. These compounds should only be handled in a well-
ventilated fume hood while wear proper personal protective equipment. 
 
4.2.1 Chemicals and Enzymes 
[Pyridine-D4]NNN and [pyridine-D4]keto acid were purchased from Toronto 
Research Chemicals (Toronto, ON) and [pyridine-D4]hydroxy acid, [13C6]4.9, [pyridine-
D4]methyl 4-hexanoyl-4-(3-pyridyl)butanoate and [13C6]methyl 4-hexanoyl-4-(3-
pyridyl)butanoate were all synthesized as previously described224. [13C6]NNN was 
purchased from Cambridge Isotope Laboratories (Andover, MA). Recombinant ß-
glucuronidase from E. coli was purchased from Sigma Aldrich (St. Louis, MO). 
Phosphate-buffered saline (PBS) was purchased from Invitrogen (Grand Island, NY). All 
other chemicals, reagents, and consumable glassware were obtained from Sigma Aldrich 
or Fisher Scientific (Waltham, MA). 
 
4.2.2 Rat Study 
Approval for this study was gained by the University of Minnesota Institutional 
Animal Care and Use Committee. Three male F-344 rats (Charles River Laboratories) 
were housed individually in metabolism cages designed to collect urine and feces (20 – 
24 oC, 12 h light/dark cycle). After 1 week of acclimation, the rats were administered 1 
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mL of [pyridine-D4]NNN solution (1 M, 1X PBS) by gavage. Rats were put back into 
their cages and urine was collected for 24 hours. After a week to re-establish baseline 
urine, rats were similarly treated with 1 mL of NNN solution (1 M, 1X PBS) and had 
their urine collected for 24 hours. Each urine sample was assayed and analyzed for 
[pyridine-D4]hydroxy acid or hydroxy acid as described in the corresponding section 
below. 
 
4.2.3 Production of [Pyridine-D4]NNN-enriched Chewing Tobacco 
Prior to clinical study use, the commercially-obtained [pyridine-D4]NNN was 
purified under GMP conditions at the FDA-registered Institute of Therapeutics Discovery 
& Development at the University of Minnesota. Briefly, [pyridine-D4]NNN was applied 
to a 2.5-gram RediSep Rf silica gel cartridge (Teledyne, Lincoln, NE) and eluted with 
100% EtOAc. Five mL fractions were collected and those containing product were 
combined and evaporated in vacuo. Purity was determined to be 98-102% by HPLC-UV 
(254 nm) and 1H-NMR. 
 In the same facility and under analogous conditions, the purified [pyridine-
D4]NNN was then applied to General Swedish Snus (Swedish Match, Stockholm, 
Sweden) by a spraying method. Briefly, an aqueous solution of [pyridine-D4]NNN (4.0 
g/mL) was poured into a 250 mL flask-type sprayer (Sigma Aldrich) equipped with an 
air compressor (TCP Global) and a HEPA filter (Sigma Aldrich). The [pyridine-D4]NNN 
solution was then sprayed at a measured flow rate over a thinly-laid bed of tobacco for 
the necessary time to enrich the product by 2.0 g/g wet tobacco. The flow rate was 
determined by spraying the solution into an empty Erlenmeyer flask for 1 min and 
measuring the increase in weight; 5 replicates were averaged to obtain the flow rate. 
Spray time was then calculated based on the accurate solution concentration and flow rate 
of the apparatus. Once the tobacco was sprayed, the product was thoroughly mixed and 
packaged into tobacco tins designated for clinical use. To ensure sufficient product 
enrichment and uniformity, five 30 mg samples were taken for [pyridine-D4]NNN 
quantitation by LC-ESI+-MS/MS307,308.  
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4.2.4 Subject Recruitment and Urine Collection 
Subjects were recruited by the University of Minnesota Tobacco Research 
Program after study and urine collection approval by the University of Minnesota 
Institutional Review Board and the U.S. Food and Drug Administration. Criteria for 
selection included being older than 18, using smokeless tobacco regularly for at least 1 
year, and having appropriate physical and mental health. Recruited subjects were given 
enough tobacco for 1 tin per day and asked to solely use our product while enrolled in the 
study. Similar to an analogous study with [pyridine-D4]NNK224, subjects were asked to 
collect their 24-hour urine after a 7-day acclimation period. This sample was brought 
back the next day to the Tobacco Research Programs clinic at the University of 
Minnesota. This was repeated for 2 additional days, giving us three 24-hour urine 
samples per subject. All subject urine was stored at -20 oC. 
 
4.2.5 Analysis of [Pyridine-D4]hydroxy Acid in Tobacco Users’ Urine 
Urinary levels of [pyridine-D4]hydroxy acid (D4-4.9) were determined as 
previously described224. Briefly, 1 – 3 mL of each urine sample was spiked with 
[13C6]hydroxy acid (5 pg) and treated with excess NaBH4 under basic conditions. After 2 
h, samples were neutralized with 1N HCl and reduced to ~1 mL. These samples were 
applied to 3 mL pre-conditioned, 200 mg Strata-X cartridges (Phenomenex - Torrance, 
CA) and eluted with H2O. The aqueous samples were evaporated to dryness and 
reconstituted in 3% (v/v) H2SO4 in MeOH. Samples were incubated for 2 h at room 
temperature before neutralization with aqueous NaHCO3. These samples were then 
applied to 5 mL, unbuffered ChemElut cartridges (Agilent Technologies – Santa Clara, 
CA) and extracted with CH2Cl2. The organic extracts were reduced to ~0.5 – 1.0 mL by 
SpeedVac and added to activated BondElut silica cartridges (Agilent Technologies). The 
cartridges were washed with CH2Cl2 and 1:1 CH2Cl2/EtOAc before elution with 100% 
EtOAc. The eluents were evaporated to dryness by SpeedVac and immediately 
derivatized with hexanoic anhydride. After incubation at 70 oC for 20 min, samples were 
diluted with 9:1 hexanes/EtOAc and extracted twice with 1N HCl. Aqueous extracts were 
applied to 60 mg Oasis MCX cartridges (Waters – Milford, MA), rigorously washed with 
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1N HCl, 4:6 1N HCl/MeOH, and 80:15:4 H2O/MeOH/NH4OH, and finally eluted with 
30:60:5 H2O/MeOH/NH4OH. Eluents were dried by Speedvac, reconstituted in MeCN, 
and filtered through Spin-X centrifuge tubes before evaporation into 300 L LC 
autosampler vials (Agilent Technologies). Samples were reconstituted in 25 L of 5 mM 
NH4OAc and analyzed by liquid chromatography-positive electrospray ionization-tandem 
mass spectrometry (LC-ESI+-MS/MS). Prior to analysis, samples were stored frozen at -
20 oC.  
A previously described LC-ESI+-MS/MS analysis was performed with modifications. LC 
was performed identically except with a 0.5 x 150 mm Zorbax SB-C18 5 m column 
(Agilent Technologies) and 5 mM NH4OAc and MeCN as mobile phases. MS was 
performed on a TSQ Quantiva triple quadrupole mass analyzer (Thermo Scientific) with 
identical selected reaction monitoring (SRM) transitions. The Q1 and Q3 resolutions 
were set to 0.4 and 0.7 amu, respectively. The collision gas was 1.0 mTorr, the spray 
voltage was 3500 V, and the ion transfer tube temperature was 250 oC. Lastly, the 
collision energy was 18 eV for m/z 298 → m/z 182 and m/z 300 → m/z 184, and 35 eV 
for m/z 298 → m/z 122 and m/z 300 → m/z 124. 
To measure the urinary level of [pyridine-D4]keto acid, the same sample work-up 
protocol was followed except without using NaBH4. Accordingly, the urinary level of 
[pyridine-D4]keto acid was calculated as the difference between [pyridine-D4]hydroxy 
acid levels measured in the NaBH4-containing and NaBH4-lacking protocols. 
  
4.2.6 Analysis of [Pyridine-D4]NNN in Tobacco Users’ Urine 
Urinary levels of [pyridine-D4]NNN were determined as previously described224 
but with modification. Briefly, 3 mL of subject urine was spiked with [13C6]NNN (5 pg) 
and incubated with ß-glucuronidase (Sigma Aldrich) overnight. The next morning, 
samples were adjusted to pH 5 with 1M NaOAc buffer and applied to 5 mL Isolute 
cartridges (Biotage – Charlotte, NC). Cartridges were eluted with CH2Cl2 and evaporated 
to dryness by SpeedVac. Samples were reconstituted with 1 mL 1N HCl and applied to 
60 mg Oasis MCX cartridges (Waters). These were extensively washed with 1N HCl, 
MeOH, and 90:5:5 H2O/MeOH/NH4OH before eluting with 35:60:5 
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H2O/MeOH/NH4OH. The eluents were then dried by SpeedVac and reconstituted in 1 
mL of CH2Cl2. The samples were applied to BondElut cartridges (Agilent Technologies), 
washed with CH2Cl2 and 1:1 CH2Cl2/EtOAc, and eluted with 100% EtOAc. Samples 
were evaporated to dryness, reconstituted in MeOH, and dried down in 300 L LC vials. 
Samples were reconstituted in 25 L of 5 mM NH4OAc immediately before LC-ESI+-
MS/MS analysis or stored frozen at -20 oC. 
 LC was performed with the same column described for [pyridine-D4]hydroxy acid 
analysis at 40 oC and a flow rate of 10 L/min. Using a binary solvent system of 5 mM 
NH4OAc and MeOH, the column was eluted with a linear ramp of 30% MeOH to 40% 
MeOH over 10 min. The column was then brought to 90% MeOH over 1 min, held at 
90% MeOH for 1 min, and brought back to 30% MeOH over 1 min. The column was re-
equilibrated for 5 min before each injection. MS was performed on a Quantiva triple 
quadrupole mass analyzer (Thermo Scientific). SRM transitions were m/z 182 → m/z 124 
and m/z 182 → m/z 152 for [pyridine-D4]NNN and m/z 184 → m/z 126 and m/z 184 → 
m/z 154 for 13C6-NNN. The Q1 and Q3 resolutions were set to 0.4 and 0.7 amu, 
respectively. The collision gas was 1.0 mTorr, the spray voltage was 3000 V, and the ion 
transfer tube temperature was 270 oC. Lastly, the collision energy was 11 eV for m/z 
182/184 → m/z 152/154 and 21 eV for m/z 182/184 → m/z 124/126. 
 
4.2.7 Cotinine and 3-Hydroxycotinine 
Urinary levels of total cotinine and total 3-hydroxycotinine (where “total” refers 
to the sum of the metabolite and its glucuronide) were measured as previously 
described39. Briefly, 10 l of urine was diluted with 100 mM NH4OAc and spiked with 
[methyl-D3]cotinine and [methyl-D3]3-hydroxycotinine (1 ng each). Each sample was 
incubated with ß-glucuronidase (Sigma Aldrich) overnight and then applied to a pre-
conditioned 2 mg Oasis MCX 96-well plate. Each loaded well was washed with 0.5% 
HCO2H and MeOH in succession. The analytes were eluted with 2% NH4OH/MeOH into 
a clean 96-well plate and evaporated to dryness after acidification. Samples were 
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reconstituted with 25 L of 100 mM NH4OAc:MeOH just before LC-ESI+-MS/MS 
analysis. Otherwise, samples were stored at -20 oC until analysis.  
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4.3 Results 
 
4.3.1 Rat Study 
To confirm that [pyridine-D4]NNN does not possess a metabolic isotope effect, 
we compared urinary total hydroxy acid, the combination of [pyridine-D4]keto acid and 
[pyridine-D4]keto acid, between three rats administered 1 nmol of [pyridine-D4]NNN or 
NNN by gavage. Urine was collected from each rat separately and assayed for both 
[pyridine-D4]hydroxy acid or hydroxy acid. The average urinary concentrations for each 
metabolite are shown in Figure 4-1. Baseline urine contained no [pyridine-D4]hydroxy 
acid and only minor levels hydroxy acid. In comparison, urinary concentrations for 
[pyridine-D4]hydroxy acid and hydroxy acid were significantly higher after treatment 
with the corresponding NNN derivative. Importantly, there was no statistical difference 
between the levels, indicating that hydroxy acid excretion is not affected by deuterium-
labelling. 
 
Figure 4-1: Total hydroxy acid levels in the urine of rats treated with 1 nmol of NNN or [pyridineD4]NNN. Blue and 
red bars indicate [pyridine-D4]hydroxy acid and hydroxy acid concentration, respectively. Values are the average of 
three replicates and error bars denote their standard deviation. 
4.3.2 Tobacco Enrichment and Production 
[Pyridine-D4]NNN was purified to 98 – 102% under GMP conditions and sprayed 
onto loose Swedish Snus as an aqueous solution. Each lot of tobacco was thoroughly 
mixed and analyzed for accuracy and uniformity. As shown in Table 4-1, the average 
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enrichment value of [pyridine-D4]NNN was 0.1927 ± 0.0303 g/g tobacco, which is in 
very close agreement to our desired value of 0.2 g/g. Additionally, each lot was uniform 
as indicated by the relative standard deviations never exceeding 10%. Together, this 
indicates our spraying method produces smokeless tobacco that is accurately and 
uniformly enriched with [pyridine-D4]NNN. 
 
Table 4-1: Accuracy and uniformity of [pyridine-D4]NNN-enriched tobacco 
 
Avg. [pyridine-D4]NNN 
(g/g tobacco) St. Dev % CV % Expected 
Lot 001 0.2162 0.00613 2.84 108 
Lot 002 0.1585 0.00952 6.01 79.3 
Lot 003 0.2033 0.01778 8.75 102 
Average 0.1927 0.03025 15.7 96.3 
 
4.3.3 Urinary Analysis of [Pyridine-D4]hydroxy Acid and [Pyridine-D4]keto Acid 
24-hour urine samples were collected and analyzed from 10 subjects whom were 
given 1 tin (~30 g) of [pyridine-D4]NNN-enriched tobacco per day for a 3-day period. As 
seen in Figure 4-2, [pyridine-D4]hydroxy acid was seen in all subjects’ urine except for 
one, who used less than 5 g of product per day. Similarly, [pyridine-D4]hydroxy acid was 
not detected in negative control urine. Representative chromatograms of assayed urine 
samples are shown in Figure 4-3. Daily tobacco use was recorded for each subject and 
found to directly correlate with their daily [pyridine-D4]hydroxy acid excretion (R2 = 
0.817, Fig. 4-4). 
  
Figure 4-2: Urinary levels of total hydroxy acid for each subject. Blue, red, and green bars denote Day 1, Day 2, and 
Day 3 urine collections. N.D. – Not detectable 
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Figure 4-3: Representative LC-ESI+-MS/MS chromatograms for total hydroxy acid. In each case, the top two channels 
are monitoring separate transitions for derivatized [pyridine-D4]hydroxy acid 4.9 (m/z 298 → m/z 182, 148). The 
bottom two channels are monitoring derivatized 13C6-4.9 (m/z 300 → m/z 184, 124). 
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Figure 4-4: Urinary total hydroxy acid plotted against estimated [pyridine-D4]NNN dose. 
To measure [pyridine-D4]keto acid, we omitted NaBH4 from the total hydroxy 
acid assay; all other steps and procedures were analogous to before. The difference in 
[pyridine-D4]hydroxy acid levels measured with and without NaBH4 theoretically equates 
to [pyridine-D4]keto acid levels because NaBH4 reduction normally converts all 
[pyridine-D4]keto acid to [pyridine-D4]hydroxy acid during the assay. Surprisingly, 
samples with and without reduction were shown to be nearly identical (Fig 4-5). 
Importantly, [pyridine-D4]keto acid is only quantified with this assay when NaBH4 is 
used (Fig. 4-3), indicating no artefactual reduction is occurring during the assay. For this 
reason, we assume that little to no [pyridine-D4]keto acid is present in any subject’s urine. 
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Figure 4-5: Comparison of Total Hydroxy Acid levels with and without NaBH4 reduction during the assay. 
4.3.4 Urinary Analysis of Total [Pyridine-D4]NNN 
Total [pyridine-D4]NNN, the sum of [pyridine-D4]NNN-N-glucuronide and 
unmetabolized [pyridine-D4]NNN, was measured in the same urine samples described for 
total hydroxy acid analysis. Representative chromatograms for total [pyridine-D4]NNN 
analysis are shown in Fig. 4-6. In agreement with past reports, total [pyridine-D4]NNN 
levels were very low overall and generally did not exceed 90 pmol/day (Fig. 4-7). 
[pyridine-D4]NNN was found in all subjects except subject 5 who used < 5 g of the 
product. Likewise, [pyridine-D4]NNN was not observed in negative control urine (Fig. 4-
6). In contrast to [pyridine-D4]hydroxy acid, daily total [pyridine-D4]NNN levels did not 
correlate to daily tobacco use (data not shown). 
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Figure 4-6: Representative LC-ESI+-MS/MS chromatograms for total [pyridine-D4]NNN. In each case, the top two 
channels are monitoring separate transitions for [pyridine-D4]NNN (m/z 182 → m/z 152, 124). The bottom two 
channels are monitoring [13C6]NNN (m/z 184 → m/z 154, 126). 
 
Figure 4-7: Urinary levels of total [pyridine-D4]NNN in each subject. Blue, red, and green bars denote Day 1, Day 2, 
and Day 3 urine collections. N.D. – Not detectable 
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4.3.5 Comparison of “Metabolic Activation Ratio” to “Nicotine Metabolite Ratio” 
To compare metabolic activation between subjects, we computed the average 
ratio of total hydroxy acid to total [pyridine-D4]NNN over their 3-day study period. In 
this study, we refer to this value as Metabolic Activation Ratio (MAR). This ratio is 
informative because total [pyridine-D4]NNN is an established biomarker for exposure 
and normalizes total hydroxy acid levels for 24-hour urine volume and [pyridine-
D4]NNN dose. MAR values for all subjects in ascending order are shown in Fig. 4-8. 
While the denoted groups were not statistically significant different (p > 0.05), this ratio 
begins to show a trend of low, medium, and high activators (Fig. 4-8). To further 
evaluate this ratio to metabolic activation proficiency, we measured the Nicotine 
Metabolite Ratio (total 3'-hydroxycotinine/cotinine), an established biomarker for P450 
2A6 activity, for each subject39. When plotted against MAR (Fig. 4-9), we observe a 
strong, positive correlation, potentially indicating that P450 2A6 activity is associated 
with metabolic activation of NNN.  
 
Figure 4-8: Metabolic Activation Ratio (total hydroxy acid/ total [pyridine-D4]NNN) for each subject arranged in 
ascending order. Based on error bars, three potential activation groups are denoted: low, medium, and high. 
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Figure 4-9: Metabolic Activation Ratio plotted against Nicotine Metabolite Ratio, a phenotypic marker for P450 2A6 
activity. The red data point is Subject 1 whom had abnormally high Day 2-[pyridine-D4]hydroxy acid excretion.  
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4.4 Discussion 
In this study, we report the first direct evidence of NNN bioactivation in humans 
through use of tobacco enriched with [pyridine-D4]NNN. Past studies have gathered 
indirect evidence such as HPB-releasing adducts from both hemoglobin309 and oral 
cells192,245, but neither of these are specific to NNN since they also result from NNK 
metabolism and potentially unknown sources. As mentioned previously, efforts to 
measure activation metabolites, keto acid 4.5 and hydroxy acid 4.9, suffer the same 
problem, and are also overwhelmed by nicotine metabolism. The use of [pyridine-
D4NNN circumvented these issues as all metabolites will be 4 mass units higher, 
allowing selective analysis by LC-ESI+-MS/MS. 
The measured [pyridine-D4]hydroxy acid levels varied significantly among 
subjects. For example, Subjects 1, 2, and 8 had generally higher [pyridine-D4]hydroxy 
acid excretion (~1500 – 11,600 pmol/day) than Subjects 3, 6, 7, 9, and 10 (~65 – 640 
pmol/day). Levels for each subject also varied over the 3-day period. The most obvious 
example is Subject 1 who had intraday levels varying from ~2500 – 11,600 pmol/day. 
These inter-individual and intraday differences could be related to how subjects use the 
product. In our study, these variations were partially explained by overall tobacco usage. 
Figure 4-4 shows a strong, positive correlation between daily [pyridine-D4]hydroxy acid 
excretion and the theoretical [pyridine-D4]NNN dose ingested. Another explanation for 
the variation is the time and frequency of tobacco use, however, this was outside the 
scope of this study. Ideally, subjects would use the product uniformly throughout the day. 
Deviations from this could result in abnormally high [pyridine-D4]hydroxy acid excretion 
that is not representative of daily use. Subject 1– Day 2 is a possible example of this may 
behavior. 
In a related study with [pyridine-D4]NNK-enriched cigarettes (0.225 g/g 
tobacco), smokers had urinary [pyridine-D4]hydroxy acid concentrations of 130 
fmol/mL224. If we assume an average 24-h urine volume of 1400 mL310, subjects excreted 
~182 pmol/day. This is completely in line with the data found in this study and is even on 
the lower end of values observed for [pyridine-D4]NNN; however, this finding could be 
reflecting the differences in carcinogen uptake from cigarettes and smokeless tobacco 
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rather than differences in NNK and NNN metabolism. In accordance with the current 
study, subjects in the [pyridine-D4]NNK study showed a range of urinary [pyridine-
D4]hydroxy acid concentrations, which implicates inter-individual differences in 
metabolism. 
 Our study indicates that [pyridine-D4]keto acid excretion in humans is extremely 
minor. Levels of urinary [pyridine-D4]hydroxy acid excretion with and without NaBH4 
reduction were very similar for each subject and each day of collection (Figure 4-5). 
While each sample has only a single analysis, we expect the reduced- and non-reduced 
samples to not be statistically similar after repeated assays. Currently, our data does not 
explain the reason for low to non-existent [pyridine-D4]keto acid level, but two 
hypotheses are likely. The first is humans preferentially perform 5-hydroxylation relative 
to 2-hydroxylation. This is supported by work conducted by Zarth et al which found Py-
Py-dIno, a 5-specific adduct, to be the major adduct produced in human liver S9 fraction 
and human liver microsomes208. The other hypothesis is that almost all [pyridine-D4]keto 
acid is reduced to [pyridine-D4]hydroxy acid in vivo. This also seems likely because 
~85% of keto acid 4.5 resulting from nicotine metabolism was reduced to [pyridine-
D4]hydroxy acid306. Future work is necessary to fully test these hypotheses. 
In agreement with past studies, total [pyridine-D4]NNN was an extremely minor 
component of urinary metabolites200. The highest levels of [pyridine-D4]NNN were seen 
in subjects 1, 4, and 8, who also had high levels of hydroxy acid excretion, and ranged 
from ~23 – 187 pmol/day. The lowest levels of NNN were found in subjects 6, 7, 9, and 
10 (0.42 – 5.7 pmol/day). Likewise, these subjects had comparatively low hydroxy acid 
excretion, however, this behavior was not always seen. Interestingly, daily [pyridine-
D4]NNN levels did not correlate to daily tobacco use. While this rejects the notion that 
total [pyridine-D4]NNN is a good biomarker for tobacco use, total NNN was correlated 
with risk for esophageal cancer199 and is inevitably a biomarker its own exposure. For 
these reasons, we felt it was a suitable measure for normalizing total hydroxy acid. In 
future studies, it will be worthwhile to explore if using other biomarkers of exposure, 
such as Total Nicotine Equivalents36, changes the overall bioactivation trends. 
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Figure 4-8 displays Metabolic Activation Ratio (MAR, total hydroxy acid/ total 
[pyridine-D4]NNN) for each subject. A major finding is subjects with high total hydroxy 
acid levels do not necessarily have high MAR. For example, subjects 1 and 11 have low 
MAR values (43.5 ± 15.9 and 38.1 ± 15.8) while possessing the highest total hydroxy 
acid values. In contrast, subject 13 has the highest average MAR value (188.6 ± 105.8) 
and relatively low total hydroxy acid excretion. It was also noted that almost no MAR 
values had statistically significance between each other; however, the data does show a 
trend for three groups of relative activation. Subjects 2, 6, and 9 are tentatively “high 
activators”, Subjects 1, 4, and 8 are tentatively “medium activators”, and Subject 3 is 
tentatively a “low activator”.  Subjects 7 and 10 appear to be between these groups. The 
only subjects with statistically significant MAR values, as determined by Student’s t-test, 
are Subjects 2 and 3 (p = 0.0373), indicating that Subject 2 -hydroxylates NNN to a 
higher extent than Subject 3, the “low activator”. Additionally, the MAR value of Subject 
2 was nearly statistical different than Subject 8 (p = 0.052), Subject 1 (p = 0.068), and 
Subject 10 (p = 0.071), whom are all tentatively “medium” activators. Together, this 
suggests a trend towards different activation groups that may gain true statistical 
significance as more subjects complete the study. 
 Potentially the most important finding from this study is that MAR is directly 
correlated to Nicotine Metabolite Ratio, a biomarker for P450 2A6 activity (Fig. 4-9). 
This finding supports the hypothesis that high metabolic activation of NNN is due to 
increased P450 activity. Additionally, it may indicate that Nicotine Metabolite Ratio, a 
biomarker measurable without using specialized tobacco, could be a surrogate for NNN 
bioactivation. Likewise, MAR could potentially be a biomarker for cancer risk because 
Nicotine Metabolite Ratio was recently linked to prospective lung cancer risk in a large 
epidemiology study40. Either way, the strong association between NNN bioactivation and 
P450 2A6 activity is an important link for the general scheme of tobacco carcinogenesis. 
Because P450 2A6 activity is also linked to changes in tobacco use behavior, future work 
is necessary to fully establish how P450 2A6 activity relates to NNN bioactivation and 
individual cancer risk. 
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 Another major goal of the overall study is understanding the overall pattern of 
human NNN metabolism in relation to monkeys and rats. With regards to -
hydroxylation, rats and monkeys excreted 31.8 and 43.8% of their NNN dose as hydroxy 
acid 4.9, respectively197,204. In rats, only 1.1% of keto acid administered was converted to 
hydroxy acid 4.9, indicating almost all of the hydroxy acid observed is through 5-
hydroxylation204. In monkeys, it is not known how much keto acid is reduced to hydroxy 
acid, but overall keto acid is only 2.7% of the recovered dose. This indicates that in 
monkeys either 2-hydroxylation is a minor pathway or keto acid reduction is a major 
pathway, which is what we hypothesize for subjects in the current study. It is hard to 
estimate the dose of [pyridine-D4]NNN for each subject in this study due to presumed 
differences in individual tobacco use; however, if we assume 35% of NNN is extracted 
from tobacco and absorbed by the user311, [pyridine-D4]hydroxy acid is ~3 – 47% of the 
dose. Using the same assumptions, total [pyridine-D4]NNN is 0.01 – 2% of the dose. 
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Scheme 4-3: Known metabolism of NNN in patas monkeys. 
In addition to activation metabolites, patas monkeys excrete a variety of putative 
detoxification metabolites such as norcotinine and 3-hydroxynorcotinine (Scheme 4-3). 
3-Hydroxynorcotinine is of particular interest because it is not known to be a nicotine 
metabolite36. However, a recent report measured this analyte in the urine of both smokers 
and nicotine patch users, suggesting that 3-hydroxynorcotinine is a metabolite of 
nicotine and NNN198. Current efforts in our lab seek to reanalyze urine from this study to 
specifically determine the contribution of NNN to the observed 3-hydroxynorcotinine 
levels. Ultimately, we hope to use this unique [pyridine-D4]NNN methodology to fully 
characterize the metabolic profile of NNN in humans and establish novel biomarkers, or 
biomarker ratios, for metabolic activation and detoxification and apply them to 
identifying individuals at high risk for tobacco-related cancer.  
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4.5 Conclusion 
This study established -hydroxylation as a significant route of human NNN 
metabolism for the first time. While the overall dose percent is difficult to predict, 
hydroxy acid was > 12-fold higher than total [pyridine-D4]NNN, which is usually less 
than ~1% of the total dose. The ratio of total hydroxy acid to total [pyridine-D4]NNN has 
been defined as the Metabolic Activation Ratio (MAR) and was found to vary amongst 
individuals and showed a trend towards three separate groups of activators. Additionally, 
the Metabolic Activation Ratio strongly correlated to a phenotypic biomarker for P450 
2A6 activity, linking our bioactivation marker to a distinct enzyme with carcinogenic 
implications. As this study continues and gains more subjects, we hope to more 
confidently establish this link, stratify subjects into activation groups, and potentially 
develop this ratio into a biomarker of tobacco-related cancer risk. 
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